



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

Plaintiff,)

vs.)

PART F

Case No. CJ-2017-816
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
- PHARMACEUTICALS, INC., n/k/a)
- JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
- n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
- f/k/a ACTAVIS, INC., f/k/a WATSON)
- PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
- f/k/a WATSON PHARMA, INC.,)

Defendants.)

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

S-4523	Excerpts from Dana Gripka's call notes	"POK001852070 POK003477669"				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4524	Excerpts from Jon Hendricks's call notes	"JAN-OK-00145252 - 263 JAN-OK-000000001- 4"				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4525	Excerpts from Elizabeth Hightower's call notes	"JAN-OK-00145252 - 263 JAN-OK-000000001- 4"				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4526	Excerpts from Kevin Potas's call notes	"JAN-OK-00145252 - 263 JAN-OK-000000001- 4"				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4527	Excerpts from Patricia Sides's call notes	"POK001852070 POK003477669"				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4528	Excerpts from Jennifer Wells's call notes	"POK001852070 POK003477669"				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4529	Analysis of Duragesic Brand Prescribing April 2002 Data	JAN-MS-00787243				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4530	Duragesic HRP Newsletter Program, Updated Store Rx Data July 2002	JAN-MS-00787269				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4531	Duragesic HRP Newsletter Program, Analysis of HRP Provided Store Data 12/16/02 Email from Chupa to Wood re Duragesic HRP Newsletter Program Analysis	JAN-MS-00787272				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4532		JAN-MS-00787273				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4533		JAN-MS-00788892				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4534		JAN-MS-01130477				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4535		JAN-MS-01474228				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4536			JAN-MS-01973739				R; PRE; CON; CU; AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4537			JAN-MS-01973745				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4538			JAN-MS-04238511				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4539		"8/29/11 Email from Marshall to Anderson re Peer to Peer Hotspots for live speaker programs post approval"	JAN-OK-00134489				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4540		"Backstories on the US Opioid Epidemic. Good intentions Gone Bad, an Industry Gone Rogue, and Watch Dogs Gone to Sleep; deShazo et al; The American Journal of Medicine 2017.12.045"	N/A				H; R; PRE; CON; CU; AU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-4541		Top 60 Hotspots	JAN-MS-00836156				R; PRE; CON; CU; AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4542		Welcomefinal.ppt	JAN-OK-00132825				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4543		RE: Nucynta ?	JAN-OK-00132906				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4544		RE: PriCara AIGI Incentive Survey Feedback Request	JAN-OK-00133002				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4545		2010 Leaders Board Updates OKC District - AIGI.pptx	JAN-OK-00133209				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4546		3754205 Oklahoma City N, OK AIGI Territory Goals Q2 2011	JAN-OK-00133224				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4547		3754205 Oklahoma City N, OK Territory Q2 2011 Pricara Goals.xls	JAN-OK-00133225				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4548	3754206 Oklahoma City, OK AIGI Territory Goals Q2 2011	JAN-OK-00133226				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4549	3754206 Oklahoma City, OK Territory Q2 2011 Pricara Goals.xls	JAN-OK-00133227				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4550	UPDATEDQ2 2012 IM IC Plan Design Rollout 04-05-2012_v2.pptx	JAN-OK-00134939				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4551	2012 Q2 IM Retail Incentive Plan Book-DM.pdf	JAN-OK-00135523				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4552	2012 Representative PDM Information Sheet M Dickson.docx	JAN-OK-00135564				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4553	2012 Representative PDM Information Sheet Wakefield.doc	JAN-OK-00135567				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4554	7420000 Tulsa OK District Report Q4 2012 IM Retail Goals - U.xls	JAN-OK-00135597				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4555	Q4_PriCara_Pain_DM Plan Book.pdf	JAN-OK-00135665				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4556	2010 PriCara PAIN Incentive Plan Cycle 1 - FINAL.pptx	JAN-OK-00135734				R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4557	Nucynta SPRINT Contest - November 1-5'10 Results.xlsx	JAN-OK-00135802				R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4558	Nucynta SPRINT Contest - November 15-19'10 Results.xlsx	JAN-OK-00135803				R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4559	Nucynta SPRINT Contest - November 8-12 '10.xlsx	JAN-OK-00135805				R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4560	2764208 Tulsa S OK Territory Q1 2011 Pricara Pain Goals (2).xls	JAN-OK-00135943				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4561	2001 Incentive Compensation.rtf	JAN-OK-00136520				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4562	2001 IC Plan - 500 Blue w-addendum.doc	JAN-OK-00136557				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4563	[Unnamed Spreadsheet]	JAN-OK-00136572				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4564	2004 PC IC Overview - RBDs.ppt	JAN-OK-00136590				Inadmissible Character Evidence; R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4565	55) Nucynta Hotsheet 070910.pdf	JAN-OK-00136748				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4566	2010 PriCara AIGI Incentive Compensation Plan - Q3'10 FINAL.pptx	JAN-OK-00136813				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4567	FW: Sales Compensation: Announcing the NUCYN TA Power Ahead Contest!	JAN-OK-00136965				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4568	4412708 Tulsa E, OK Levaquin IV & Nucynta Territory Goals	JAN-OK-00137326				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4569	4412708 Tulsa E, OK Territory H2 2010 CVI Goals.xls	JAN-OK-00137327				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4570	Action Required - CVI Q1'11 NUCYN TA Compensation Universe Guidelines/Timelines	JAN-OK-00137345				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4571	RE: Nucynta Power Ahead	JAN-OK-00137419				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4572	B Karnig 5_10_5_12_10.docx	JAN-OK-00137667				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4573	2012 Flanary Mid Year Template.docx	JAN-OK-00138517				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4574	2H'11 IM Institutional Incentive Plan Overview (FINAL).pptx	JAN-OK-00138934				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4575	50P54432800_Call_Activity_View.xls	JAN-OK-00140601				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4576	50P54432602_Incentive_Compensati on.pdf	JAN-OK-00140608				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4577	50P54432603_Incentive_Compensati on.pdf	JAN-OK-00140610				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4578	2006 Mid-Year Update - Final.txt	JAN-OK-00140836				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4579	5/3/10 Harper Distance Coaching Overview	JAN-OK-00141312				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4580	Hotsheet april 30.pdf	JAN-OK-00141380				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4581	FW: Nucynta Tools	JAN-OK-00141406				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4582	FW: Duragesic press kit	JAN-MS-00303811				PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4583	Chronic Pain Fact Sheet FINAL1.doc	JAN-MS-00303813				INC; H; AU; CON	
S-4584	Duragesic Fact Sheet FINAL1.doc	JAN-MS-00303816				PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4585	Duragesic folder5 to client.pdf	JAN-MS-00303820				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4586	Fentanyl-DAWN Fact Sheet FINAL1.doc	JAN-MS-00303823				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4587	Opioid Dependence Fact Sheet FINAL1.doc	JAN-MS-00303825				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4588	Patch Tech fact sheet FINAL1.doc	JAN-MS-00303826				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4589	RE: UPDATE: Duragesic Communication Plan	JAN-MS-00781325				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4590	GYMR written info to REVIEW Responses to Questions about Duragesic.doc	JAN-MS-02775194				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4591		JAN-MS-02775197				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4592	5/30/12 Email from Rosenthal to others re Milwaukee Journal Sentinel E-Edition Article	Acquired_Actavis_002 13639				AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4593	International Conference on Opioids.msg	Acquired_Actavis_004 50939				AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4594	A Safer, Better Treatment for Chronic Low Back Pain?	JAN-MS-00284862				H	12 O.S. 2802
S-4595	RE: Certified Pain Rep	JAN-MS-00863855				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4596	RE: Life Beyond Pain Follow-Up	JAN-MS-00918806				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4597	RE: Opioid REMS	JAN-MS-00928307				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4598	Re: A question for you...	JAN-MS-00929411				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4599	OMIP and Aventine Confidentiality Agreement--March 2011.pdf	JAN-MS-02494468				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4600	Nuggest Video (https://www.youtube.com/watch?v=HUngLgGRJpo&feature=youtu.be)	N/A				First Amendment; AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4601	"Understanding the Diverse Needs of Children whose Parents Abuse Substances, Solis et al; Curr Drug Abuse Rev. 2012 June; 5(2): 135-147"	N/A				H; R; PRE; CON; CU; AU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-4602	"Parenting under the influence: the effects of opioids, alcohol and cocaine on mother-child interaction, Slesnick et al; Addictive Behaviors 39 (2014) 897-900"	N/A				H; R; PRE; CON; CU; AU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-4603	"A Family Study of the High-Risk Children of Opioid- and Alcohol-Dependent Parents, Wlens et al; American Journal on Addictions 11:41-51, 2002"	N/A				H; R; PRE; CON; CU; AU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802

S-4604	Children of Mothers with Serious Substance Abuse Problems: An Accumulation of Risks, Connors et al; American Journal of Drug and Alcohol Abuse Vol. 30, No. 1, 85-100 (2004)	N/A				H; R; PRE; CON; CU; AU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-4605	"Multiple jeopardy: Risk and protective factors among addicted mothers' offspring, Luthar et al; Development and Psychopathology, 10 (1998), 117-136"	N/A				H; R; PRE; CON; CU; AU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-4606	https://www.janssen.com/us/hcp-resources	N/A				AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4607	Grants for AGS funding	JAN-MS-00262996				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4608	J&J as part of AGS "Corporate Roundtable"	JAN-MS-00263139				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4609	Bio for Barry Cole	NPRO0001TPP000209 13				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4610	2011 Issue if Purdue online	PMA000203706				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4611	State Pain Initiative Leaders	JAN-MS-02499175				H	12 O.S. 2802
S-4612	Email with ASPI conference flyer	POK003552762				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4613	Massachusetts Pain Initiative 2009 Purdue 2008 Linda Barefoot Performance Partnership Appraisal Form	PPLP004079729				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4614		PPLPC030000440179				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4615	ASPI newsletter	PPLPC035000041865				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4616	grant proposal for Oklahoma state pain initiative	PKY180787390				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4617	grant proposal for Oklahoma state pain initiative	PKY180787396				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4618	grant request for oklahoma pain project	PKY180787384				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4619	Meeting minutes from ASPI meeting	TEVA_OK_08964092				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4620	2009 ASPI front group flyer	JAN-MS-00395169				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4621	Flyer for 20th annual meeting	TEVA_OK_00526696				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4622	American Chronic Pain Association newsletter	PPLP003476333				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4623	Purdue - OxyContin Tablets: Proper Use vs. Criminal Abuse	PKY180567853				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4624	Draft Public Health Rationale for Oxycontin Tablets	PKY181995186				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4625	Email from Greg Panico to Robyn Kohn re WSJ article - Dr Portenoy	JAN-MS-01248814				Discovery Violations; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4626	JCAHO sponsorship agreement	JAN-MS-00920938				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4627	Email re confusion about the Joint Commission standards	NPRO00011TPP000074 10				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4628	The Fifth Vital Sign: New Standards for Effective Pain Management	PKY180798408				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4629	Finding Relief: Pain Management for Older Adults	JAN-MS-03776714				Judicial Estoppel; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4630	Email from Scott Hulka re Milwaukee Journal Sentinel E-Edition Article	Acquired_Actavis_002 13632				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4631	ASG Implementation Procedures for Identifying and Resolving Conflicts of Interest	AGS000000078				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4632	Pain Advocacy Organizations Index Letter to Pamela Bennett of Purdue re support of American Chronic Pain Association	TEVA_OK_00101638 NPRO0001TPP000203 65				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA First Amendment; AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4634	Letter to Robyn Kohn with ACPA Objectives for 2007	JAN-MS-00406796				First Amendment; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4635	Letter to Committee Members re National Pain Strategy	TWILLMAN 017738				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4636	"Letter to Mary Bono Mack and House Commerce Subcommittee Members re unmanaged pain and oxycodone"	PPLPC029000391330				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4637	Letter to Congress re vote of FDA to recommend rescheduling hydrocodone	ACS-CAN-000363				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4638	Achieving Balance in State Pain Policy - A Progress Report Card (CY 2013)	ACS-CAN-003454				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4639	Achieving Balance in State Pain Policy - A Progress Report Card (CY 2015)	ACS-CAN-003329				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4640	Management of Chronic Pain: Focus on Duragesic	JAN-MS-02340018				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4641	Extended Release Nucynta ER prescribing information	JAN-MS-00230017					
S-4642	Email from Christian Wood re Palladone/Dilaudid CR Blocking Program	JAN-MS-00246770				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4643	Email from Molly McDonald re October 5-7 Regional Advisory Board Summary	JAN-MS-00246787				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4644	Email from Pam Dotter re Duragesic PR Revised	JAN-MS-00303806				R; PRE; CON; CU; AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4645	Duragesic 2002/2003 US Public Relations Overview	JAN-MS-00303807				AU; H; PRE; R	
S-4646	Email from Molly McDonald re New York Times 2/9: OxyContin Abuse	JAN-MS-00304026				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4647	American Chronic Pain Association Organizational Chart	ACPA00000001				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4648	Email to Kati Chupa re AP77 Orientation for Kati Chupa	JAN-MS-00782733				AU; H; R; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4649	Management of Pain - Module steps	JAN-MS-00016322				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4650	Email to Robyn Kohn re INROADS Invitation & Faculty Bios	JAN-MS-00406385				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4651	INROADS Faculty bios	JAN-MS-00406388				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4652	Steven Simon's CV	JAN-MS-01545263				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4653	Gerald Aronoff CV	TEVA_OK_09603637				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4654	Daniel Bennett CV	TEVA_OK_05238100				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4655	CV of Dr. Daniel Brookoff	JAN-MS-01139135				First Amendment; AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4656	Pain Management Speaker Training Program for Physicians	PKY180170423				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4657	Janssen - Community Connect Project, Summary and Request	JAN-MS-00421910				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4658	Donald Taylor's CV	TEVA_OK_09523664				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4659	Jeffrey Gudin's CV	TEVA_OK_09739795				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4660	Steven Stanos's CV	JAN-MS-00836894				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4661	Sunil Panchal's CV	PPLPC037000246503				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4662	AGS - Pharmacological Management of Persistent Pain in Older Persons	N/A				First Amendment; AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4663	Judith Paice CV	PPLP004272057				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4664	Seddon Savage CV	PKY183233448				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4665	Joseph Pergolizzi CV	JAN-MS-02404674				AU; H; R; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4666	Stevan Litman CV	TEVA_OK_00666482				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4667	James Cleary CV	NPRO0001TPP0000036 23				First Amendment; AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4668	American Cancer Society - Addressing State Policy Barriers to Cancer Pain Management	N/A				First Amendment; AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4669	"12/21/18 American Chronic Pain Association About Us website (https://theacpa.org/About-Us)"	N/A				First Amendment; AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4670	Martin Grabois's CV	JAN-MS-01008057				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4671	Barry Elliot Cole CV	PTN000089127			First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4672	June Dahl CV	TEVA_OK_00594176			AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4673	Discovery International - Response to Key Issues - March 15, 2001	JAN-MS-02395046			First Amendment; AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4674	"American Chronic Pain Association - ACPA History (https://www.theacpa.org/about- us/acpa-history/)"	N/A			First Amendment; AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4675	ASCAN Comment of Concern	JAN-MS-00455280			First Amendment; AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4676	Feb 2013 FDA Public Hearing Minutes	PPLPC031001020407			AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4677	Hydrocodone Rescheduling Advocacy Group Positions	TEVA_OK_07846241			AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4678	Take Control of Your Pain Grant Request	USPF00000895			First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4679	Grant Closing Letter for ASPMIN	ASPMN00001609			AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4680	Grant Approval to ASPMIN Communication Strategic Plan	ASPMN00001647			AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4681	Teva Corporate Letter of Membership Agreement	ASPMN00001744			AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4682	Janssen Activities Summary	JAN-MS-00132637			First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4683	PAINNS Call to Action	JAN-MS-00392883			First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4684	Memo re Ortho and AAPM partnership	JAN-MS-00500094				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4685	Letter from AAPM to Johnson and Johnson	JAN-MS-00500322				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4686	2005 Pain educators forum	ASPE00001909				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4687	Pain representative training program	ASPE00030789				First Amendment; AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4688	2013 Nucynta Brand Planning	JAN-MS-006664253				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4689	Email to spreadsheet showing payment of Passik's teletopics	JAN-MS-00303731				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4690	Budget showing payment to Passik, payment for creation of teletopic, etc	JAN-MS-00303732				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4691	Email showing dates for extension of Passik's teletopic with additional dates	JAN-MS-00776179				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4692	Email about having Passik do extra teletopics and him wanting to increase his honoraria	JAN-MS-00303741				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4693	Spreadsheet of presentation times for the teletopic	JAN-MS-00303742				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4694	"Email showing they edited Brookoff's (other guy in teletopics) tape and just received the cut of Passik's so will be sending it for review shortly"	JAN-MS-00303673				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4695	"Email talking about reaching the caps on Passik's program as far as 600 sites per program; his reached capacity so no additional reservations allowed"	JAN-MS-00303694				AU; H; R; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4696	Tapentadol Global Commercial Team Long Term Safety and Tolerability of Fentanyl Buccal Tablet for the Treatment of Breakthrough pain in Opioid-Tolerant Patients with Chronic Pain: An 18-Month Study	JAN-MS-00457581				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4697		PDD801370892				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4698	Myra Christopher CV	JAN-MS-00935194				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4699	Lynn Webster CV	JAN-MS-00811437				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4700	Charles Argoff CV	JAN-MS-01545199				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4701	Michael J. Brennan CV	PPLPC031001254500				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4702	Perry Fine CV	FIN000001				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4703	Perry Fine CV	PPLP003376227				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4704	Michael J. Brennan CV	PPLP003400410				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4705	Howard Heit CV	JAN-MS-00924775				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4706	Howard Heit CV	JAN-MS-01474487				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4707	Steven Passik CV	PPLP003376435				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4708	Richard Payne CV	JAN-MS-01474511				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4709	June Dahl CV	TEVA_OK_00594176				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4710	Nat Katz CV	TEVA_OK_03012681				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4711	Steven Shoemaker CV	TEVA_OK_05175574				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4712	Russell Portenoy CV	TEVA_OK_03012702				AU; CON; INC; LF; P; R; PRE; H; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4713	Bill McCarberg CV	Acquired_Actavis_024 36054				AU; H; R; PRE; CON; CU; INC; LF; P; PO; 2701; V; INA	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4714	Bill McCarberg CV	PPLP003375946				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4715	2006 Pain Care Forum Directory	POK003341641				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4716	2007 Pain Care Forum Directory - Email	POK003341648				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4717	2007 Pain Care Forum Directory	POK003341649				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4718	2008 Email Pain Care Forum	POK003336130				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4719	2008 Pain Care Forum Directory	POK003336132				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4720	2009 Pain Care Forum Directory	JAN-MS-02494561				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4721	2010 Pain Care Forum Directory	JAN-MS-00922357				AU; PRE; H; First Amendment; J-MIL #3;	
S-4722	2011 Pain Care Forum Directory	JAN-MS-00874697				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-4723	2012 Pain Care Forum Directory	POK003436418				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4724	2012 Pain Care Forum Directory	JAN-MS-00926749				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4725	2013 Pain Care Forum Directory	JAN-MS-00992113				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4726	2014 Pain Care Forum Directory	JAN-MS-00996691				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4727	2015 Pain Care Forum Directory	JAN-MS-00994961				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4728	2016 Pain Care Forum Directory	POK003324976				AU; H; R; PRE; CON; CU; PO; INA; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-4729	2009 Opioid Treatment Guidelines	JAN-MS-00326173				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

Exhibit E

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1	09/2002	Charles E. Argoff, M.D., Pharmacologic Management of Chronic Pain, JAOA Supplement 3 Vol. 102 No. 9			Argoff (2018.12.18) EX. 002		
J2	2010	Bradley S. Galin, M.D. and Charles E. Argoff, M.D., "Defeat Chronic Pain Now!"			Argoff (2018.12.18) EX. 003		
J3	06/24/2009	Tapentadol Team Status - 2008/2009 Acute Pain Publications	JAN-MS-00323309	JAN-MS-00323309	Argoff (2018.12.18) EX. 020	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J4	3/25/2019	Materials Reviewed by Bruce Bagley, Ph.D.			Bagley (3.26.19) Ex. 2	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J5	3/26/2019	Further Explanation of Certain Disclosed Expert Opinion Testimony of Bruce Bagley, Ph.D.			Bagley (3.26.19) Ex. 3	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J6	04/2007	Guidelines for Reporting Violations of the Oklahoma Nursing Practice Act - Oklahoma Board of Nursing			Barnhouse (2019.01.18) EX. 04	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J7	1/8/2018	Email from Gina Stafford to Louise Robley re Board Update OU Nursing School 2018.ppt	OKNB-00003551	OKNB-00003551	Barnhouse (2019.01.18) EX. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J8	07/26/2018	Email from Jenny Barnhouse to Sheila St.Cyr re PAC Presentation / Diversion Surveillance OU Medicine, Inc.	OKNB-00004003	OKNB-00004003	Barnhouse (2019.01.18) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J9		Oklahoma State Department of Health Website - Tom Bates / About State Public Health			Bates (2019.03.12) EX. 01	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J10	4/11/2018	Letter from Tracy Wendling to LaQuanda Lewis of CDC re Annual Progress Report and Continuation Application for the Enhanced State Surveillance of Opioid -Involved Morbidity and Mortality cooperative agreement	OSDH-01541689	OSDH-01541690	Bates (2019.03.12) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J11	5/16/18	Letter from Tracy Wendling to LaQuanda Lewis of CDC re Annual Progress Report	OSDH-00405457	OSDH-00405458	Bates (2019.03.12) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J12	4/2/2018	Critical Bills of Interest - Oklahoma State Dept. of Health	OSDH-00118688	OSDH-00118691	Bates (2019.03.12) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J13	2014	2014 State of the State Health / Oklahoma State Dept. of Health	OSDH-00144684	OSDH-00144731	Bates (2019.03.12) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J14		Binder for Teva Topic Nos. 5, 6, 7, 9, 36 / Chart with Product Name; Strength; Form / Based on Teva's reasonable investigation			Beaman (2019.03.14) EX. 01		
J15		Binder for Teva Topic Nos. 11 & 12 - Understanding of the proper prescribing & appropriate use of Actiq, Fentora or other prescription Opioids manufactured by Teva			Beaman (2019.03.14) EX. 02		
J16	3/10/2019	Notice to Take Section 3232(C)(5) Videotaped Deposition of Corporate Representative(s) of the State			Beaman (2019.03.14) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J17		Disclosure of Expert Jason Beaman, D.O.			Beaman (2019.03.14) EX. 05		
J18	03/26/1999	Center for Drug Evaluation and Research Approval Package for Application No.20-747/S003 - Actiq			Beaman (2019.03.14) EX. 07		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J19	12/2016	Package insert for Actiq			Beaman (2019.03.14) EX. 08		
J20		Package Insert for Fentora			Beaman (2019.03.14) EX. 09		
J21	12/2011	Package Insert for Fentora			Beaman (2019.03.14) EX. 10		
J22	03/23/2004	Package Insert for Oxycodone Hydrochloride Extended-Release Tablets			Beaman (2019.03.14) EX. 11		
J23	2019	Oklahoma Administrative Code Title 317, Chapter 30, Subchapter 3, Part 1 - Creation and implementation of rules; applicability			Beaman (2019.03.14) EX. 12		
J24		Spreadsheet of prescriptions made and dispensed, 2004-2016			Beaman (2019.03.14) EX. 13	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J25		Spreadsheet showing reimbursements for Actiq & Fentora			Beaman (2019.03.14) EX. 14	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J26		Strategies Aimed at Controlling Misuse and Abuse of Opioid Prescription Medications in a State Medicaid Program: A Policymaker's Perspective Article, The American Journal of Drug and Alcohol Abuse			Beaman (2019.03.14) EX. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J27		Spreadsheet titled Generic Excerpts 2012			Beaman (2019.03.15) EX. 16	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J28		Spreadsheet titled Generic Excerpt 2012			Beaman (2019.03.15) EX. 17	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J29		Spreadsheet of Merged Claims Data for Patient 912853			Beaman (2019.03.15) EX. 18	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J30	06/20/2018	Facsimile from TeamHealth Sunrise Billing Center to Oklahoma Health Care Authority	OKAGSS_00225040	OKAGSS_00225131	Beaman (2019.03.15) EX. 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J31	07/30/2018	Fax from Sylvia Haynes to Oklahoma Health Care Authority	OKAGSS_00327531	OKAGSS_00327552	Beaman (2019.03.15) EX. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J32		Spreadsheet of Merged Claims Data with Dispensed Date from 2009-2016			Beaman (2019.03.15) EX. 21	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J33	2003	Package Insert for Duragesic	JAN-MS-00780844	JAN-MS-00780888	Beaman (2019.03.15) EX. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J34	03/04/2019	Notice to take Videotaped Expert Deposition of Jason Beaman, M.D.			Beaman (2019.03.26) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J35		Spreadsheet containing prescription data			Beaman (2019.03.26) EX. 02		
J36	03/22/19	Letter from Nancy L. Patterson to Reggie Whitten et al			Beaman (2019.03.26) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J37		Disclosure of Expert Witness Jason Beaman, D.O.			Beaman (2019.03.26) EX. 04		
J38		State's Responses to Teva Topic Nos. 5, 6, 7, 9, and 36			Beaman (2019.03.26) EX. 05		
J39		State's Responses to Teva Topic Nos. 11 and 12			Beaman (2019.03.26) EX. 06		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J40	08/03/2017	Andrew Ross, et al., Methodological quality of systematic reviews referenced in clinical practice guidelines for the treatment of opioid use disorder, PLoS ONE 12(8), e0181927			Beaman (2019.03.26) EX. 07		
J41	03/18/2016	CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016, Morbidity and Mortality Weekly Report, Vol. 65, No. 1, 18 March 2016			Beaman (2019.03.26) EX. 08		
J42		Spreadsheet of Actiq and Fentora prescriptions			Beaman (2019.03.26) EX. 09	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J43		Spreadsheet of Reimbursements			Beaman (2019.03.26) EX. 10	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J44		Spreadsheet of merged claims data for Patient ID No. 912853			Beaman (2019.03.26) EX. 11	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J45		Spreadsheet of merged claims data on Patient ID No. 909237			Beaman (2019.03.26) EX. 13	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J46		Medical records of Patient ID No. 909237	OKAGSS_00226803	OKAGSS_00226807	Beaman (2019.03.26) EX. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J47		Spreadsheet of merged claims data for Patient ID No. 573966			Beaman (2019.03.26) EX. 15	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J48	7/30/2018	Facsimile from Sylvia Haynes to Oklahoma Health Care Authority re Patient ID No. 573966 medical records	OKAGSS_00327531	OKAGSS_00327552	Beaman (2019.03.26) EX. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J49		Spreadsheet of merged claims data re Patient ID No. 965115			Beaman (2019.03.26) EX. 17	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J50	06/25/2018	Medical records re Patient ID No. 965115	OKAGSS_00233933	OKAGSS_00233343	Beaman (2019.03.26) EX. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J51		Spreadsheet of merged claims data re Patient ID No. 917788			Beaman (2019.03.26) EX. 19	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J52		Medical records for Patient ID No. 917788	OKAGSS_00167322	OKAGSS_00167349	Beaman (2019.03.26) EX. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J53		Spreadsheet of merged claims data for Patient ID No. 159615			Beaman (2019.03.26) EX. 21	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J54		Medical records for Patient ID No. 159615	OKAGSS_00063485	OKAGSS_00063528	Beaman (2019.03.26) EX. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J55		Spreadsheet of merged claims data for Patient ID No. 273627			Beaman (2019.03.26) EX. 23	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J56		Medical records for Patient ID No. 273627	OKAGSS_00071915	OKAGSS_00071941	Beaman (2019.03.26) EX. 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J57		Spreadsheet of merged claims data for Patient ID No. 155892			Beaman (2019.03.26) EX. 25	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J58		Medical records for Patient ID No. 155892	OKAGSS_00124468	OKAGSS_00124494	Beaman (2019.03.26) EX. 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J59		Spreadsheet of merged claims data for Patient ID No. 908951			Beaman (2019.03.26) EX. 27	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J60		Medical records for Patient ID No. 908951	OKAGSS_00037714	OKAGSS_00037730	Beaman (2019.03.26) EX. 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J61		Spreadsheet of merged claims data for Patient ID No. 273172			Beaman (2019.03.26) EX. 29	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J62		Medical records for Patient ID No. 273172	OKAGSS_00119906	OKAGSS_00119932	Beaman (2019.03.26) EX. 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J63		Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors			Beaman (2019.03.27) EX. 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J64	5/24/2018	Ashok Kache, M.D., Patient ICN No. 2510307329029 Medical Records	OKAGSS_00077627	OKAGSS_00077674	Beaman (2019.03.27) EX. 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J65		Patient No. 47627 Merged Claims Data			Beaman (2019.03.27) EX. 33	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J66	8/8/2018	Patient No. 47627 Medical Records	OKAGSS_00001040	OKAGSS_00001111	Beaman (2019.03.27) EX. 34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J67		Patient No. 295864 Merged Claims Data			Beaman (2019.03.27) EX. 35	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J68	06/15/2018	Patient No. 295864 Medical Records	OKAGSS_00212405	OKAGSS_00212510	Beaman (2019.03.27) EX. 36	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J69	06/27/2018	Patient No. 264620 Medical Records	OKAGSS_00110313	OKAGSS_00110339	Beaman (2019.03.27) EX. 37	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J70	07/12/2018	Patient No. 730957 Medical Records	OKAGSS_00110047	OKAGSS_00110078	Beaman (2019.03.27) EX. 38	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J71	02/04/2005	Duragesic Label (Fentanyl Transdermal Systems) 2005	JAN-MS-00780844	JAN-MS-00780888	Beaman (2019.03.27) EX. 39		
J72	05/24/2018	Patient ID No. 573966 Medical Records	OKAGSS_00111168	OKAGSS_00111213	Beaman (2019.03.27) EX. 40	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J73	10/2009	Oklahoma SoonerCare DUR Update for Pharmaceutical Industry Representatives, October 2009			Beasley (2019.02.12) EX. 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J74	3/20/2018	Letter from Andrew Eveleth to Reggie Whitten attaching a list of materials reviewed by Dr. Berry			Berry (2019.03.21) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J75		Expert Disclosure - Expected Expert Opinion Testimony of James Berry, M.D			Berry (2019.03.21) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J76	3/20/2019	Materials Supporting the Expert Opinion of James Berry, M.D.			Berry (3.21.19) Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J77	07/06/2017	Email from Nate Brown to Kevin Duckworth re EBP ribbon with attached Oklahoma Risk Assessment Tools, June 2017 by Ricci Cross	ODOC-00023510	ODOC-00023510	Brown (2018.12.18) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J78	7/7/2017	Email from Bruce to Anthony (OSBOE-00010654)	OSBOE-00010654		Bruce (2.19.19) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J79	11/15/2017	Anthony email to Bruce (OSBOE-00011197)	OSBOE-00011197		Bruce (2.19.19) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J80	6/21/2012	Oklahoma State Board of Osteopathic Examiners' Order of Revocation re: C. Allen Moore, D.O.	OSBOE-00001386		Bruce (2.19.19) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J81	6/20/2013	Oklahoma State Board of Osteopathic Examiners Regular Quarterly Board Meeting	OSBOE-00001993		Bruce (2.19.19) Ex. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J82	6/18/2015	Oklahoma State Board of Osteopathic Examiners' Findings of Fact, Conclusions of Law and Agreed Order re: Jacob Andrew Moore, D.O.	OSBOE-00002630		Bruce (2.19.19) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J83	3/17/2016	Oklahoma State Board of Osteopathic Examiners' Order Clarifying Terms and Conditions re: D. Scott Dycus, D.O.	OSBOE-00001960		Bruce (2.19.19) Ex. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J84	6/15/2017	Oklahoma State Board of Osteopathic Examiners' Findings of Fact, Conclusion of law and Order of Probation re: Margie D. Ott, D.O.	OSBOE-00003758		Bruce (2.19.19) Ex. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J85	1/4/2018	Zimmer email to Herndon attaching Oklahoma State Board of Osteopathic Examiners' December 2017 Board Orders	OHCA-00421727		Bruce (2.19.19) Ex. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J86		The Oklahoma Osteopathic Medicine Act, Title 59 Sections 620-645; 650			Bruce (2.19.19) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J87		Administrative Rules for the State Board of Osteopathic Examiners, Title 510			Bruce (2.19.19) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J88		Oklahoma State Board of Osteopathic Examiners Powerpoint	OSBOE-00005448		Bruce (2.19.19) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J89		Oklahoma State Board of Osteopathic Examiners Powerpoint	OSBOE-00005450		Bruce (2.19.19) Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J90	2/19/2013	Email from Subera to Archer and Bruce	OSBOE-00005965		Bruce (2.19.19) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J91	7/4/2013	Email from Subera to Ogle, Couch, and Bruce	OSBOE-00006990		Bruce (2.19.19) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J92	5/14/2014	Email from Bruce to Langerman et al.	OSBOE-00008285		Bruce (2.19.19) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J93		Resume of Deborah Bruce	OSBOE-00008425	OSBOE-00008425	Bruce (2019.02.19) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J94		The Oklahoma Osteopathic Medicine Act - Regulation & Licensing			Bruce (2019.02.19) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J95	9/11/2016	State of Oklahoma - Title 510: State Board of Osteopathic Examiners			Bruce (2019.02.19) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J96		PowerPoint Presentation re Oklahoma State Board of Osteopathic Examiners; Learning Objectives by D. Bruce	OSBOE-00005448	OSBOE-00005448	Bruce (2019.02.19) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J97		PowerPoint Presentation re Oklahoma State Board of Osteopathic Examiners by Deborah Bruce & LeRoy E. Young	OSBOE-00005450	OSBOE-00005450	Bruce (2019.02.19) EX. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J98	2/19/2013	Email from Layne Subera to Pam Archer & Deborah Bruce re Prescribing Guidelines - Materials to Review	OSBOE-00005965	OSBOE-00005967	Bruce (2019.02.19) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J99	7/4/2013	Email from Layne Subera to Michael Ogle re OBND Prescription Monitoring Program	OSBOE-00006990	OSBOE-00006993	Bruce (2019.02.19) EX. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J100	5/19/2014	Email from D. Bruce to B. Langerman and L. Subera re Letter	OSBOE-00008285	OSBOE-00008288	Bruce (2019.02.19) EX. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J101	7/7/2017	Email from D. Bruce to Scott Anthony re Help / Pain Management	OSBOE-00010654	OSBOE-00010655	Bruce (2019.02.19) EX. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J102	11/15/2017	Email from Scott Anthony to D. Bruce re Did she ask you / AG's Opioid Commission in December - going to promote the interests of the pain patient	OSBOE-00011197	OSBOE-00011197	Bruce (2019.02.19) EX. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J103	6/21/2012	Order of Revocation; Findings of Fact, Conclusions of Law & Emergency Order of Suspension; Emergency Order; Emergency Complaint; Citation & Notice of Hearing / State Board of Osteopathic Examiners State of Oklahoma v. C. Allen Moore	OSBOE-00001386	OSBOE-00001400	Bruce (2019.02.19) EX. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J104	6/20/2013	Oklahoma State Board of Osteopathic Examiners with Regular Quarterly Board Meeting / Collection of Pleadings related to State of Oklahoma v. David Moon	OSBOE-00001996	OSBOE-00001996	Bruce (2019.02.19) EX. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J105	4/28/2015	Collection of Pleadings related to Jacob Andrew Moore / State of Oklahoma v. Jacob Andrew Moore	OSBOE-00002630	OSBOE-00002637	Bruce (2019.02.19) EX. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J106	3/16/2016	Collection of Pleadings related to Scott Dycus / State of Oklahoma v. D. Scott Dycus	OSBOE-00001960	OSBOE-00001978	Bruce (2019.02.19) EX. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J107	6/15/2017	Collection of Pleadings related to Margie Ott / State of Oklahoma v. Margie D. Ott	OSBOE-00003758	OSBOE-00003767	Bruce (2019.02.19) EX. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J108	1/4/2018	Email from Richard Zimmer to Micheal W. Herndon re OSBOE December 2017 Board Orders with attached compilation of pleadings re State of Oklahoma v. May Kathryn Mercer	OHCA-00421728	OHCA-00421748	Bruce (2019.02.19) EX. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J109	02/06/2012	Email from Linda Barefoot to Jeff Buel	SFC00007801	SFC00007802	Buel (2019.02.05) EX. 08		
J110	10/12/2011	Email from Margaret Quinn to Malcolm Monaghan	JAN-MS-00935073	JAN-MS-00935076	Buel (2019.02.05) EX. 13		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J111	11/15/2018	GAO-04-110, OxyContin Abuse and Diversion and Efforts to Address the Problem			Cambra (11.15.18) Ex. 13		
J112	09/29/2017	Oklahoma Commission on Opioid Abuse Meeting Minutes / Second Meeting, 09/29/2017			Carter (2018.12.18) EX. 008		
J113	11/2013	A State Plan - Reducing Prescription Drug Abuse in Oklahoma			Carter (2018.12.18) EX. 017		
J114	8/15/2016	Oklahoma Health Care Authority Pharmacy Services / Brand Name Oxycontin			Carter (2018.12.18) EX. 019	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J115	03/2018	Oklahoma Department of Corrections Drug of Formulary	ODOC-00001764	ODOC-00001820	Castleberry (2018.09.05) EX. 007	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J116	08/2018	Oklahoma Department of Corrections Drug of Formulary			Castleberry (2018.09.05) EX. 008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J117	7/8/2016	Oklahoma Opioid Prescribing Guidelines			Castleberry (2018.09.05) EX. 009	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J118	11/1/2017	MSRM Guide for Detoxification	ODOC-00001741	ODOC-00001746	Castleberry (2018.09.05) EX. 014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J119	04/17/2018	Resource Manual MSRM re Use of Naloxone (Narcan)	ODOC-00001729; O	ODOC-00001729; O	Castleberry (2018.09.05) EX. 015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J120	3/20/2018	Press Release re American Correctional Association & American Society of Addiction Medicine Release Joint Policy Statement on Opioid Use Disorder Treatment in the Justice System			Castleberry (2018.09.05) EX. 016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J121	03/06/2018	Operational Policy of Care of the Actively Chemical Dependent Inmate	ODOC-00001420	ODOC-00001421	Castleberry (2018.09.05) EX. 017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J122	3/26/2001	[Email] Key reprints presentation used in IPT	JAN-MS-00304252	JAN-MS-00304252	Chupa (1/9/2019) EX. 03		
J123	3/26/2001	Key reprints presentation used in IPT	JAN-MS-00304253	JAN-MS-00304253	Chupa (1/9/2019) EX. 03		
J124	7/16/2002	[Email] Dawn Q&A re: Potential for Misuse of Duragesic	JAN-MS-00781332	JAN-MS-00781332	Chupa (1/9/2019) EX. 06		
J125	7/16/2002	Q&A, Potential for Misuse of Duragesic	JAN-MS-00781333	JAN-MS-00781333	Chupa (1/9/2019) EX. 06		
J126	4/17/2001	Palladone Backgrounder Update	JAN-MS-00304039	JAN-MS-00304039	Chupa (1/9/2019) EX. 07		
J127	11/5/2002	[Email] Duragesic Clinical Presentation-Psychological Abuse with Opioids	JAN-MS-00786434	JAN-MS-00786434	Chupa (1/9/2019) EX. 10		
J128	11/5/2002	Psychological Dependence with Opioids: Focus on Duragesic	JAN-MS-00786435	JAN-MS-00786435	Chupa (1/9/2019) EX. 10		
J129	2/2/2005	Drug Information for Duragesic Letter	JAN-MS-00776286	JAN-MS-00776287	Chupa (1/9/2019) EX. 12		
J130		Disclosure of Expert Witness Dr. Daniel Clauw, M.D.			Clauw (2019.03.26) EX. 01		
J131	2009	Schatzberg M.D., Alan & Nemeroff M.D., Charles., The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Ed., Ch. 66, pp.1441-1474, 2009			Clauw (2019.03.26) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J132		Disclosure of Expert Witness Jason Beaman, D.O.			Clauw (2019.03.26) EX. 05		
J133	2008	Clauw, M.D. Daniel, Pharmacotherapy for Patients With Fibromyalgia, J Clin Psychiatry, 69, pp. 25-29, 2008			Clauw (2019.03.26) EX. 06		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J134	05/26/2016	Stanos Steven, et al., Rethinking Chronic Pain in a Primary Care Setting, Vol 128, No. 5, pp. 502-515, 2016			Clauw (2019.03.26) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J135	06/12/2018	Curriculum Vitae Daniel J. Clauw, M.D.			Clauw (2019.03.26) EX. 08		
J136	12/2011	Proposed Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)			Clauw (2019.03.26) EX. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J137		Disclosure of Expert Witness Joshua Cohen			Cohen (2019.01.01) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J138		Further Disclosure of Expert Witness Joshua P. Cohen, Ph.D.			Cohen (2019.01.01) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J139		Materials Reviewed by Joshua P. Cohen, Ph.D.			Cohen (2019.01.01) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J140	4/1/2019	Further Explanation of Certain Disclosed Opinion Testimony of Joshua Cohen, Ph.D.			Cohen (4.1.19) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J141	4/1/2019	Materials Reviewed by Joshua Cohen, Ph.D.			Cohen (4.1.19) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J142	2007	[Report] Responsible Opioid Prescribing: A Physician's Guide by Scott M. Fishman, MD			Colligen (11/27/2018) EX. 09		
J143		Handwritten Notes re People Spoken With & Other Involved			Colligen (2018.11.27) EX. 001	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J144		Topic 41 Reference Binder 1 of 2			Colligen (2019.01.31) EX. 003A	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J145		Topic 41 Reference Binder 2 of 2			Colligen (2019.01.31) EX. 003B	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J146		Topic 41 Reference Binder (1 of 2)			Colligen (2019.01.31) EX. 03A	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J147		Topic 41 Reference Binder (2 of 2)			Colligen (2019.01.31) EX. 03B	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J148	11/01/2006	63 Okl.St. Ann. section 5030.1 - Medicaid Drug Utilization Review Board			Cothran (2019.02.27) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J149	09/12/1994	U.S. vs. Clary, 34F.3d 709 (1994)			Courtwright (2019.03.22) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J150	12/21/2018	The State's Expert Witness Disclosures			Courtwright (2019.03.22) EX. 03		
J151		Courtwright David T., Dark Paradise: A History of Opiate Addiction in America, Excerpt pp. 6-7			Courtwright (2019.03.22) EX. 04		
J152		Courtwright David T., Dark Paradise: A History of Opiate Addiction in America, Excerpt pp. 260-261			Courtwright (2019.03.22) EX. 05		
J153		Disclosure of Expert Witness Dr. Julie Croff, Ph.D., MPH			Croff (2019.03.28) EX. 02		
J154		Disclosure of Expert Witness Christopher J. Ruhm Ph.D.			Croff (2019.03.28) EX. 03		
J155	3/15/2019	Amended Expected Expert Opinion Testimony of Richard De La Garza, Ph.D.			De La Garza (3.20.19) Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J156	3/19/2019	Materials Reviewed by Richard De La Garza, Ph.D.			De La Garza (3.20.19) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2402	
J157	12/26/2000	News releases; Healthbeat: Hospitals Told to Treat Patients' Pain, New Efforts Against an Old Foe: Pain by Laurie Tarkan	JAN-MS-00311736	JAN-MS-00311741	Deem-Eshelman (2018.12.19) EX. 019		
J158	11/01/2017	The President's Commission on Combating Drug Addiction and The Opioid Crisis			Deem-Eshelman (2018.12.19) EX. 020		
J159		Chronology of the Declaration of the Fifth Vital Sign - Chronology of the Declaration of the Fifth Vital Sign			Deem-Eshelman (2018.12.19) EX. 021		
J160	10/08/2002	Duragesic: The Tipping Point 2003 Tactical Plan			Deem-Eshelman (2018.12.19) EX. 026		
J161	04/26/2006	Treating Pain in the 21st Century: How to Reduce Abuse and Diversion - Proposal for a CME/CE initiative	JAN-MS-00411490	JAN-MS-00411496	Deem-Eshelman (2018.12.19) EX. 027		
J162		Johnson & Johnson Code of Business Conduct / Live Our Credo, Know Our Code by Alex Gorsky			Deem-Eshelman (2019.02.05) EX. 03		
J163	8/25/2004	Pain Therapeutic Area Strategy - New Product Development Committee			Deem-Eshelman (2019.02.07) EX. 78		
J164	07/2004	Medical Affairs Agenda - Medical Science Liaison Report	JAN-MS-01203019	JAN-MS-01203030	Deem-Eshelman (1/25/2019) EX. 02		
J165	7/2/2015	"Use of Opioid Analgesics in Pain Management" by Keith Candiotti, M.D.	JAN-MS-03090610	JAN-MS-03090613	Deem-Eshelman (1/25/2019) EX. 08		
J166	6/17/2002	Appropriate Opioid Pharmacotherapy for Chronic Pain Management	OKEXPERT-00013098	OKEXPERT-00013011	Deem-Eshelman (1/25/2019) EX. 09		
J167	7/8/2003	[Email] RE: Top 10 KOLs for all JPI business	JAN-MS-00481527	JAN-MS-00481531	Deem-Eshelman (1/25/2019) EX. 1		
J168	1/16/2013	NUCYNTA ER/ NUCYNTA Pain Force Core Targets Analytics	JAN-MS-00826110	JAN-MS-00826113	Deem-Eshelman (1/25/2019) EX. 10		
J169	11/30/2001	Executive Summary: Chronic Pain Scientific Advisory Board	JAN-MS-00654435	JAN-MS-00654444	Deem-Eshelman (1/25/2019) EX. 14		
J170	1/25/2019	Defendant's Written Responses and Objections to Topic 17 and 43			Deem-Eshelman (1/25/2019) EX. 17		
J171		Data and Analytics Summary Sheet			Deem-Eshelman (12/18/2018) EX. 03		
J172	7/27/2010	NUCYNTA 2011 Business Plan (Draft)	JAN-MS-00132333	JAN-MS-00132386	Deem-Eshelman (12/18/2018) EX. 05		
J173	12/12/2012	Nucynta & Nucynta ER 2012 Business Plan	JAN-MS-00010801	JAN-MS-00010885	Deem-Eshelman (12/18/2018) EX. 09		
J174		[PowerPoint] Training Workshops - Nucynta & Nucynta ER	JAN-MS-00668921	JAN-MS-00668921	Deem-Eshelman (12/18/2018) EX. 12		
J175		Medical Education and Medical Communication Summary Sheet			Deem-Eshelman (12/19/2018) EX. 22		
J176	10/18/2010	Grant Request to PriCara: Pain Management Strategies for the Hospital-Based Care Team: Focus on Pain Related Osteoarthritis, Diabetic Neuropathy, and Cancer	JAN-MS-00626860	JAN-MS-00626893	Deem-Eshelman (12/19/2018) EX. 28		
J177		Medical Science Liaisons Summary Sheet			Deem-Eshelman (12/19/2018) EX. 29		
J178	7/19/2001	Medical Affairs Pain and Mycology Franchise Quarterly Meeting Presentation	JAN-MS-02321925	JAN-MS-02321925	Deem-Eshelman (12/19/2018) EX. 30		
J179	2/25/2019	Contributions to Advocacy Organizations			Deem-Eshelman (2/25/2019) EX. 79		
J180	1/25/2019	Janssen KOL Payment History			Deem-Eshelman (2/25/2019) EX. 80		
J181	2/5/2019	Continuing Medical Education			Deem-Eshelman (2/25/2019) EX. 81		
J182	7/2/2009	Beth Israel Medical Center Invoice to Ortho-McNeil Janssen	JAN-MS-00394853	JAN-MS-00394853	Deem-Eshelman (2/25/2019) EX. 86		
J183	9/15/2009	Beth Israel Medical Center Invoice to Ortho-McNeil Janssen	JAN-MS-00395835	JAN-MS-00395835	Deem-Eshelman (2/25/2019) EX. 87		
J184	2003	[PDF] DURAGESIC (Fentanyl transdermal system) CII- 2003 Business Plan Summary	JAN-MS-00726353	JAN-MS-00726386	Deem-Eshelman (2/25/2019) EX. 88		
J185	7/21/2009	Nucynta IR & ER 2010 Business Plan	JAN-MS-00454883	JAN-MS-00454883	Deem-Eshelman (2/25/2019) EX. 96		
J186		Growing Pains Website - Accepting the Pain			Deem-Eshelman (2/25/2019) EX. 13		
J187		Growing Pains Website - Know Your Emotions			Deem-Eshelman (2/25/2019) EX. 14		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J188		Growing Pains Website - Communicating to Others			Deem-Eshleman (2/5/2019) EX. 15		
J189		Growing Pains Website - Family			Deem-Eshleman (2/5/2019) EX. 16		
J190		Growing Pains Website - Parents			Deem-Eshleman (2/5/2019) EX. 17		
J191		Growing Pains Website - Know Your Rights			Deem-Eshleman (2/5/2019) EX. 18		
J192		Growing Pains Website - Assert Your Rights			Deem-Eshleman (2/5/2019) EX. 19		
J193		Growing Pains Website - Assert Your Rights			Deem-Eshleman (2/5/2019) EX. 20		
J194	01/2013	Pain Care Forum - Participating Organizations	JAN-MS-00992093	JAN-MS-00992093	Deem-Eshleman (2/6/2019) EX. 41		
J195	8/30/2012	PAINS Project - 2012 Annual Meeting - Invitees	JAN-MS-00411906	JAN-MS-00411907	Deem-Eshleman (2/5/2019) EX. 42		
J196	3/28/2011	[Email] Prescribe Responsibly Copy & Insert: Pain Resource Guide	JAN-MS-00320771	JAN-MS-00320771	Deem-Eshleman (2/6/2019) EX. 50		
J197	06/2009	Pain Resource Guide	JAN-MS-00320772	JAN-MS-00320803	Deem-Eshleman (2/6/2019) EX. 50		
J198	2/5/2019	Defendant's Written Responses and Objections to Topic 23			Deem-Eshleman (2/6/2019) EX. 54		
J199	2/5/2019	Contributions to Advocacy Organizations			Deem-Eshleman (2/6/2019) EX. 55		
J200	8/29/2011	NUCYNTA ER Train-the-Trainer	JAN-MS-00064792	JAN-MS-00064792	Deem-Eshleman (2/6/2019) EX. 57		
J201		Non-Branded Promotion	JAN-MS-00442058	JAN-MS-00442058	Deem-Eshleman (2/6/2019) EX. 62		
J202	11/2011	Mutual Accountability for Pain - Driving Demand for NUCYNTA and NUCYNTA ER	JAN-MS-00937860	JAN-MS-00937904	Deem-Eshleman (2/7/2019) EX. 63		
J203	3/4/2010	A Call to Revolutionize Chronic Pain Care in America: An Opportunity in Health Care Reform			Deem-Eshleman (2/7/2019) EX. 64		
J204	11/14/2012	[Email] PAINS Update	JAN-MS-00948094	JAN-MS-00948094	Deem-Eshleman (2/7/2019) EX. 65		
J205	11/14/2012	List of Companies that Contributed to Develop PAINS	JAN-MS-00948095	JAN-MS-00948095	Deem-Eshleman (2/7/2019) EX. 65		
J206	2009	Finding Relief: Pain Management in Older Adults			Deem-Eshleman (2/7/2019) EX. 68		
J207	12/6/2010	[Email] Permission to Reproduce APF Materials	JAN-MS-00329343	JAN-MS-00329343	Deem-Eshleman (2/7/2019) EX. 69		
J208	12/6/2010	Target Chronic Pain Notebook	JAN-MS-00329344	JAN-MS-00329381	Deem-Eshleman (2/7/2019) EX. 69		
J209	12/6/2010	[Email] Permission to Reproduce APF Materials	JAN-MS-00329331	JAN-MS-00329331	Deem-Eshleman (2/7/2019) EX. 70		
J210	12/6/2010	Target Chronic Pain Provider Card	JAN-MS-00329332	JAN-MS-00329337	Deem-Eshleman (2/7/2019) EX. 70		
J211	12/6/2010	[Email] Re: Permission to Reproduce APF Materials	JAN-MS-00250471	JAN-MS-00250471	Deem-Eshleman (2/7/2019) EX. 71		
J212	12/6/2010	Top 10 Tips: Making the Most of Your Medical Visits (tip sheet)	JAN-MS-00250472	JAN-MS-00250473	Deem-Eshleman (2/7/2019) EX. 71		
J213	07/06/2008	Expert Report of John Duncan, Ph.D.			Duncan (2019.03.27) EX. 03		
J214	12/21/2018	The State's Expert Witness Disclosures			Duncan (2019.03.27) EX. 04		
J215		Curriculum Vitae John L. Duncan, Ph.D.			Duncan (2019.03.27) EX. 05		
J216		Disclosure of Expert Witness Dr. John Duncan, Ph.D.			Duncan (2019.03.27) EX. 06		
J217	09/18/2006	Email from Darrell Waiver to Portia McNeil	OBN-00113236	OBN-00113248	Duncan (2019.03.27) EX. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J218	09/25/2014	Oklahoma Bureau of Narcotics ACISS Investigative Supplemental Report	OKAG-00145612	OKAG-00145620	Duncan (2019.03.27) EX. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J219	05/04/2007	Email from Margie Miller to Lyle Kelsey re Replacement Speaker for Dr. John Duncan / With attached Addiction and Drug-Seeking Behavior PowerPoint (5/4/2007)	OKMB-00109101	OKMB-00109103	Duncan (2019.03.27) EX. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J220	3/12/2019	Oklahoma ex rel. OBND v. Kathy's Pharmacy			Edminsten (3.12.19) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J221	3/12/2019	Email re: 10 Additional Diversion Agents			Edminsten (3.12.19) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J222	3/12/2019	Email re: Prescription Paper Problem			Edminsten (3.12.19) Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J223	3/12/2019	Email re: Omnibus Diversion Project			Edminsten (3.12.19) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J224	03/2008	Scott M. Fishman, M.D. Curriculum Vitae	FISH00000001	FISH00000046	Fishman (2019.02.26) Ex. 001		
J225	3/1/2009	Scott M. Fishman, M.D., Responsible Opioid Prescribing: A Physician's Guide			Fishman (2019.02.26) Ex. 026		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J226	8/1/2018	Settlement Agreement & Mutual General Release	PLTF_2804_0000045	PLTF_2804_0000045	Fishman (2019.02.27) EX. 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J227		Prescription Opioid Forgery: Reporting to Law Enforcement and HIPAA, by Naileshni Singh, M.D., Scott Fishman, M.D., Anna Oriowski, J.D., and Ben Rich, J.D., Ph.D.	FISH00000933	FISH00000951	Fishman (2019.02.27) EX. 34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J228		Scott M. Fishman, M.D., Responsible Opioid Prescribing: A Clinician's Guide (Second Edition Revised and Expanded)	FISH00006902	FISH007050	Fishman (2019.02.27) EX. 37		
J229	7/1/1999	Scott M. Fishman et al., "The Opioid Contract in the Management of Chronic Pain," J. Pain and Symptom Management, Vol. 18 No. 1			Fishman (2019.02.27) EX. 39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J230		Duragesic Label	JAN-MS-00780844	JAN-MS-00780888	Fishman (2019.02.27) EX. 40	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J231	8/1/2018	Settlement Agreement and Mutual General Release	OKPURDFISH000006	OKPURDFISH000045	Fishman (2019.02.27) EX. 41	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J232	2009	Derek McGinnis, Exit Wounds: A Survival Guide to Pain Management for Returning Veterans and Their Families			Fishman (2019.02.27) EX. 45		
J233	2012	Chapter 1, The Clinician's Dilemma: Under-Treated Pain Versus Prescription Drug Misuse	FISH00000609	FISH 000619	Fishman (2019.02.27) EX. 46	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J234		Email string, from Mary Vargas to Scott Fishman, re: So it didn't take long			Fishman (2019.02.27) EX. 47	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J235	2/26/2012	Email string, from Mary Vargas to Scott Fishman, re: So it didn't take long	FISH00007069	FISH007070	Fishman (2019.02.27) EX. 48	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J236		Binder of select documents reviewed by deponent in preparation of testimony			Fitzsimons (2018.06.01) EX. 003	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J237		Composite Janssen Deponent Documents (Fitzsimons)			Fitzsimons (2018.06.01) EX. 003	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J238	04/2008	Briefing Document of Tasmanian Alkaloids Pty Ltd			Fitzsimons (2018.06.01) EX. 004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J239	07/19/2014	The New York Times Shake-Up on Opium Island			Fitzsimons (2018.06.01) EX. 010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J240	3/28/2019	Materials Reviewed by Timothy Fong, M.D.			Fong (3.29.19) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J241	06/30/2017	Original Petition			Fugh-Berman (2019.03.06) EX. 01		
J242	02/19/2019	Notice to take Section 3230(C) Videotaped Deposition of the State's Expert Witness & Subpoena Duces Tecum			Fugh-Berman (2019.03.06) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J243	07/20/2012	In re Prempro Products Liability Litigation v. Wyerth, et al., 2012 WL 12918418 (E.D. Ark. July 20, 2012)			Fugh-Berman (2019.03.06) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J244	08/29/2012	In re Prempro Products Liability Litigation v. Wyerth, et al., 2012 WL 12906583, (E.D. Ark. Aug. 29, 2012)			Fugh-Berman (2019.03.06) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J245	09/16/2011	IEA v Wyeth LLC, 2011 WL 13195974 (E.T. Tex. Sept. 16, 2011)			Fugh-Berman (2019.03.06) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J246	01/14/2014	Allen v Takeda Pharms., et al., 2014 U.S. LEXIS 5289 (W.D. La. Jan. 14, 2014)			Fugh-Berman (2019.03.06) EX. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J247		Curriculum Vitae Adriane Fugh-Berman, M.D.			Fugh-Berman (2019.03.06) EX. 07		
J248		Expert Disclosure for Dr. Adriane Fugh-Berman, M.D.			Fugh-Berman (2019.03.06) EX. 08		
J249		Call Notes			Fugh-Berman (2019.03.06) EX. 09		
J250		Handwritten Notes			Fugh-Berman (2019.03.06) EX. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J251		Typewritten notes			Fugh-Berman (2019.03.06) EX. 11		
J252		Total Sales Calls in Oklahoma 1994-2017			Fugh-Berman (2019.03.06) EX. 13		
J253	12/10/2010	Email from E. Anderson to R. Marshall to Russell Marshall	JAN-OK-00134401	JAN-OK-00134402	Fugh-Berman (2019.03.06) EX. 14		
J254	05/06/2013	Oklahoma City, Ken Murphy Presentation			Fugh-Berman (2019.03.06) EX. 16		
J255	08/03/2009	Email from Jean Nycz to Lisa Ferguson	JAN-MS-00358879	JAN-MS-00358880	Fugh-Berman (2019.03.06) EX. 17		
J256		The President's Commission on Combating Drug Addiction & The Opioid Crisis Report			Fugh-Berman (2019.03.06) EX. 18		
J257	4/10/2008	Email from Lynn Leonard to Ron Kuntz	JANS-MS-00500562	JANS-MS-00500562	Fugh-Berman (2019.03.06) EX. 21		
J258	6/12/2000	Memo from Medical Services, Product, Sales Training to 275 Field Sales Force, etc.	JAN-MS-02767597	JAN-MS-02767598	Fugh-Berman (2019.03.06) EX. 22		
J259		Warning Letter from Thomas W. Abrams, RPh, MBA to Ajit Shetty, M.D.	JAN-MS-00747492	JAN-MS-00747496	Fugh-Berman (2019.03.06) EX. 23		
J260	4/10/2008	Email from Lynn Leonard to Ron Kuntz	JAN-MS-00500562	JAN-MS-00500562	Fugh-Berman (2019.03.06) EX. 24		
J261	3/14/2002	Duragesic Disease Modeling Workshop 2 Takeaways Report March 14, 2002			Fugh-Berman (2019.03.06) EX. 25		
J262	2/18/2002	Email from Heather Thomson to Michele Cole; Marina Rijaenova and Karen Ceung	JAN-MS-00492412	JAN-MS-00492413	Fugh-Berman (2019.03.06) EX. 26		
J263		Duragesic - Market Research: Trends in Promotion & Message Delivery Presentation			Fugh-Berman (2019.03.06) EX. 27		
J264	05/22/2000	Advertisement: Leadership Summit On Pain Management - New Standards Expectation for Pain Assessment & Treatment on May 22, 2000 & July 31, 2000	PDD1502321109	PDD1502321148	Fugh-Berman (2019.03.06) EX. 32		
J265	1/19/1999	Patient Evaluation Initiative	PDD1701018048	PDD1701018048	Fugh-Berman (2019.03.06) EX. 33		
J266	8/23/2000	Speaker's Bureau Speaker Recommendation Form	PDD1701311A26	PDD1701311A28	Fugh-Berman (2019.03.06) EX. 40		
J267		Summary re Prescription Drug Overdose Prevention for States and State Innovation Model	OSDH-00030523	OSDH-00030524	Geiger (2018.03.29) EX. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J268	2/5/2019	Supplemental Disclosure by James L. Gibson			Gibson (2019.03.11) EX. 003		
J269	12/21/2018	December Disclosure by James Gibson			Gibson (2019.03.11) EX. 02		
J270		Expert Disclosure by James L. Gibson, Ph.D.			Gibson (2019.03.11) EX. 03		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J271		Disclosure by Jason Beaman / Dr. Beaman is expected to offer an expert opinion on matters related to addiction			Gibson (2019.03.11) EX. 04		
J272	10/2016	Curtis S. Florence, PhD., et al., The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013			Gibson (2019.03.12) EX. 06		
J273	12/21/2018	The State's Expert Witness Disclosures			Griffith (2019.02.22) EX. 01		
J274	2/15/2019	Notice to take Section 3230(C) Videotaped Deposition of the State's Expert Witness			Griffith (2019.02.22) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J275	2/18/2019	Amended Notice to take Section 3230(C) Videotaped Deposition of the State's Expert Witness and Subpoena Duces Tecum			Griffith (2019.02.22) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J276		Curriculum Vitae Ty D. Griffith			Griffith (2019.02.22) EX. 04		
J277		LinkedIn page Ty Griffith			Griffith (2019.02.22) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J278	5/18/2018	Weekend Schedule for Seminar held on 05/18-19/2018			Griffith (2019.02.22) EX. 06		
J279	12/2003	United States General Accounting Office Report to Congressional Requesters - Prescription Drugs, OxyContin Abuse and Diversion and Efforts to Address the Problem			Griffith (2019.02.22) EX. 07		
J280	11/1/2017	The President's Commission on Combating Drug Addiction and the Opioid Crisis			Griffith (2019.02.22) EX. 08		
J281		List of Medical Conditions			Halford (2019.02.22) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J282		Title 21 US Code §812 Schedules of controlled substances			Hamilton-Fain (2019.02.19) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J283	10/28/2013	Email from C. Hamilton to J. Foust re Edited Dispensing Guidelines			Hamilton-Fain (2019.02.19) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J284	1/31/2017	Letter from Cindy Fain to Dennis Casey re purpose of the State Board of Pharmacy	OSBP00082480	OSBP00082480	Hamilton-Fain (2019.02.19) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J285	5/14/2012	DEA Form 106 - Report of Theft or Loss of Controlled Substances	OSBP00050975	OSBP00050976	Hamilton-Fain (2019.02.19) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J286	3/2/2015	Fax from Newberry Express Pharmacy attaching DEA Form 106	OSBP00073828	OSBP00073832	Hamilton-Fain (2019.02.19) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J287	3/9/2012	Email from Cindy Hamilton to Chelsea Church re Larry's Pharmacy	OSBP00050973	OSBP00050973	Hamilton-Fain (2019.02.19) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J288	4/25/2005	Email from Cindy Hamilton to NADDI RxNews re Charged with murder	OSBVME-00007097	OSBVME-00007097	Hamilton-Fain (2019.02.19) EX. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J289	8/6/2012	Email from Cindy Hamilton to Chelsea Church re Diversion prevention PP	OSBP00057400	OSBP00057401	Hamilton-Fain (2019.02.19) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J290	4/12/2013	Email from Cindy Hamilton to John Foust; Gary Larue; Betty Beil, et al re Walgreens new plan	OSBP00052206	OSBP00052206	Hamilton-Fain (2019.02.19) EX. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J291	10/28/2013	Email from John Foust to Cindy Hamilton	OSBP00089931	OSBP00089943	Hamilton-Fain (2019.02.19) EX. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J292	11/4/2015	Email from Cindy Hamilton to Emily Popp re Mandell's Clinical Pharmacy	OSBP00098994	OSBP00098995	Hamilton-Fain (2019.02.19) EX. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J293	1/21/2013	Email from Nancy Nesser to Kertti Wade re Allen Community Pharmacy	OHCA-00149988	OHCA-00149988	Hamilton-Fain (2019.02.19) EX. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J294	1/27/2017	Email from Mary S. Surovec to Cindy Fain re Wellston Pharmacy	OSBP00086323	OSBP00086323	Hamilton-Fain (2019.02.19) EX. 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J295	8/17/2017	Email from Jeff Mouakket to Cindy Fain re Regional Opioid Summit	OSBP00086406	OSBP00086407	Hamilton-Fain (2019.02.19) EX. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J296	11/14/2013	Email from Sandra G. LaVenue to John Foust; Cindy Hamilton re Request for information from NADDI	OSBP00090251	OSBP00090252	Hamilton-Fain (2019.02.19) EX. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J297	6/13/2013	Email from Cindy Hamilton to John Foust; Susan Dozal re Newsletter disciplinary summary	OSBP00071417	OSBP00071420	Hamilton-Fain (2019.02.19) EX. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J298	6/15/2015	Final Order / State of Oklahoma v. Dr. Harvey Jenkins			Hamilton-Fain (2019.02.19) EX. 17		
J299	2018	Oklahoma Statutes Annotated; Title 63. Public Health and Safety (Refs & Annos); Chapter 80. Health Care Services; Medicaid Drug Utilization Review Board; 63 Okl.St. Ann. § 5030.1			Harrell (2018.11.01) EX. 005	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J300	08/20/2018	Oklahoma Health Care Authority - Drug Utilization Review (DUR) Board			Harrell (2018.11.01) EX. 006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J301	08/06/2009	DURB Packet for 8-12-2009	OKAG-00001069	OKAG-00001118	Harrell (2018.11.01) EX. 011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J302	09/09/2009	DURB Packet for 9-9-2009	OKAG-00001174	OKAG-00001253	Harrell (2018.11.01) EX. 012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J303	05/05/2011	DURB Packet for 5-11-2011	OKAG-00013226	OKAG-00013302	Harrell (2018.11.01) EX. 016	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J304	04/04/2013	DURB Packet for 4-10-2013	OKAG-03013555	OKAG-00013636	Harrell (2018.11.01) EX. 018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J305	07/10/2013	DURB Packet for 7-10-2013	OKAG-00014022	OKAG-00014106	Harrell (2018.11.01) EX. 020	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J306	07/03/2017	DURB Packet for 7-12-2017	OKAG-00010602	OKAG-00010792	Harrell (2018.11.01) EX. 024	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J307		DURB Packet for 7-11-2018			Harrell (2018.11.01) EX. 025	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J308	10/23/2017	Journal Record Staff, Opioid Epidemic Roundtable, The Journal Record, October 23, 2017			Hawkins (2018.10.26) EX. 012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J309	07/19/2017	Round Table Discussion meeting minutes, Opioid Epidemic in Oklahoma			Hawkins (2018.10.26) EX. 013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J310	01/2015	Nguyen, et al., Unintentional Poisoning Deaths in Oklahoma, 2007-2012, Injury Prevention Service Oklahoma State Department of Health, pp.1-14, January 2015			Hawkins (2018.10.26) EX. 014		
J311	12/05/2014	Profiting from Pain: Clinics Help Fuel Prescription Pill Epidemic, The Oklahoman and Oklahoma Watch			Hawkins (2018.10.26) EX. 015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J312	03/26/2017	With Surge in Meth, Overdose Deaths Reach New Records, Oklahoma Watch			Hawkins (2018.10.26) EX. 018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J313		Admissions to ODMHSAS Funded Substance Abuse Treatment by Drug of Choice and County of Residence; 2012 - 2017			Hawkins (2018.10.26) EX. 019		
J314		Actions Taken to Address the Opioid Addiction Epidemic			Hawkins (2019.03.06) EX. 02		
J315		Depo. Ex. 2 - Hawkins			Hawkins (2019.03.07) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J316	12/4/2013	Email from Amy Mercar to Mike Herndon Enclosing OHCA Presentation:Oklahoma Guidelines for Opioids for 12/9/2013	OHCA -00115865	OHCA -00115865	Herndon (2019.01.25) Ex. 011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J317	3/12/2019	345 Binder			Holderread (3.12.19) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J318		Spreadsheet re Mkt Res - Reg KOL	JAN-MS-02533814	JAN_MS_02533814	Keast (2019.02.12) EX. 27		
J319		Shellie Keast webpage			Keast depo Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J320		Drug List (Teva)			Kolodny M.D. (2019.03.07) EX. 01		
J321	12/18/2018	Busse JW, Wang L, Kamaleldin M, et al. Opioids for Chronic Noncancer Pain A Systematic Review and Meta-analysis. JAMA. 2018;320(23):2448-2460			Krebs (2019.03.19) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J322	12/18/2014	Mosher HJ, Krebs EE, Carrel M, Kabali PI, Vander Weg MW, Lund BC., Trends in prevalent and incident opioid receipt: an observational study in Veterans Health Administration 2004-2012. Journal of General Internal Medicine. 2015;30:597-604			Krebs (2019.03.19) EX. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J323	01/11/2016	Krebs EE, Paudel M, Taylor BC, Bauer DC, Fink HA, Lane NE, Ensrud KE for the Osteoporotic Fractures in Men (MrOS) Study Research Group. Association of Opioids with Falls, Fractures, and Physical Performance among Older Men with Persistent Musculoskeletal Pain. Journal of General Internal Medicine 2016;31:463-9			Krebs (2019.03.19) EX. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J324	2009	Kroenke K, Krebs EE, Bair MJ. Treatment of chronic pain syndromas. In Schatzberg AB, Nemeroff CB. Textbook of Psychopharmacology, 4th Edition. American Psychiatric Publishing, Inc., Washington DC, 2009			Krebs (2019.03.19) EX. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J325	01/2019	HealthChoice Standard Medication List - January 2019			Lawler (2019.02.20) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J326		Amended Expected Expert Opinion Testimony of Laurentius Marais, Ph.D.			Marais (2019.03.20) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J327		Further Explanation of Certain Disclosed Expert Opinion Testimony of Laurentius Marais, Ph.D.			Marais (2019.03.20) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J328		List of Documents Considered in forming Marais' Expert Opinion			Marais (2019.03.20) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J329	3/15/2019	Amended Expected Expert Opinion Testimony of Laurentius Marais, Ph.D.			Marais (3.20.19) Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J330	3/20/2019	Further Explanation of Certain Disclosed Expert Opinion Testimony of Laurentius Marais, Ph.D.			Marais (3.20.19) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J331	3/20/2019	Documents Considered list for Laurentius Marais, Ph.D.			Marais (3.20.19) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J332	09/2015	Noramco World Wide Narcotics Franchise	JAN-OK-00149914	JAN-OK-00149914	Martin (2019.02.20) EX. 01		
J333	02/13/2019	Noramco Website: Johnson & Johnson - Our Credo, available at https://web.archive.org/web/20060511212052fw_/http://www.noramco.com/credo.htm			Martin (2019.02.20) EX. 03		
J334	5/30/2003	Email from Mike Kindergan to Rick Blockinger Enclosing Noramco presentation: Organizational Alignment (J&J)	JAN-MS-00725218	JAN-MS-00725218	Martin (2019.02.20) EX. 06		
J335		A.J. Fist: The Tasmanian Poppy Industry: A Case-Study of the Application of Science and Technology, Tasmanian Alkaloids Pty Ltd, Westbury, Tasmania			Martin (2019.02.20) EX. 07		
J336	2/6/2008	Rules and Regulations, 73 Fed. Reg. 6,833 (Feb. 6, 2008)			Martin (2019.02.20) EX. 08		
J337		Disclosure of the subject matters in the Declaration of Dr. Samuel Martin, enclosing Curriculum Vitae of Samuel Martin, Exhibit L & L-1			Martin (2019.03.06) EX. 01		
J338	2013	Excerpts from Diagnostic and Statistical Manual of Mental Disorders, DSM-5, Pages 541-546, American Psychiatric Publishing, "Opioid Use Disorder"			Martin (2019.03.06) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J339		Oklahoma State University Center for Health Sciences Presentation: Treatment of Opioid Use Disorder by Samuel Martin, MD			Martin (2019.03.06) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J340	2006	David Fishbain et al., Review Article, "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors?" Pain Medicine, Volume 9, Number 4-2008			Martin (2019.03.06) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J341		J&J Presentation: Code of Business Conduct - Live Our Credo, Know Our Code			Mashett (2019.01.30) EX. 01		
J342	10/2015	Noramco Presentation: Noramco World Wide Narcotics Franchise (Oct. 2015)	JAN-OK-00149992	JAN-OK-00150068	Mashett (2019.01.30) EX. 05		
J343	01/01/2008	Supply Agreement between Noramco Inc. and Purdue Pharma L.P. (Jan. 1, 2008)	JAN-OK-00152231	JAN-OK-00152261	Mashett (2019.03.12) EX. 35		
J344	08/15/2016	Letter from SoonerCare to Pharmacists re Brand Name Oxycontin Preferred Over Generic	OKAG-00001669	OKAG-00001669	Mashett (2019.03.12) EX. 36	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J345		Danesh Mazloomdoost Curriculum Vitae			Mazloomdoost (2019.03.07) EX. 02		
J346		OHCA - Prior Authorization (Pharmacy) Archives			Mazloomdoost (2019.03.07) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J347		Kentucky Medical Association - Policy Manual 2018 House of Delegates			Mazloomdoost (2019.03.07) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J348		Checklist for prescribing opioids for chronic pain			Mazloomdoost (2019.03.07) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J349		Dr. Danesh Mazloomdoost, M.D. Discloses			Mazloomdoost (2019.03.07) EX. 06		
J350	5/10/2017	Article re Claire McCaskill cites disproven figure on opioid use			Mazloomdoost (2019.03.07) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J351	2015	Original Investigation - Trends in Prescription Drug Use Among Adults in the United States From 1999 - 2012			Mazloomdoost (2019.03.07) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J352		Article re Opioids compared to placebo or other treatments for chronic low -back pain (Review) by LE Chaparro, et al			Mazloomdoost (2019.03.07) EX. 0	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J353		Duragesic Label (Fentanyl Transdermal System)	JAN-MS-00780844	JAN-MS-00780888	Mazloomdoost (2019.03.07) EX. 1	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J354	2010	Johns Hopkins Anesthesiology Handbook by Eugenie S. Heitmeller, Deborah A. Schwengel			Mazloomdoost (2019.03.07) EX. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J355		Drug Diplomacy in the Twentieth Century by William B. McAllister			McAllister (2019.03.19) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J356		Chart created by McAllister showing the governmental and private actors responsible for opioid control			McAllister (2019.03.19) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J357	2003	W, McAllister and J. Spillane: Keeping the lid on: a century of drug regulation and control, Drug and Alcohol Dependence 70 (2003) 55 -512			McAllister (2019.03.19) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J358	12/9/2016	Email From Chief Medical Officer to Clint Castleberry re ASCA:	ODOC-00018265	ODOC-00018265	McCurdy (2018.12.13) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J359	05/22/2018	Email from J. Allbaugh to C. Castleberry re American Correctional Association (ACA) and American Society for Addiction Medicine (ASAM) Adopt Policy on Opioid Epidemic / attached Joint Public Correctional Policy on the Treatment of Opioid Use Disorders For Justice Involved Individuals	ODOC-00005487	ODOC-00005491	McCurdy (2018.12.13) EX. 05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J360		Johnson & Johnson Overview & Meeting Objectives			McGregor-Beck (1/16/2019) EX. 03		
J361	11/12/2010	NDA #022304: NUCYNTA (tapentadol) immediate-release oral tablets	JAN-MS-05456115	JAN-MS-05456123	McGregor-Beck (1/16/2019) EX. 04		
J362	8/20/2008	[Approval Form] Let's Talk Pain Video/Transcript - Myth v. Reality	JAN-MS-00007320	JAN-MS-00007325	McGregor-Beck (1/16/2019) EX. 05		
J363	8/13/2008	[Approval Form] Let's Talk Pain Video/Transcript - Getting Started	JAN-MS-00007215	JAN-MS-00007221	McGregor-Beck (1/16/2019) EX. 06		
J364	8/27/2009	Let's Talk Pain Web Site Manuscript 12-Month Review	JAN-MS-00006865	JAN-MS-00006943	McGregor-Beck (2019.01.16) EX. 007		
J365		Finding Relief - Pain Management for Older Adults	CONRAD00000006	CONRAD00000025	McGregor-Beck (2019.01.16) EX. 008		
J366	10/22/2008	Copy Review Approval Form - Guidebook on Pain Management	JAN-MS-00000330	JAN-MS-00000343	McGregor-Beck (2019.01.16) EX. 009		
J367	12/09/2008	Copy Review Approval Form - Pain Management Script & DVD	JAN-MS-00000344	JAN-MS-00000372	McGregor-Beck (2019.01.16) EX. 010		
J368	1/5/2018	Tami L. Mark, et al., Health Affairs Blog, Improving Addiction Treatment With Consumer Report Cards, 01/05/2018			Mendell (2019.03.20) EX. 02		
J369	6/16/2017	Memo from G. Mendell to Gov. Chris Christie re Shatterproof Recommendations for the Presidential Commission, 6/16/2017			Mendell (2019.03.20) EX. 03		
J370		Handwritten notes			Mendell (2019.03.20) EX. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J371	09/2015	Noramco Presentation: Noramco World Wide Narcotics Franchise (Sept. 2015)			Minardi (2019.02.27) Ex. 002		
J372		Notes Bruce Moskovitz brought with him to deposition			Moskovitz (2018.08.28) EX. 011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J373		Moskovitz' typewritten notes re: labeling, issues of abuse & misuse of opioids etc.			Moskovitz (2018.08.28) EX. 011	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J374		Binder (Part 1)- used by Bruce Moscovitz			Moskovitz (2018.08.28) EX. 012	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J375		Binder containing Class-wide ER/LA REMS, select Duragesic labels, select Nucynta IR and ER labels, and documents related to Janssen's educational efforts			Moskovitz (2018.08.28) EX. 012 pt	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J376	6/1/2012	Binder containing Duragesic RMP 12th Progress Report			Moskovitz (2018.08.28) EX. 012 pt	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J377		Binder 1: produced by Janssen			Moskovitz (2018.08.28) EX. 012 pt	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J378	03/29/2002	FDA Advisory Committee Meeting - Media-Response Document	JAN-MS-00303831	JAN-MS-00303836	Moskovitz (2018.08.28) EX. 017		
J379	9/9/2003	FDA Advisory Committee Meeting -- Media Response Document, Issues/Responses Related to Duragesic	JAN-MS-00303831	JAN-MS-00303836	Moskovitz (2018.08.28) EX. 017		
J380	9/2/2004	FDA Warning Letter re Duragesic			Moskovitz (2018.08.28) EX. 018		
J381	09/02/2004	Dept. of Health & Human Services Warning Letter to A. Shetty re NDA #19-813 - Duragesic (Fentanyl transdermal system) CII MACMIS #12386			Moskovitz (2018.08.28) EX. 018		
J382	3/18/2016	CDC Guideline for Prescribing Opioids for Chronic Pain -- United States, 2016			Moskovitz (2018.08.28) EX. 023		
J383	03/18/2016	Morbidity and Mortality Weekly Report: CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016, Recommendations and Reports, Vol. 65/No. 1			Moskovitz (2018.08.28) EX. 023		
J384	12/16/2010	Analgesic treatment for moderate-to-severe acute pain in the United States: Patients' perspectives in the Physicians Partnering Against Pain (P3) Survey, B. Moskovitz and others			Moskovitz (2018.12.12) EX. 001	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J385	08/2011	Bruce Moskovitz et al., Analgesic treatment for moderate-to-severe acute pain in the United States: Patients' perspectives in the Physicians Partnering Against Pain (P3) Survey, Journal of Opioid Management 7.4/ July-August 2011			Moskovitz (2018.12.12) EX. 001	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J386	3/14/2002	Duragesic Disease Modeling Workshop 2 Takeaways			Moskovitz (2018.12.12) EX. 009		
J387	03/14/2002	J&J Presentation: Duragesic Disease Modeling Workshop 2 Takeaways			Moskovitz (2018.12.12) EX. 009		
J388	3/8/2002	Medical Affairs Pain Mycology Monthly Status Report, February 23, 2002	JAN-MS-02326363	JAN-MS-02326387	Moskovitz (2018.12.12) EX. 010		
J389	03/08/2008	Memo from Surya Vangala to Bruce Moskovitz, et al., re Medical Affairs Pain Mycology Monthly Status Report - February 28, 2002	JAN-MS-02326363	JAN-MS-02326387	Moskovitz (2018.12.12) EX. 010		
J390		Investigator Initiated Studies-Duragesic, Ongoing/Completed/Terminated Studies	JAN-MS-00274787	JAN-MS-00274789	Moskovitz (2018.12.12) EX. 011		
J391		Chart: Investigator Initiated Studies - Duragesic - Ongoing/Completed/Terminated Studies	JAN-MS-00274787	JAN-MS-00274789	Moskovitz (2018.12.12) EX. 011		
J392	7/6/2006	Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy, Michael Fleming and others			Moskovitz (2018.12.12) EX. 017		
J393	07/2007	Michael Fleming et al., re Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy. The Journal of Pain, Vol. 8, No. 7 (July) 2007 pp 573-582			Moskovitz (2018.12.12) EX. 017	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J394	12/5/2008	Opioid use behaviors, mental health and pain-- Development of a typology of chronic pain patients, Caleb Banta-Green and others			Moskovitz (2018.12.12) EX. 018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J395	2009	Caleb Banta-green et al., Opioid use behaviors, mental health and pain - Development of a typology of chronic pain patients, Drug and Alcohol Dependence 104 (2009) 34-42			Moskovitz (2018.12.12) EX. 018	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J396	9/28/2009	Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system, Joseph Boscarino and others			Moskovitz (2018.12.12) EX. 019		
J397		Joseph A. Boscarino et al., Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system, Addiction Research Report, Vol. 105, pp 1775-1782			Moskovitz (2018.12.12) EX. 019		
J398	2008	What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review, David Fishbain and others			Moskovitz (2018.12.12) EX. 020	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J399	2008	David A. Fishbain, MD, FAPA et al., What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors" a Structured Evidence-Based Review, Pain Medicine Vol. 9, No. 4, 2008			Moskovitz (2018.12.12) EX. 020	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J400	2010	Cochrane Library Long-term opioid management for chronic noncancer pain (Review), Treadwell and others			Moskovitz (2018.12.12) EX. 021	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J401	2010	Long-term opioid management for chronic noncancer pain (Review), Cochrane Database of Systematic reviews, 2010, Issue 1, Art. No. CD006605			Moskovitz (2018.12.12) EX. 021	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J402	4/28/2005	Evaluation of Abuse of Prescription and Illicit Drugs in Chronic Pain Patients Receiving Short-Acting (Hydrocodone) or Long-Acting (Methadone) Opioids			Moskovitz (2018.12.12) EX. 022	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J403	2005	Laxmaiah Manchikanti, M.D., et al., Evaluation of Abuse of Prescription and Illicit Drugs in Chronic Pain Patients Receiving Short-Acting (Hydrocodone) or Long-Acting (Methadone) Opioids, Pain Physician, Vol. 8, No. 3, pp. 257-261, 2005			Moskovitz (2018.12.12) EX. 022	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J404	12/12/2018	ScienceDirect website: Hydrocodone - an overview, Science Direct Topics available at www.sciencedirect.com/topics/medicine-and-dentistry/hydrocodone			Moskovitz (2018.12.12) EX. 023	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J405		ScienceDirect website on Hydrocodone			Moskovitz (2018.12.12) EX. 023	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J406	09/08/2006	Dawn Sanderson-Bongiovanni, PharmD., Cumulative Review of Iatrogenic Addiction Associated with Use of Transdermal DURAGESIC (fentanyl) Patch, Johnson & Johnson Pharmaceutical Research & Development, LLC, September 2006	JAN-MS-02754767	JAN-MS-02754783	Moskovitz (2018.12.12) EX. 024	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J407	09/2006	Cumulative Review of Iatrogenic Addiction Associated with the Use of Transdermal Duragesic (fentanyl) Patch, Dawn Sanderson-Bongiovanni	JAN-MS-02754767	JAN-MS-02754783	Moskovitz (2018.12.12) EX. 024	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J408		INTENTIONALLY LEFT BLANK					
J409		INTENTIONALLY LEFT BLANK					

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J410	12/12/2018	2018 Duragesic Label and Prescription Guide			Moskovitz (2018.12.12) EX. 026	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J411	09/2018	Product information sheet for Duragesic			Moskovitz (2018.12.12) EX. 026	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J412	4/20/2007	Duragesic Risk Management Overview	JAN-MS-00493882	JAN-MS-00493882	Moskovitz (2018.12.12) EX. 23A	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J413	04/20/2007	Ortho-MacNeil Janssen Scientific Affairs Presentation: Duragesic Risk Management Overview	JAN-MS-00493882	JAN-MS-00493882	Moskovitz (2018.12.12) EX. 23A	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J414		Selected Studies, Research, and Analysis of Safety and Efficacy of Duragesic and Nucynta			Moskovitz (2019.01.09) EX. 003	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J415		Table of Selected Studies, Research and Analysis of Safety and Efficacy of Duragesic and Nucynta			Moskovitz (2019.01.09) EX. 003	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J416	2009	Finding Relief, Pain Management for Older Adults, Conrad & Associates, LLC			Moskovitz (2019.01.09) EX. 004		
J417		Finding Relief Pain Management for Older Adults			Moskovitz (2019.01.09) EX. 004		
J418		Finding Relief References Binder			Moskovitz (2019.01.09) EX. 006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J419		Finding Relief References			Moskovitz (2019.01.09) EX. 006	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J420	12/29/2008	Finding Relief Pain Management for Older Adults Video Script	JAN-MS-00000433	JAN-MS-00000456	Moskovitz (2019.01.09) EX. 007		
J421	12/29/2008	Video Script, Finding relief, Pain Management for Older Adults, Dec. 29, 2008	JAN-MS-00000433	JAN-MS-00000456	Moskovitz (2019.01.09) EX. 007		
J422		Index to SUPP Binder including Nucynta ER IND/NDAs, Response to FDA Warning Letter, ALZA Citizen Petition, Brookoff Citizen Petition, PADT Study by Passik, Kosinski Article, Simpson Article, and copies of articles at Ex. 17-21 from 12/12/2018 deposition			Moskovitz (2019.01.09) EX. 008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J423		Supplemental Nucynta binder			Moskovitz (2019.01.09) EX. 008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J424		PrescribeResponsibly overview draft	JAN-MS-00320056	JAN-MS-00320087	Moskovitz (2019.01.09) EX. 009		
J425		Promotional materials on prescribing responsibly	JAN-MS-00320056	JAN-MS-00320087	Moskovitz (2019.01.09) EX. 009		
J426	04/16/2014	Binder of articles marked as Depo. Ex. 10	JAN-MS-03088062	JAN-MS-02744171	Moskovitz (2019.01.09) EX. 010	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J427		Selected Support for Statements and Representations Regarding Pseudoaddiction			Moskovitz (2019.01.09) EX. 010	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J428	6/1/1988	Opioid pseudoaddiction -- an iatrogenic syndrom, David Weissman and David Haddox	PYK183228610	PYK183228613	Moskovitz (2019.01.09) EX. 011		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J429	1989	David E. Weissman, et al., Clinical Note - Opioid Pseudoaddiction - An Iatrogenic Syndrome, Elsevier Science Publishers B.V., 1989	PKY183228610	PKY183228613	Moskovitz (2019.01.09) EX. 011		
J430		Sources of Knowledge Regarding Abuse, Misuse, Dependence or Addiction			Moskovitz (2019.01.09) EX. 013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J431		Binder marked as Depo. Ex. 13	JAN-MS-01139518	JAN-MS-02051874	Moskovitz (2019.01.09) EX. 013	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J432		PrescribeResponsibly.com References			Moskovitz (2019.01.09) EX. 014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J433		Binder of articles marked as Depo. Ex. 14			Moskovitz (2019.01.09) EX. 014	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J434		Duragesic/Nucynta/Nucynta ER Timeline			Moskovitz (2019.01.09) EX. 018		
J435		Timeline for Duragesic/Nucynta/Nucynta ER			Moskovitz (2019.01.09) EX. 018		
J436		Selected Studies, Research, and Analysis Supporting Certain Categories of Statements			Moskovitz (2019.01.09) EX. 019	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J437		Table of Selected Studies, Research and Analysis Supporting Certain Categories of Statements			Moskovitz (2019.01.09) EX. 019	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J438		Let's Talk Pain References			Moskovitz (2019.01.09) EX. 021	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J439		Table of References for Let's Talk Pain			Moskovitz (2019.01.09) EX. 021	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J440	7/11/2011	Prevalence of Prescription Opioid-Use Disorder Among Chronic Pain Patients: Comparison of the DSM-5 vs. DSM-4 Diagnostic Criteria, Joseph Boscarino and others	PDD8013710549	PDD8013710559	Moskovitz (2019.01.10) EX. 029		
J441	07/11/2011	Joseph A. Boscarino, Ph.D., Prevalence of Prescription Opioid-Use Disorder Among Chronic Pain Patients: Comparison of the DSM-5 vs. DSM-4 Diagnostic Criteria, Journal of Addictive Diseases, 30:3, pp. 185-194	PDD8013710549	PDD8013710559	Moskovitz (2019.01.10) EX. 029		
J442	2010	Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind placebo and active-controlled Phase III Study, Robert Buynak and others			Moskovitz (2019.01.10) EX. 034	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J443	2010	Robert Buynak, et al., Efficacy and Safety of Tapentadol Extended Release for the Management of Chronic Low Back pain: results of a prospective, randomized, double-blind, placebo- and active- controlled Phase III Study, Expert Opinion, 11(11), 2010	JAN-MS-00074450	JAN-MS-00074477	Moskovitz (2019.01.10) EX. 034	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J444		Opioids Manufactured, Owned, and/or Developed by Janssen Since 1996			Moskovitz (2019.01.10) EX. 035	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J445		Binder of Package Inserts for Opioids Manufactured, Owned and/or Developed by Janssen Since 1996 marked as Depo. Ex. 35			Moskovitz (2019.01.10) EX. 035	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J446		Index to Duragesic Risk Management Plans			Moskovitz (2019.01.10) EX. 036	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J447		Index to DURAGESIC Risk Management Plans	JAN-MS-00213750	JAN-MS-00132845	Moskovitz (2019.01.10) EX. 036	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J448		Index to Nucynta IR and ER Safety Surveillance Plans			Moskovitz (2019.01.10) EX. 037	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J449		Binder of Nucynta IR and ER Safety Surveillance Plans marked as Depo. Ex. 37	JAN-MS-00230429	JAN-MS-00228548	Moskovitz (2019.01.10) EX. 037	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J450	12/21/2009	Smart Moves, Smart Choices: A Prescription Drug Abuse Prevention Program	JAN-MS-00508121	JAN-MS-00508121	Moskovitz (8/28/2018) EX. 12	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J451	06/14/2006	DURB Packet for 6-14-2006	OKAG-00006436	OKAG-00006438	Muchmore (2018.12.05) EX. 071	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J452	10/11/2006	DURB Packet for 10-11-2006	OKAG-00007416	OKAG-00007491	Muchmore (2018.12.05) EX. 072	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J453	12/13/2006	DURB Packet for 12-13-2006	OKAG-00008039	OKAG-00008108	Muchmore (2018.12.05) EX. 073	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J454	05/09/2007	DURB Packet for 5-9-2007	OKAG-00006047	OKAG-00006121	Muchmore (2018.12.05) EX. 074	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J455	02/13/2008	DURB Packet for 2-13-2008	OKAG-00001828	OKAG-00001890	Muchmore (2018.12.05) EX. 077	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J456	05/14/2008	DURB Packet for 5-14-2008	OKAG-00000754	OKAG-00000818	Muchmore (2018.12.05) EX. 079	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J457	04/09/2014	Post DUR Meeting Notes for 4-9-2014	OHCA-00157152	OHCA-00157152	Muchmore (2018.12.05) EX. 080	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J458	02/14/2018	State's Responses to Janssens' First Set of Interrogatories			Muchmore (2018.12.05) EX. 082	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J459	07/13/2016	Post DUR Meeting Notes for 7-13-2006	OHCA-00337365	OHCA-00337367	Muchmore (2018.12.05) EX. 083	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J460	09/13/2017	Post DUR Meeting Notes for 9-13-2017	OHCA-00000525	OHCA-00000527	Muchmore (2018.12.05) EX. 084	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J461		Pharmacy Operations	ODOC-00001747	ODOC-00001763	Murphy (2018.12.18) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J462	08/2018	Oklahoma - Formulary Addendum form Aug. 2018 / Diamond Pharmacy Services			Murphy (2018.12.18) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J463	05/07/2018	Email from Clint Castleberry to Buddy Honaker re Controlled Drugs Blue Books	ODOC-00007324	ODOC-00007328	Murphy (2018.12.18) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J464	5/18/2018	Email from Robin Murphy to SheeTu]ler re : MBCC Narcotics Inventory	ODOC-00043517	ODOC-00043559	Murphy (2018.12.18) EX. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J465		Expert Disclosures of Claire Nguyen, M.S.			Nguyen (2019.03.22) EX. 03		
J466	07/2015	Svetla Slavova, PhD, et al., Drug Overdose Deaths: Let's Get Specific, Public Health Reports, Vol. 130, pp. 339-342, July-August 2015			Nguyen (2019.03.22) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J467	01/2015	Claire Nguyen, MS, et al., Unintentional Poisoning Deaths in Oklahoma, 2007-2012, Oklahoma State Department of Health, January 2015			Nguyen (2019.03.22) EX. 08		
J468		Oklahoma State Department of Health Injury Prevention Service Presentation: Prescription Drug Abuse/Misuse in Oklahoma			Nguyen (2019.03.22) EX. 09		
J469	02/17/2015	Heroin deaths increased tenfold in Oklahoma, The Oklahoman			Nguyen (2019.03.22) EX. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J470		Oklahoma State Department of Health presentation: Fatal Unintentional Poisoning Surveillan System: Data Update			Nguyen (2019.03.22) EX. 11		
J471		Disclosure of Expert Witness Nathan Novemsky, Ph.D.			Novemsky (2019.03.27) EX. 01	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J472	3/26/2019	Documents Considered by Nathan Novemsky			Novemsky (3.27.19) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J473	04/2012	Pohl M & Smith L, Chronic Pain and Addiction Challenging Co-occurring Disorders, J. of Psychoactive Drugs, 44(2), pp. 119-124 (Apr. 2012)			Pohl (2019.03.08) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J474	05/19/2014	Colameco S. & Pohl M, Buprenorphine in the workers' compensation setting, J. of Opioid Mgmt , 10:4, 277-283 (May 19, 2014)			Pohl (2019.03.08) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J475	1/16/2019	[Email] Subject: FYI (email from B. Beckworth to S. Spencer)			Portenoy (1/24/2019) EX. 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J476	02/11/2009	DURB Packet for 2-11-2009	OKAG-00000139	OKAG-00000190	Preslar (2018.11.02) EX. 031	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J477	06/10/2009	Cleaner Copy of DURB Packet for 6-10-2009	OKAG-00010556	OKAG-00010601	Preslar (2018.11.02) EX. 033	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J478	06/10/2009	DURB Packet for 6-10-2009			Preslar (2018.11.02) EX. 034	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J479	02/13/2013	DURB Packet for 2-13-2013	OKAG-00013377	OKAG-00013429	Preslar (2018.11.02) EX. 038	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J480	08/14/2013	DURB Packet for 8-14-2013	OKAG-00014275	OKAG-00014361	Preslar (2018.11.02) EX. 039	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J481		Tonya Ratcliff Experience Slide			Ratcliff (3.13.2019) Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J482	9/9/2015	DURB Minutes of Meeting of Sept. 9, 2015			Ratcliff (3.13.2019) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J483	2/13/2018	News Article re President's Response to McCaskill Report			Reisner (2018.12.11) EX. 002	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J484	8/20/1996	The Use of Opioids for the Treatment of Chronic Pain	APS-MDL00000058	APS-MDL00000060	Reisner (2018.12.11) EX. 008	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J485	07/2010	Pain Care Forum - 2010 Meetings Schedule	WISPPSG00010776	WISPPSG00010787	Reisner (2018.12.11) EX. 013	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J486	4/21/2018	Affidavit of Catherine H. Underwood, MBA, CAE	APS-MDL00000054	APS-MDL00000055	Reisner (2018.12.11) EX. 027	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J487	4/23/2018	Affidavit of Gregory Terman, MD PHD	APS-MDL00000056	APS-MDL00000056	Reisner (2018.12.11) EX. 028	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J488		Opioid Treatment Guidelines - Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain	APS-MDL00000140	APS-MDL00000179	Reisner (2018.12.11) EX. 029		
J489		Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain - Evidence Review	APS-MDL00000186	APS-MDL00000403	Reisner (2018.12.11) EX. 030	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J490	04/01/2004	Accreditation Council for Continuing Medical Education / Standards for Commercial Support - Standards to Ensure the Independence of CME Activities			Reisner (2018.12.11) EX. 031	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J491		ODnQues - Number of Admissions			Reynolds (2019.03.11) EX. 04		
J492		ODMH SAS Online Query System / Admissions to ODMHSAS Funded Substance Abuse Treatment* by Drug of Choice and County of Residence (Ages 12+)			Reynolds (2019.03.11) EX. 05		
J493	2/18/2016	Email from Christie Tapp to Carrie Slatton- Hodges re ODMHSAS Online Query System (ODnQues)	ODMHSAS-00040774	ODMHSAS-0004077	Reynolds (2019.03.11) EX. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J494	5/6/2014	Email from Claire B. Nguyen to Mark A. Reynolds re Treatment admissions	ODMHSAS-0065691	ODMHSAS-0065691	Reynolds (2019.03.11) EX. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J495	4/25/2014	Claire Nguyen; Tracy Wendling; Mark Reynolds; Jessica Hawkins; Pam Archer; Nancy Nesser; Marlene Asmussen; Sarah Walker; Bill Garrison; Brigido Ramirez	OSDH-01333551	OSDH-01333554	Reynolds (2019.03.11) EX. 09	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J496		Prescription Drug Abuse Workgroup - Strengthening Collaborative Measures			Reynolds (2019.03.11) EX. 10		
J497	2013	Prescription Drug Abuse Workgroup, Strengthening Collaborative Measures	OHCA-00006212	OHCA-00006224	Reynolds (2019.03.11) EX. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J498		Oklahoma's Plan to Reduce Prescription Drug Abuse and Prevent Overdose			Reynolds (2019.03.11) EX. 12		
J499		Oklahoma State Board of Dentistry - Information Sheet for Senate Bill 603			Rodgers (2019.02.21) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J500		List of Medical Conditions			Schick (2019.03.01) EX. 001	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J501		Chart ODMHSAS Online Query System / Admissions to ODMHSAS Funded Substance Abuse Treatment* by Drug of Choice and County of Residence (Ages 12 +)			Slatton-Hodges (2019.03.08) EX. 02		
J502		Chart - ODMHSAS Online Query System / Admissions to ODMHSAS Funded Substance Abuse Treatment* by Drug of Choice and County of Residence (Ages 12 +)			Slatton-Hodges (2019.03.08) EX. 03		
J503	01/14/2019	Chart of actions			Stewart (1.22.19) Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J504		Undated document about diversion division (different than Ex. 8 or 9)			Stewart (1.22.19) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J505	06/23/2016	Email re: AIC Meeting			Stewart (1.22.19) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J506	2013	OBN FTE Justification Fact Sheet			Stewart (1.22.19) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J507	01/21/2014	Email re: Goals of the Tulsa Office			Stewart (1.22.19) Ex. 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J508	06/19/2017	Prescription Drug Diversion Trends and the Opioid Crisis			Stewart (1.22.19) Ex. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J509	07/10/2014	Diversion of Prescription Drugs ppt			Stewart (1.22.19) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J510	2014	NAMSDL Overview of Pain Clinic Regulation			Stewart (1.22.19) Ex. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J511	2015	Undated document about diversion division			Stewart (1.22.19) Ex. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J512		The D.O. and Diversion powerpoint			Stewart (1.22.19) Ex. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J513	06/16/2017	Email re: threat assess. jun. 15			Stewart (1.22.19) Ex. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J514	2011	Understanding PMP Programs			Stewart (1.22.19) Ex. 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J515	09/12/2018	2018 Oklahoma Drug Threat Assessment			Stewart (1.22.19) Ex. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J516	2018	Drug Investigators Course Announcement			Stewart (1.22.19) Ex. 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J517	09/25/2012	FY 2014-2018 Strategic Plan			Stewart (1.22.19) Ex. 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J518	12/10/2013	Email re: new direction of task force			Stewart (1.22.19) Ex. 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J519	03/29/2018	Email re: Organizational Change			Stewart (1.22.19) Ex. 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J520	11/01/2010	Email re: Oxycodone (Oxycotin)			Stewart (1.22.19) Ex. 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J521	06/18/2012	OBND v. Bobby Daniel, D.O.			Stewart (1.22.19) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J522	02/07/2012	OBND v. Darrell Mease, M.D.			Stewart (1.22.19) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J523	05/14/2018	OBND v. James Michael Ferris, MD			Stewart (1.22.19) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J524	06/19/2017	Oklahoma Drug Threat Assessment 2017			Stewart (1.22.19) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J525		Undated document about diversion division			Stewart (1.22.19) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J526	2017	Undated document about diversion division (different than Ex. 8)			Stewart (1.22.19) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J527		Curriculum Vitae C. Renzi Stone			Stone (2019.03.15) EX. 01		
J528	07/06/2007	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_OK_00009795	TEVA_OK_00009805	Stone (2019.03.15) EX. 02	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J529		Disclosure of Expert Witness - C. Renzi Stone			Stone (2019.03.15) EX. 03		
J530		Abatement Statistics for Renzi Stone	OKEXPERT-STONE-0	OKEXPERT-STONE-0	Stone (2019.03.15) EX. 04		
J531	05/02/2018	OnQues FAQs webpage			Stoneking (5.16.18) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J532	05/08/2018	OK AG Medicaid Fraud Control Unit webpage			Stoneking (5.16.18) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J533	04/17/2018	Use of Naloxone (Narcan)			Stoneking (5.16.18) Ex. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J534	01/28/2016	Controlled Drug Procedures Manual for ODOC			Stoneking (5.16.18) Ex. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J535		Top Reported Drugs of 2015			Stoneking (5.16.18) Ex. 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J536	06/04/2010	MMIS RFP			Stoneking (5.16.18) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J537		Oklahoma Dentist Opioid Crisis Strategies			Stoneking (5.16.18) Ex. 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J538		Workers Comp Schedule II Guidelines			Stoneking (5.16.18) Ex. 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J539	04/20/2018	DXC Technology article			Stoneking (5.16.18) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J540	01/22/2015	Records Disposition Schedule			Stoneking (5.16.18) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J541	07/28/2016	PMP Data Submission Dispenser Guide			Stoneking (5.16.18) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J542	2003	OBND Annual Report 2003			Stoneking (5.16.18) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J543		Oklahoma Opioid Prescribing Guidelines			Tate (03.01.2019) Ex. 1		
J544		Oklahoma Employer Group Insurance Division - Commercial Formulary Exhibit			Tate (03.01.2019) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J545		CareMark Provider Agreement			Tate (03.01.2019) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J546		HealthChoice Standard Medication List			Tate (03.01.2019) Ex. 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J547		2018 HealthChoice Abridged Formulary			Tate (03.01.2019) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J548		January 2018 Employees Group Insurance Division Chart			Tate (03.01.2019) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J549	1/1/2016	State of Oklahoma Contract to Provide Claims Processing Services (CVS/CareMark)			Tate (03.01.2019) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J550	1/1/2016	State of Oklahoma Contract to Provide Claims Processing Services (Siverscript Insurance Co.)			Tate (03.01.2019) Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J551	11/21/2014	Letter from S. Anzaldi, CVS/CareMark, to K. Hallum, enclosing response to proposal for PBM services			Tate (03.01.2019) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J552		Solicitation Specification for CVS/CareMark PBM services contract			Tate (03.01.2019) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J553		CVS/CareMark Formulary Analysis			Tate (03.01.2019) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J554		HealthChoice High Option and Basic Health Plans Handbook			Tate (03.11.2019) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J555		HealthChoice Plan Handbooks			Tate (03.11.2019) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J556	7/1/2000	HealthChoice Select Medication List (effective 7/1/2000)			Tate (03.11.2019) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J557		Tabbed HealthChoice Documents			Tate (03.11.2019) Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J558		CVS/CareMark Coverage Tables			Tate (03.11.2019) Ex. 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J559		CVS/CareMark Specialty Guideline Management for Harvoni			Tate (03.11.2019) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J560		ExpressScripts Coverage Rules			Tate (03.11.2019) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J561	11/6/2014	[Email] Nucynta TRx Volume	JAN-MS-01569185	JAN-MS-01969185	Tewell (1/8/2019) EX. 05		
J562	2012	Nucynta 2012 Marketing Strategies	JAN-MS-02735137	JAN-MS-02735137	Tewell (1/8/2019) EX. 07		
J563	6/19/2014	[Email] Pain Franchise - Bi Weekly CI Report (6/6 thru 6/19)	JAN-MS-00996343	JAN-MS-00996344	Tewell (1/8/2019) EX. 09		
J564	6/19/2014	Competitive Intelligence Bi-Weekly Brief	JAN-MS-00996345	JAN-MS-00996345	Tewell (1/8/2019) EX. 10		
J565	12/18/2008	[Presentation] Tapentadol Chronic Pain Management Message Platform	JAN-MS-00298408	JAN-MS-00298408	Tewell (1/8/2019) EX. 12		
J566	10/1/2015	RE: Organization Announcement: Fred Tewell	JAN-MS-01974211	JAN-MS-01974213	Tewell (1/8/2019) EX. 16		
J567	04/05/2014	Email from F. Tewell to T. Davidson re FY: NUCYNTA Weekly Media Monitoring Report (4/04)	JAN-MS-00576394	JAN-MS-00576409	Tewell (2019.01.08) EX. 14		
J568		List of Disciplinary and Legal Actions Taken by the Oklahoma Medical Board Relating to Opioids, 1996 - Present [Files related to disciplinary actions produced at OKMB-00004459 - OKMB00036562]			Varghese (2019.02.26) EX. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J569		Excel Spreadsheet re Over prescribing from 1996 - 2019	OKMB00003529	OKMB00003529	Varghese (2019.02.26) EX. 03	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J570		Complaints Filed in the Year 2001 - 2018 with Chart re Percentage of Complaints by Source	OKMB-00004434	OKMB-00004452	Varghese (2019.02.26) EX. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J571	05/04/2017	Email re: clinical alert message			Vogt (1.21.19) Ex 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J572	02/12/2009	Email re: 2009 PMP Grant Application			Vogt (1.21.19) Ex 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J573	02/12/2009	2009 PMP Grant Application			Vogt (1.21.19) Ex 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J574	06/20/2017	Email re: Grant Stats			Vogt (1.21.19) Ex 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J575	02/26/2015	PDMP Report fro July 1 - December 31 2014			Vogt (1.21.19) Ex 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J576	08/30/2012	Email re: Question please!			Vogt (1.21.19) Ex 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J577	01/14/2011	Email re: 68 day non-fatal overdose charts			Vogt (1.21.19) Ex 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J578	01/07/2011	State of Oklahoma Non-Fatal Overdose Charts			Vogt (1.21.19) Ex 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J579		SCEPTRE Duplicate Case Search - Janssen Scientific Affairs Drug Diversion and Street RX Analysis for Tapentadol	JAN-MS-02102667	JAN-MS-02102671	Vorsanger (2019.01.17) EX. 010	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J580	01/2018	Highlights of Prescribing Information re DURAGESIC (fentanyl transdermal system), CI: [Reference ID: 4211188]			Vorsanger (2019.01.17) EX. 015	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J581	05/09/2005	PowerPoint: Risk Management Plan for Our Products	JAN-MS-022321524	JAN-MS-022321524	Vorsanger (2019.01.17) EX. 016	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J582	04/20/2007	PowerPoint: Duragesic Risk Management Overview	JAN-MS-02305132	JAN-MS-02305132	Vorsanger (2019.01.17) EX. 017	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J583	06/16/2008	Duragesic (fentanyl transdermal system): Fourth Risk Management Plan Progress Report	JAN-MS-00151777	JAN-MS-00151777	Vorsanger (2019.01.17) EX. 018	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J584	01/16/2019	Pain Medicine: Volume 9 - Number 4 2008: Review Article: What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review			Vorsanger (2019.01.17) EX. 020	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J585		Cochrane Library; Cochrane Database of Systematic Review: Long-term opioid management for chronic noncancer pain (Review)			Vorsanger (2019.01.17) EX. 021	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J586	02/06/2014	Original Article: Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses [Journal of Opioid Management]			Vorsanger (2019.01.17) EX. 022	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J587	08/25/2011	NDA 200533 - NUCYNTA ER (tapentadol) tablets - Opioid analgesic - Risk Evaluation and Mitigation Strategy (REMS) [Reference ID: 3006589]	JAN-MS-01489228	JAN-MS-01489275	Vorsanger (2019.01.17) EX. 023	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J588	12/02/2013	Global Medical Safety Janssen Research & Development, LLC - NUCYNTA (Tapentadol) Extended-Release: Fourth Safety Surveillance Plan Progress Report [Document No: EDMS-ERI-74585390]			Vorsanger (2019.01.17) EX. 024	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J589	04/08/2009	OBND v. Mosier			Weaver (3.08.19) Ex. 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J590	11/13/2006	OBND v. Childs			Weaver (3.08.19) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J591	03/26/2011	OBND v. Bhandary			Weaver (3.08.19) Ex. 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J592	06/02/2015	OBNDD v. Fioravanti			Weaver (3.08.19) Ex. 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J593	08/13/2013	OBNDD v. Gilmore			Weaver (3.08.19) Ex. 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J594	02/04/2015	Harvey Clarke Jenkins Immediate Suspension			Weaver (3.08.19) Ex. 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J595	04/02/2015	OBNDD v. Ron Myers			Weaver (3.08.19) Ex. 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J596	11/20/2007	OBNDD v. Nguyen			Weaver (3.08.19) Ex. 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J597	05/28/2013	OBNDD v. Rezaei			Weaver (3.08.19) Ex. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J598	09/25/2015	OBNDD v. Rozsa			Weaver (3.08.19) Ex. 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J599	06/18/2008	OBNDD v. Sims			Weaver (3.08.19) Ex. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J600	06/02/2011	OBNDD v. Tyrrell			Weaver (3.08.19) Ex. 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J601	12/12/2013	Valuck Immediate Suspension			Weaver (3.08.19) Ex. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J602	03/24/2009	OBNDD v. Winchester			Weaver (3.08.19) Ex. 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J603	06/27/2014	Wyly Immediate Suspension			Weaver (3.08.19) Ex. 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J604	08/10/2018	OBNDD v. Collier			Weaver (3.08.19) Ex. 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J605	05/05/2006	OBND v. Hall			Weaver (3.08.19) Ex. 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J606	04/26/2018	OBND v. Hallaba			Weaver (3.08.19) Ex. 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J607	05/17/2018	OBND v. David Thomas			Weaver (3.08.19) Ex. 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J608	04/24/2003	OBND v. Russell			Weaver (3.08.19) Ex. 29	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J609	05/31/2018	Kovacs Immediate Suspension			Weaver (3.08.19) Ex. 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J610	07/16/2018	Hallaba Voluntary Surrender			Weaver (3.08.19) Ex. 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J611	03/10/2011	Email re: Safe Trip for Scripts Program			Weaver (3.08.19) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J612	09/21/2009	Email re: Budget Summaries			Weaver (3.08.19) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J613	12/02/2013	OBND v. Buschman			Weaver (3.08.19) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J614	01/14/2008	OBND v. Clayton			Weaver (3.08.19) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J615	2012	American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers			Webster (2/18/2019) EX. 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J616		Curriculum Vitae of Lynn R. Webster			Webster (2019.02.18) EX. 01		
J617	03/14/2002	PowerPoint: Duragesic Disease Modeling Workshop 2 Takeaways			Webster (2019.02.18) EX. 13		
J618	02/17/2016	United States Cancer Pain Relief Committee Request for Support; Project Title: No Longer Silent	FOLEY-0001070	FOLEY-0001078	Webster (2019.02.18) EX. 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J619	2011	Management Perspective: Pseudoaddiction revisited: a commentary on clinical and historical considerations; Future Medicine Ltd. [ISSN 1758-1869]			Webster (2019.02.18) EX. 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J620	10/2015	Journal of Managed Care & Specialty Pharmacy - Vol. 21, No. 10 - The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain			Webster (2019.02.18) Ex. 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J621		Curriculum Vitae			White (04.11.2019) Ex. 01		
J622	9/12/2018	2018 OBN Drug Threat Assessment			White (04.11.2019) Ex. 02	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J623		List of Actions Taken to Address the Opioid Addiction Epidemic			White (04.11.2019) Ex. 03		
J624	6/19/2017	2017 OBN Oklahoma Drug Threat Assessment			White (04.11.2019) Ex. 04	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J625		Chart re ODMHSAS Online Query System			White (04.11.2019) Ex. 05		
J626	4/29/2018	The Daily Oklahoman re New funding has OK mental health agency in better spot			White (04.11.2019) Ex. 06	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J627		Fiscal Year 2020 ODMHSAS Budget Presentation			White (04.11.2019) Ex. 07	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J628	2/26/2017	Email from Mark Reynolds to Terri White re Oplate	ODMHSAS-0016125	ODMHSAS-0016125	White (04.11.2019) Ex. 08	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J629		Expert Disclosure of T. White			White (04.11.2019) Ex. 09		
J630		Expert Disclosure of Christopher J. Ruhm			White (04.11.2019) Ex. 10		
J631	3/27/2019	Supplementary Tables and Exhibit / Supplemental Expert Disclosure of Christopher Ruhm			White (04.11.2019) Ex. 11		
J632		ASAM Levels of Care Gaps			White (04.11.2019) Ex. 12		
J633	10/2010	Increase in Unintentional Medication Overdose Deaths, Oklahoma, 1994 - 2005			White (04.11.2019) Ex. 13		
J634	12/17/2009	State's Top "Doctor Shopper" Charged			Woodward (2.12.19) Ex. 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J635	03/19/2009	OAG Daily News Clips March 2009			Woodward (2.12.19) Ex. 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J636	09/17/2018	Facebook post about counterfeit oxy laced with fentanyl			Woodward (2.12.19) Ex. 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J637	09/29/2008	Email re: OBNDD Prescription Drug Abuse Data			Woodward (2.12.19) Ex. 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J638	01/29/2013	Prescription Drug Use and Abuse Assessment and Strategy			Woodward (2.12.19) Ex. 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J639	05/10/2007	Email re: Oxycontin maker pleads guilty			Woodward (2.12.19) Ex. 7		

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J640	08/11/2016	Email re: OBN Meth Death Stats (and ppt attachment)			Woodward (2.12.19) Ex. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J641	04/25/2017	Email re: drug trends and patterns committee meeting			Woodward (2.12.19) Ex. 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J642	06/19/2017	2017 Oklahoma Drug Treat Assessment, Oklahoma Bureau of Narcotics	OBN-00001848	OBN-00001882	Woodward (2019.02.12) Ex. 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J643	2002	D. Fishbain, "Medico-legal Rounds: Medico-legal Issues and Breaches of Standards of Medical Care in Opioid Tapering for Alleged Opioid Addiction," Pain Medicine				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J644	2006	Julia Buxton, The Political Economy of Narcotics: Production, Consumption and Global Markets. London and New York: Zed Books, 2006, 246 p				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J645	2007	Fleming, Michael F. - "Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J646	2002	D. Fishbain, "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review," Pain Medicine				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J647	2008	Fishbain, David A. - "What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug- Related Behaviors? A Structured Evidence-Based Review"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J648	05/26/2009	C. Banta-Green, "Opioid use behaviors, mental health and pain—Development of a typology of chronic pain patients," 104 Drug and Alcohol Dependence 34				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J649	2009	George W. Grayson, Mexico's Struggle with 'Drugs and Thugs'. Foreign Policy Association, Headline Series, No. 331, Winter 2009, 96 p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J650	2009	Nucynta advertisement card				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J651	2009	Nucynta Savings Card				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J652	2009	Nucynta Savings Card and coupon				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J653	2010	e-Pharm alert Nucynta "Reimbursement Status Nationwide"	JAN-MS-00235806			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J654	2010	WebMD-Nucynta Alert Email	JAN-MS-00236004			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J655	2011	Nucynta brochure "Opioid Efficacy Meets Unexpected Tolerability"	JAN-MS-00236398			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J656	2010	Nucynta advertisement "Available on the Ohio Bureau of Workers' Compensation"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J657	2010	Noble M. - "Long-term opioid management for chronic noncancer pain (Review)"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J658	2011	Mark A. R. Kleiman, Jonathan P. Caulkins, Angela Hawken, Drugs and Drug Policy: What Everyone Needs to Know. New York: Oxford University press, 2011, 234p.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J659	2011	Nucynta ER Pharmacy Stocking Request Tool	JAN-MS-00229607			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J660	2013	Nucynta ER "Powerful Pain Management"	JAN-MS-00229171			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J661	2012	Nucynta brochure "Opioid Efficacy Meets Unexpected Tolerability: A Single Molecule with a Different Approach to Pain Relief"	JAN-MS-00229335			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J662	2011	Passik, Steven D. - "Pseudoaddiction revisited: a commentary on clinical and historical considerations"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J663	2012	Nucynta advertisement "Eligible for Reimbursement by Indiana Medicaid"	JAN-MS-00229313			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J664	2012	Nucynta ER slide presentation "A Different Option for Chronic Pain Management"	JAN-MS-00229314			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J665	2012	Nucynta brochure "Opioid Efficacy Meets Unexpected Tolerability: A Single Molecule with a Different Approach to Pain Relief"	JAN-MS-00229335			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J666	2012	Nucynta ER brochure "The First and Only Opioid Approved by the FDA for Neuropathic Pain Associated with DPN in Adults"	JAN-MS-00229337			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J667	11/2013	Nucynta ER brochure summarizing study "Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial" by S. Schwartz et al.	JAN-MS-00577327			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J668	2012	Nucynta ER brochure "Which is the First and Only Long-Acting Opioid with a DPN Pain Indication?"	JAN-MS-00229775			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J669	2012	Nucynta ER & Nucynta Infosite on Medscape	JAN-MS-00229930			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J670	2012	Nucynta advertisement "Minimize Callbacks"	JAN-MS-00867324			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J671	2012	Nucynta ER Medication Guides	JAN-MS-00229100			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J672	2012	Minozzi, Silvia - "Development of dependence following treatment with opioid analgesics for pain relief: a systematic review"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J673	2013	2013 Drug Diversion Slidedeck	OSBP00057925			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J674	2013	Nucynta ER brochure "Reimbursement Status Prepared for Southeast Pain Care"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J675	2013	Nucynta ER slide presentation "Powerful Pain Management: Proven Across Multiple Acute and Chronic Pain Models"	JAN-MS-00229171			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J676	01/2014	Nucynta ER "Dosing and Titration Guide"	JAN-MS-00577278			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J677	2013	Nucynta ER & Nucynta slide presentation "Powerful Chronic and Acute Pain Management"	JAN-MS-00229356			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J678	2013	Muhuri, Pradip K. - "Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J679	2014	Nucynta ER brochure "Extended Release; Extended Control"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J680	2015	State-by-state reimbursement status	JAN-MS-00416816			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J681	2015	Jones, Christopher M. - "Vital Signs: Demographic and Substance Use Trends Among Heroin Users—United States, 2002-2013"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J682	2015	Mowbray, Orion - "Prescription pain reliever misuse prevalence, correlates, and origin of possession throughout the life course"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J683	2016	American Medical Association House of Delegates Resolution on CDC Guidelines				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J684	2016	American Medical Association House of Delegates Resolution on CDC Guidelines				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J685	2018	Jala, Hawre - "Changing Dynamics of drug overdose epidemic in the United States from 1979 through 2016" (2018)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J686	2018	Jala, Hawre - "Changing Dynamics of drug overdose epidemic in the United States from 1979 through 2016"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J687	2019	Leshner, Alan I. - "Medications for Opioid Use Disorder Save Lives"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J688	02/01/1973	Marks R., et al., Undertreatment of Medical Inpatients with Narcotic Analgesics, Annals of Internal Medicine, Volume 78, No. 2, pp. 173-181, February 1973				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J689	12/21/1987	Alza Corporation, Section 314.50(c)(viii) Integrated Summary of Safety Data Short-Term Use of TTS (Fentanyl)	JAN-MS-00213627	JAN-MS-00213627		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J690	11/16/1988	Weissman D., et al., Opioid pseudoaddiction - an iatrogenic syndrome, The Journal of the International Association for the Study of Pain Management, 36, pp. 363-366, 1989				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J691	11/29/88	Rationale for the Development, Therapeutic Use, and Clinical Program for Transdermal Therapeutic System (Fentanyl)	JAN-MS-02908137			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J692	12/25/1988	New York Times. Synthetic Heroin Seen As Cause in 18 Deaths. December 25, 1988.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J693	08/07/1990	Duragesic NDA Medical Official Reviews Vols 1-5	JAN-MS-00551711	JAN-MS-00552054		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J694	6/27/1994	Duragesic PADER Feb 1994-May 1994	JAN-MS-00291329	JAN-MS-00291329		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J695	10/7/1994	Duragesic PADER May 1994-Jul 1994	JAN-MS-00291330	JAN-MS-00291330		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J696	11/8/1995	Duragesic PADER Aug 1994-Jul 1995	JAN-MS-00291365	JAN-MS-00291365		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J697	05/24/1996	DUR 12, 1999-2000 Duragesic Annual Report	JAN-MS-03087746	JAN-MS-03087746		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J698	7/1/96	Three-Party CE Educational Grant Agreement (Re Grant ID #29040)	JAN-MS-00394196	JAN-MS-00394200		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J699	10/18/1996	Duragesic PADER Aug 1995-Jul 1996	JAN-MS-00291367	JAN-MS-00291367		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J700	9/30/1997	Duragesic PADER Aug 1995-Jul 1997	JAN-MS-00291369	JAN-MS-00291369		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J701	03/18/1998	Response to FDA Letter: MACMIS File ID #6194	JAN-MS-03090755	JAN-MS-03090851		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J702	04/20/1998	MACMIS File ID #6194	JAN-MS-03090859	JAN-MS-03090861		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J703	04/21/1998	Record of FDA Contact	JAN-MS-03090863	JAN-MS-03090863		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J704	4/28/1998	Food and Drug Administration Center for Drug Evaluation and Research Drug Abuse Advisory Committee	JAN-MS-00890718	JAN-MS-00890888		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J705	05/02/1998	The Federation of State Medical Boards of the United States, Inc., Model Guidelines for the Use of Controlled Substances for the Treatment of Pain (May 2, 1998)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J706	10/1/1998	Paul Delleijn et al., Article entitled, "Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain," Journal of Pain and System Management, Vol. 16, No. 4, October 1998				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J707	10/5/1998	Duragesic PADER Aug 1997-Jul 1998	JAN-MS-00291371	JAN-MS-00291371		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J708	10/1/1999	Duragesic PADER Aug 1998-Jul 1999	JAN-MS-00291374	JAN-MS-00291374		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J709	10/12/1999	DUR packet for 10/12/1999	OUCOP-00041903			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J710	2/8/2000	DUR packet for 2/8/2000	OUCOP-00042087			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J711	02/29/2000	[Letter] re Dissemination of homemade promotional pieces	JAN-MS-00901267	JAN-MS-00901269		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J712	02/29/2000	MACMIS ID #8664	JAN-MS-02090864	JAN-MS-03090883		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J713	03/02/2000	[Email] Duragesic Letter to DDMAC	JAN-MS-00901266	JAN-MS-00901266		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J714	03/20/2000	[Word Doc] Meeting Minutes and action plan GCT meeting Duragesic London	JAN-MS-00478443	JAN-MS-00478446		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J715	3/24/2000	[Email] Clinician Perspectives	JAN-MS-00385987	JAN-MS-00385987		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J716	04/12/2000	[Transmittal] MACMIS ID #8664 Letter re promotional pieces	JAN-MS-03090751			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J717	9/12/2000	DUR packet for 9/12/2000	OUCOP-00042412			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J718	9/20/2000	Duragesic PADER Aug 1999-Jul 2000	JAN-MS-00291381	JAN-MS-00291381		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J719	1/8/2001	Email from Ramiro Roman to Kati Chupa	JAN-MS-00785623	JAN-MS-00785623		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J720	2/9/2001	[Email] Duragesic Coupon Promotion Response	JAN-MS-00309786	JAN-MS-00309786		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J721	2/11/2001	Copy Review Submission Cover Sheet	JAN-MS-00320418	JAN-MS-00320426		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J722	3/9/2001	2001 Pain Management Experts Panel Agenda	JAN-MS-00786821	JAN-MS-00786823		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J723	03/15/2001	500 Gold Sales Force - Motivation and Confidence	JAN-MS-02395029	JAN-MS-02395038		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J724	03/28/2001	Contact Report 3/28.doc	JAN-MS-02395040	JAN-MS-02395042		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J725	04/03/2001	Contact Report 3/28/01	JAN-MS-02395023	JAN-MS-02395023		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J726	04/13/2001	[Email] SMT Comments 03.26-30.01	JAN-MS-00304764	JAN-MS-00304764		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J727	06/07/2001	Congressional Testimony of Alan I. Leshner, June 7, 2001				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J728	6/12/2001	OROS Oxycodone HCl Clinical Development Plan	JAN-MS-00618599	JAN-MS-00618611		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J729	7/10/2001	DUR packet for 7/10/2001	OUCOP-00042916			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J730	7/10/2001	DUR Minutes	OUCOP-00039190			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J731	7/18/2001	[Report/Memo] Maximizing Duragesic's Market Opportunity, A Customized Proposal for Janssen Pharmaceutica	JAN-MS-00311529	JAN-MS-00311538		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J732	8/4/2001	[Email] NUCYNTA ER - SMD Pricing & Contracting Training Deck: MRC Review	JAN-MS-00802141	JAN-MS-00802142		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J733	8/8/2001	Agenda for 8/14/2001 DUR Meeting	OUCOP-00039182			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J734	8/8/2001	DUR packet for 8/14/2001 meeting	OUCOP-00043000			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J735	09/12/2001	[Email] Review of Q&A document for post-FDA AC Meeting for Opioids	JAN-MS-02125588	JAN-MS-02125589		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J736	9/14/2001	Duragesic PADER Aug 2000-Jul 2001	JAN-MS-00291396	JAN-MS-00291396		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J737	9/14/2001	Duragesic PADER, Aug 1999-Jul 2000	JAN-MS-00291396	JAN-MS-00291396		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J738	9/18/2001	DUR Meeting Agenda	OUCOP-00039184			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J739	10/17/2001	Email from D. Bermudez to group re AP-48 core team meeting with PPRM materials attached	JAN-MS-02462097	JAN-MS-02462097		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J740	10/17/2001	D-TRANS AP-48 work plan and cost estimate	JAN-MS-02462123	JAN-MS-02462147		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J741	10/22/2001	ALZZA AP-48 D-TRANS fentanyl + naltrexone PPT	JAN-MS-02462099	JAN-MS-02462122		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J742	11/3/2001	[Meeting Minutes] National Pain Education Council Planning Session	JAN-MS-00312149	JAN-MS-00312151		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J743	11/15/2001	DUR Packet for 9/18/2001	OUCOP-00043056			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J744	11/16/2001	[Email] BPC Executive Summary from 10/29/2001 Meeting	JAN-MS-00780198	JAN-MS-00780198		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J745	11/27/2001	Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J746	11/27/2001	[Word Doc] Janssen Best Practices Council Meeting Summary	JAN-MS-00787307	JAN-MS-00787314		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J747	11/30/2001	[Doc] Executive Summary Scronic Pain Scientific Advisory Board	JAN-MS-00782617	JAN-MS-00782626		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J748	11/30/2001	[Doc] Market Research Notes: Chronic Pain Scientific Advisory Board Nov 30, 2001	JAN-MS-00782628	JAN-MS-00782629		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J749	12/6/2001	[Email] Scientific Ad Board Executive Summary	JAN-MS-00782627	JAN-MS-00782627		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J750	12/11/2001	DUR packet for 11/13/2001	OUCOP-00043144			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J751	12/14/2001	[Email] BPC Report from 11.27.2001	JAN-MS-00787306	JAN-MS-00787306		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J752	12/17/2001	D-Trans (fentanyl) Summary of Benefits and Risks: Abuse and Diversion, Prepared by Pinney Associates	JAN-MS-01139518	JAN-MS-01139597		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J753	1/29/2002	Email from L. Atkinson to group re AP-44 Background Materials	JAN-MS-00618585	JAN-MS-00618585		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J754	1/31/2002	[Letter] Medical Affairs Pain Mycology Monthly Status Report - January 31, 2002	JAN-MS-00784996	JAN-MS-00785015		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J755	1/31/2002	Email from Brian Jones to K. Chupa re: NPEC Ad	JAN-MS-00786231	JAN-MS-00786231		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J756	2/1/2002	Optimizing Product Strategy Through Disease Modeling	JAN-MS-02110740	JAN-MS-02110744		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS {Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them}
J757	02/13/2002	[Email] Follow-up items re DEA	JAN-MS-00777575	JAN-MS-00777575		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J758	2/14/2002	[Email] Review Committee Changes - Abuse Liability	JAN-MS-00786233	JAN-MS-00786233		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J759	3/7/2002	[Email] Education v Promotion Presentation	JAN-MS-04211270	JAN-MS-04211270		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J760	3/7/2002	Duragesic Promotional Speaker Agreement – Ongoing	JAN-MS-00312493	JAN-MS-00312496		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J761	3/7/2002	Email from Peter Christ to kchipa1@janus.jnj.com re CME non-CME deck	JAN-MS-04211270	JAN-MS-04211270		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J762	3/12/2002	DUR packet for 12/11/2001	QUCOP-00043226			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J763	3/17/2002	[Announcement] Announcing The National Pain Education Council- Architects of the Curriculum on "Appropriate Opioid Pharmacotherapy for Pain Management"	JAN-MS-00786232	JAN-MS-00786232		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J764	3/26/2002	D-trans sufentanil + antagonist work plan and cost estimate	JAN-MS-01032303	JAN-MS-01032312		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J765	03/27/2002	[Email] Duragesic Market Definition	JAN-MS-00247176	JAN-MS-00247177		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J766	3/27/2002	[Word Doc] Minutes from Best Practices Council Speakers' Bureau Discussion	JAN-MS-00313721	JAN-MS-00313723		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J767	3/28/2002	[Email] Speakers Bureau Meeting Report	JAN-MS-00313720	JAN-MS-00313720		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J768	04/01/2002	[Email] Discovery International Speaker Bureau	JAN-MS-02395189	JAN-MS-02395192		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J769	4/11/2002	[Email] Publication Plain Development and Competitive Message Review	JAN-MS-00786128	JAN-MS-00786128		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J770	4/11/2002	[Word Doc] 2002 Publication Planning Development and Competitive Message Review	JAN-MS-00786129	JAN-MS-00786131		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J771	4/25/2002	[Email] FW: DSTM- Breakdown by State	JAN-MS-00312486	JAN-MS-00312486		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J772	5/6/2002	[Email] Summary of OBP Performance for OBP/Janssen Partnership	JAN-MS-00313830	JAN-MS-00313830		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J773	5/14/2002	DUR packet for 3/12/2002	OUCOP-00043437			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J774	6/7/2002	[Email] 2002 Accomplishments	JAN-MS-00781930	JAN-MS-00781931		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J775	6/17/2002	NPEC: Appropriate Opioid Pharmacotherapy for Chronic Pain Management: A Multimedia CME Program, Richard Payne and Russell Portenoy				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J776	06/18/2002	Promotion of the NPEC website	JAN-MS-00247230	JAN-MS-00247230		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J777	06/24/2002	[Email] Duragesic Brand Team, 2002 Responsibilities.	JAN-MS-00246878	JAN-MS-00246879		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J778	7/15/2002	Guidance Document: Support of Continuing Medical Education [CME] Activities	JAN-MS-04211257	JAN-MS-04211269		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J779	07/24/2002	[Email] Duragesic Tactical Meeting Recap.	JAN-MS-00246834	JAN-MS-00246834		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J780	7/27/2002	Duragesic PADER Aug 2001-Apr 2002	JAN-MS-00291404	JAN-MS-00291404		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J781	7/27/2002	Duragesic PADER, Aug 2001-Apr 2002	JAN-MS-00291404	JAN-MS-00291404		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J782	9/13/2002	[Email] Duragesic Health Resource Newsletter RDI Analysis	JAN-MS-00787261	JAN-MS-00787262		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J783	9/27/2002	[Email] Duragesic Fourth Quarter Share Growth Contest	JAN-MS-00787515	JAN-MS-00787515		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J784	10/2002	Oklahoma Drug Threat Assessment, National Drug Intelligence Center, U.S. Department of Justice				Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J785	10/3/2002	[Email] NPEC Pain Management CME Meeting - Pre-meeting Teleconference	JAN-MS-00312784	JAN-MS-00312785		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J786	10/23/2002	[Cover Email] History of Duragesic Ad Campaigns	JAN-MS-00305468			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J787	11/6/2002	Email from S. Roman to K. Chupa re NPEC Presentation	JAN-MS-00314078	JAN-MS-00314078		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J788	11/12/2002	DUR Packet for 8/13/2002 meeting	OUCOP-00039246			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J789	12/6/2002	[Email] Duragesic Proposal	JAN-MS-00304926	JAN-MS-00304926		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J790	12/6/2002	Proposal for the Duragesic Regional Advisory Board Meetings to be held in 2003	JAN-MS-00304927	JAN-MS-00304935		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J791	12/16/2002	[Email] NPEC California CME Meetings-Faculty.	JAN-MS-00246792	JAN-MS-00246792		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J792	12/17/2002	[Email] December report to be submitted to Joe Scodari.	JAN-MS-00305065	JAN-MS-00305065		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J793	1/8/2003	[Email] Guidance Document: Support of Continuing Medical Education [CME] Activities	JAN-MS-04211256	JAN-MS-04211256		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J794	1/14/2003	DUR Packet for 11/12/2002	OUCOP-00039954			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J795	01/23/2003	[Email] Pain Management Communicator for Approval	JAN-MS-00777401	JAN-MS-00777401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J796	2/11/2003	DUR Packet for 1/14/2003	OUCOP-00040073			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J797	2/11/2003	[Email] Palladone Message Testing	JAN-MS-00778806	JAN-MS-00778806		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J798	2/20/2003	Health Care Authority and Oxycontin	OKAG-00099327			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J799	03/14/2003	[Email] Pain Franchise Plan	JAN-MS-02390400	JAN-MS-02390400		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J800	03/29/2003	[Report/Memo] Duragesic Regional Advisory Board Meeting - Perry Fine, MD, "Megatrends in Healthcare"	JAN-MS-00304961	JAN-MS-00304962		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J801	03/29/2003	[Report/Memo] Duragesic Regional Advisory Board Meeting - Perry Fine, MD, "Optimizing DURAGESIC in Chronic Pain Patients"	JAN-MS-00304963	JAN-MS-00304964		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J802	4/8/2003	DUR Packet for 3/11/2003	OUCOP-00040429			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J803	4/11/2003	[Email] DTP Communication Plan	JAN-MS-00789592	JAN-MS-00789593		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J804	4/11/2003	Duragesic Direct-to-Patient Pilot Program Introduction	JAN-MS-00789594	JAN-MS-00789595		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J805	5/13/2003	DUR Packet for 4/8/2003	OUCOP-00040609			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J806	5/20/2003	FDA Approval Duragesic sNDA for pediatric indication	JAN-MS-00909266	JAN-MS-00909269		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J807	5/24/2003	Email from E. Mutisya to group re Development program update	JAN-MS-02536039	JAN-MS-025360040		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J808	6/26/2003	Duragesic PSUR May 2002-Apr 2003	JAN-MS-00213714	JAN-MS-00213714		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J809	06/26/2003	Duragesic PSUR, May 2002-Apr 2003	JAN-MS-00213714	JAN-MS-00213714		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J810	7/7/2003	Pharmacodynamic Study to Evaluate AP-58 in Opioid-experienced non-dependent volunteers	JAN-MS-01195547	JAN-MS-01195562		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J811	7/8/2003	DUR packet for 5/13/2003	OUCOP-00040777			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J812	8/12/2003	DUR packet for 7/8/2003	OUCOP-00040927			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J813	8/12/2003	CME Task Force Meeting August 6, 2003	JAN-MS-01195296	JAN-MS-01195297		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J814	8/19/2003	[Email] NEW Duragesic Speaker Program Titles	JAN-MS-00789518	JAN-MS-00789518		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J815	9/9/2003	DUR packet for 8/12/2003	OUCOP-00041109			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J816	9/15/2003	Email from T. Quell re Introduction NPDC attaching presentations	JAN-MS-00423424	JAN-MS-00423425		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J817	10/1/2003	[Email] Meeting Invite for MAPM Core Team Meeting	JAN-MS-00310361	JAN-MS-00310361		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J818	10/14/2003	DUR packet for 9/9/2003	OUCOP-00041309			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J819	10/17/2003	RESOLVE (Randomized Enrollment Study of Opioid Long-term use to eValuate Efficacy)	JAN-MS-00788218	JAN-MS-00788219		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J820	11/4/2003	Key Opinion Leader Advisory Board: defining Relative Abuse Liability for modified release opioid analgesics (MROs) for chronic pain	JAN-MS-02105453	JAN-MS-02105628		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J821	11/6/2003	Marketing Research Briefing Document	JAN-MS-00778989	JAN-MS-00778990		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J822	11/06/2003	Porter-Williamson, Karen - "Pseudoaddiction" (6 Nov. 2003)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J823	11/12/2003	DUR packet for 11/18/2003	OUCOP-00041607			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J824	11/18/2003	DUR packet for 10/14/2003	OUCOP-00041435			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J825	12/19/2003	Email from A. Stephenson to B. Moskovitz re AP-48 & 007 Clinical Study	JAN-MS-01195546	JAN-MS-01195546		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J826	12/23/2003	Email from S. Lande to M. McDonald re AP-48 Report	JAN-MS-03067302	JAN-MS-03067302		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J827	1/9/2004	[Email] Primary Care Incentive Targets 2004	JAN-MS-00788573	JAN-MS-00788573		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J828	01/13/2004	OURB Meeting Packet, Jan. 13, 2004	OKAG-00011806	OKAG-00011865		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J829	1/23/2004	Draft Guidance for Industry: Help-Seeking and Other Disease Awareness Communications by or on behalf of Drug and Device Firms				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J830	1/28/2004	[Presentation] Clinical Program to Differentiate Duragesic from other MROs	JAN-MS-05370564	JAN-MS-05370596		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J831	03/04/2004	Memorandum from Ron Graham, D.Ph. to the Drug Utilization Review Board Members	OKAG-00012039	OKAG-00012087		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J832	3/9/2004	DURB Meeting Packet	OKAG-00012039	OKAG-00012087		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J833	03/10/2004	[Email] Pharmacy Deck - Strategies and Tactics from 2003	JAN-MS-0306371	JAN-MS-0306371		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J834	03/24/2004	[Email] Opening RAB Slides	JAN-MS-00777087	JAN-MS-00777087		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J835	4/1/2004	OSBOE v. Coffman	OSBOE-0000635			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J836	4/5/2004	ALZA sNDA for Duragesic for 12 mcg/h dosage strength	JAN-MS-00781142	JAN-MS-00781146		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J837	4/13/2004	DUR meeting packet; FDA/DEA updates	OKAG-00012164			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J838	04/13/2004	DURB Meeting Packet, Apr. 13, 2004	OKAG-00012164	OKAG-00012224		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J839	06/01/2004	File marked as Appendix 7 containing CIOMS II Reports	JAN-MS-00213745			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J840	6/2/2004	Grow and Defend to Build for the Future - 2005 Business Plan	JAN-MS-00788386	JAN-MS-00788386		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J841	06/12/2004	File marked as Appendix 5 containing PSUR Line Listing Report	JAN-MS-00213742			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J842	06/12/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213746			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J843	06/12/2004	File marked as Appendix A1 containing Nonserious Initial Reports for Fentanyl	JAN-MS-00213747			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J844	06/15/2004	File marked as Appendix A2 collecting Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213731			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J845	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213732			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J846	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213735			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J847	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213736			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J848	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213737			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J849	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213738			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J850	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213739			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J851	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213740			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J852	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213741			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J853	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213748			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J854	06/15/2004	File marked Appendix A2 containing Adverse Event Reports for Duragesic for 6/15/2004	JAN-MS-00213749			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J855	6/25/2004	Duragesic PSUR May 2003-Apr 2004	JAN-MS-00213733	JAN-MS-00213733		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J856	06/25/2004	Letter from Kathleen Dusek to FDA enclosing periodic report of postmarketing adverse drug experiences for Duragesic	JAN-MS-00213733			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J857	8/12/2004	AP-77 Oros Hydromorphone Business Update PPT	JAN-MS-01203031	JAN-MS-01203031		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J858	8/16/2004	Transdermal Fentanyl Systems: Reduced Safety and Increased Societal Risk of Matrix Patch Formulations - A White Paper, Prepared by Mudskipper Strategies	JAN-MS-04307987	JAN-MS-04308090		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J859	8/17/2004	Email from L. Fedow to group re Exciting Developments in the Treatment of Pain	JAN-MS-01235425	JAN-MS-01235428		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J860	09/09/2004	RE: Urgent: DDMAC Action on Duragesic	JAN-MS-02567590	JAN-MS-02567593		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J861	9/17/2004	Duragesic Warning Letter Response MACMIS #12386	JAN-MS-00291332	JAN-MS-00291332		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J862	9/27/2004	Assessment of Abuse Potential of Fentanyl Transdermal Systems in the US, prepared by Pinney Associates	JAN-MS-02130500	JAN-MS-02130546		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J863	9/30/2004	DDMAC letter regarding change of opinion	JAN-MS-00291333	JAN-MS-00291333		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J864	10/6/2004	DURB Meeting Packet	OKAG-00012635			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J865	10/06/2004	Memorandum from Ron Graham, D.Ph. to Drug Utilization Review Board Members	OKAG-00012635	OKAG-00012702		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J866	10/15/2004	Johnson & Johnson letter response	JAN-MS-00291335	JAN-MS-00291335		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J867	10/15/2004	[Email] Janssen/J&JPRD Response Letter to DDMAC 10/15/04	JAN-MS-00779368	JAN-MS-00779368		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J868	10/15/2004	MACMIS #12386	JAN-MS-00779369	JAN-MS-00779373		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J869	10/21/2004	SUPP 5, ALZA Citizens Petition	JAN-MS-00906569	JAN-MS-00306576		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J870	10/21/2004	SUPP 6, Brookoff Citizen Petition	JAN-MS-00306548	JAN-MS-00306568		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J871	11/04/2004	Memorandum from Ron Graham, D.Ph. to the Drug Utilization Review Board Members	OKAG-00012703	OKAG-00012757		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J872	11/12/2004	ALZA Citizen Petition	JAN-MS-02508937	JAN-MS-02508948		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J873	11/12/2004	ALZA Citizen Petition	JAN-MS-02508937	JAN-MS-02508948		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J874	11/12/2004	[Email] Patient Coupon Program	JAN-MS-03072697	JAN-MS-03072698		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J875	12/08/2004	Memo from Ron Graham - University of Oklahoma to Drug Utilization Review Board (DUR) Members re: Packet Contents for Board Meeting - Dec. 14, 2004				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J876	12/09/2004	United States Food and Drug Administration Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs Public Meeting (Dec. 4, 2009) (OPMSL_EREV003_00595773)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J877	12/10/2004	[Presentation] Pain Product Delivery Concepts / IONSYS LCM Recommendations	JAN-MS-00789617			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J878	12/14/2004	DURB Meeting Packet, Dec. 14, 2004	OKAG-00012758	OKAG-00012833		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J879	12/28/2004	DDMAC letter	JAN-MS-00291339	JAN-MS-00291339		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J880	12/28/2004	MACMIS #12386	JAN-MS-02778262	JAN-MS-02778266		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J881	01/06/2005	Memo from Ron Graham - University of Oklahoma to Drug Utilization Board (DUR) Members re: Packet Contents for Board Meeting - January 11, 2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J882	01/11/2005	DURB Meeting Packet, Jan. 11, 2005	OKAG-00011866	OKAG-00011944		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J883	1/12/2005	Johnson & Johnson response letter	JAN-MS-00291340	JAN-MS-00291340		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J884	2/4/2005	FDA Approval Duragesic sNDA for 12 mcg/h dosage	JAN-MS-02371740	JAN-MS-02371787		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J885	02/07/2005	[Email] Duragesic DDL "Corrective Action".	JAN-MS-00257412	JAN-MS-00257412		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J886	02/08/2005	DURB Meeting Packet, Feb. 8, 2005	OKAG-00011979	OKAG-00012038		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J887	2/11/2005	Prescription Drug Research Center "How To Manual" for Duragesic Surveillance Program	JAN-MS-02777505	JAN-MS-02777546		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J888	2/11/2005	Prescription Drug Research Center "How To Manual" for Duragesic Surveillance Program Appendix	JAN-MS-02777547	JAN-MS-02777560		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J889	02/11/2005	The 2012 Johnson Medal for Research and Development Nomination -- Full Application: Nucynta/Nucynta ER	JAN-MS-02777505	JAN-MS-02777546		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J890	2/18/2005	Duragesic (fentanyl transdermal system) Internet Monitoring Methodology (DIMM)	JAN-MS-02777561	JAN-MS-02777580		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J891	3/4/2005	Email from E. Huang to others re E-TRANS chronic/BTP product concept	JAN-MS-01032284	JAN-MS-01032285		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J892	3/10/2005	DURB Meeting Packet	OKAG-00006122	OKAG-00006184		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J893	4/1/2005	Douglas McGray, Article entitled, "The Bitter Pill," WIRED, 04/01/2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J894	4/06/2005	DUR meeting packet, re Duragesic QLs, Memo from University of Oklahoma to DUR Members re: Packet Contents for Board Meeting - April 12, 2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J895	4/12/2005	DUR meeting packet; narcotics review				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J896	04/12/2005	DURB Meeting Packet, Apr. 12, 2005	OKAG-00013715	OKAG-00013780		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J897	4/18/2005	[Word] Sales Training Materials Reviewer Grid	JAN-MS-01015527	JAN-MS-01015527		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J898	4/19/2005	[Email] Field Sales Force Training Materials	JAN-MS-01015525	JAN-MS-01015526		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J899	04/30/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291424			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J900	04/30/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291425			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J901	04/30/2005	FDA Periodic Safety Update Report for Fentanyl	JAN-MS-00291426			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J902	05/04/2005	DUR meeting packet, re federal drug rebate, Memo from University of Oklahoma to DUR Members re: Packet Contents for Board Meeting - May 10, 2005				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J903	5/5/2005	G. Vorsanger Email to K. Naim and B. Moskovitz re PDRC Responsibilities	JAN-MS-00619620	JAN-MS-00619620		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J904	05/05/2005	Email from Gary Vorsanger to Karen Naim	JAN-MS-00619620	JAN-MS-00619620		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J905	5/9/2005	Risk Management Plan for Our Products	JAN-MS-02321524	JAN-MS-02321524		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J906	5/9/2005	[Doc] ABC News/USA Today/Stanford Medical Center Poll: Pain - Broad Experience with Pain Sparks a Search for Relief	JAN-MS-00813494	JAN-MS-00813507		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J907	5/31/2005	Prescription Drug Research Center Duragesic Surveillance Program, Sentinel Network & Media Review Baseline Update Part IA	JAN-MS-02136209	JAN-MS-02136226		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J908	5/31/2005	Prescription Drug Research Center Duragesic Surveillance Program, Sentinel Network & Media Review Baseline Update Part IB	JAN-MS-02136227	JAN-MS-02136238		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J909	5/31/2005	Prescription Drug Research Center Duragesic Surveillance Program, Sentinel Network & Media Review Baseline Update Part II	JAN-MS-02130849	JAN-MS-02130884		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J910	06/09/2005	Adverse Events Reports for Duragesic	JAN-MS-00291410			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J911	06/09/2005	Adverse Events Reports for Duragesic	JAN-MS-00291411			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J912	06/09/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291413			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J913	06/09/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291414			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J914	06/09/2005	FDA Periodic Safety Update Reports, Initial Reports for Fentanyl	JAN-MS-00291422			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J915	06/09/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291428			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J916	06/09/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291429			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J917	06/09/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291430			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J918	06/09/2005	FDA Product Safety Update Reports for Fentanyl	JAN-MS-00291431			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J919	6/10/2005	Duragesic Surveillance Program, Prescription Drug Research Center	JAN-MS-00620634	JAN-MS-00620658		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J920	06/10/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291416			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J921	06/10/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291417			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J922	06/10/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291418			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J923	06/10/2005	FDA Periodic Safety Update Reports for Fentanyl	JAN-MS-00291419			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J924	06/10/2005	Prescription Drug Research Center: Duragesic Surveillance Program	JAN-MS-00620634	JAN-MS-00620658		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J925	6/14/2005	DUR meeting packet; FY 2004 Utilization Summary				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J926	06/16/2005	Treating Doctors as Drug Dealers; The DEA's War on Prescription Painkillers; Ronald T. Libby				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J927	6/24/2005	Duragesic PSUR May 2004-Apr 2005	JAN-MS-00291420	JAN-MS-00291420		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J928	06/24/2005	Letter from Mary Christian to FDA re: Duragesic PSURs	JAN-MS-00291420			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J929	7/22/2005	Letter attaching Duragesic Draft Risk Management Plan	JAN-MS-00213750	JAN-MS-00213750		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J930	08/10/2005	DURB Meeting Packet, Aug. 10, 2005	OKAG-00012447	OKAG-00012511		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J931	8/29/2005	Email from D. Hewitt to B. Moskovitz and G. Vorsanger re First Draft	JAN-MS-02136846	JAN-MS-02136846		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J932	09/16/2005	[Email] First Duragesic Product RMT Meeting	JAN-MS-00619652	JAN-MS-00619652		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J933	10/7/2005	Cumulative Review of Death Cases With the Use of Fentanyl Transdermal System	JAN-MS-00309203	JAN-MS-00309349		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J934	10/07/2005	J&J's Cumulative Review of Death Cases With the Use of Fentanyl Transdermal System	JAN-MS-00309203	JAN-MS-00309349		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J935	12/14/2005	DURB Meeting Packet, Dec. 14, 2005	OKAG-00007891	OKAG-00007948		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J936	01/11/2006	DURB Meeting Packet, Jan, 11, 2006	OKAG-00005500	OKAG-00005561		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J937	1/19/2006	Duragesic Media Monitoring Pilot Program Q4 2005 Summary Report, Karin Sorra PhD	JAN-MS-02107248	JAN-MS-02107256		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J938	02/08/2006	DURB Meeting Packet, Feb. 8, 2006	OKAG-00005681	OKAG-00005743		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J939	3/8/2006	DUR meeting recording and transcription	OUCOP-00038904			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J940	3/8/2006	DURB Meeting Packet	OKAG-00005829	OKAG-00005893		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J941	3/8/2006	DUR Board's meeting packet	OKAG-00005829	OKAG-00005893		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J942	4/2006	Lusher, Joanne - "Analgesic Addiction and Pseudoaddiction in Painful Chronic Illness"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J943	04/06/2006	DUR's meeting packet	OKAG-00005975	OKAG-00006045		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J944	04/12/2006	DURB Meeting Packet, Apr. 12, 2006	OKAG-00005975	OKAG-00006045		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J945	05/22/2006	[Email] Next Duragesic CRC Review Meeting	JAN-MS-00747381	JAN-MS-00747383		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J946	6/7/2006	Examination of Transdermal Fentanyl Patch Systems Postings on Internet Bulletin Boards	JAN-MS-02107443	JAN-MS-02107632		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J947	06/07/2006	Examination of Transdermal Fentanyl Patch Systems Postings on Internet Bulletin Boards	JAN-MS-02107443	JAN-MS-02107632		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J948	6/14/2006	DUR meeting recording and transcription	OUCOP-00038942			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J949	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291432			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J950	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291433			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J951	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291434			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J952	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291435			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J953	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291436			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J954	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291437			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J955	06/14/2006	Duragesic PSUR May 2005-Apr 2006	JAN-MS-00291438			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J956	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291439			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J957	06/14/2006	File of FDA PSURs for Fentanyl	JAN-MS-00291440			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J958	06/21/2006	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00291442	JAN-MS-00291442		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J959	07/12/2006	DURB Meeting Packet, Jul. 12, 2006	OKAG-00006431	OKAG-00006487		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J960	8/2/2006	Assessment of the Abuse of Fentanyl Products (Cicero, Inciardi, Munoz)	JAN-MS-00613857	JAN-MS-00613888		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J961	10/5/2006	[Word] Sales Training Materials Reviewer Procedure	JAN-MS-01124853	JAN-MS-01124857		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J962	10/11/2006	DURB Meeting Packet	OKAG-00007416	OKAG-00007491		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J963	11/01/2006	[Powerpoint] R331 Patient Willingness to Pay Study Topline Report	JAN-MS-00435591			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J964	11/8/2006	DURB Meeting Packet	OKAG-00007599	OKAG-00007656		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J965	11/8/2006	DURB Meeting Packet	OKAG-00012703	OKAG-00012757		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J966	12/13/2006	DURB Meeting Packet, Dec. 13, 2006	OKAG-00008039	OKAG-00008108		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J967	12/13/2006	DUR's meeting packet	OKAG-00008039	OKAG-00008108		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J968	12/20/2006	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213786	JAN-MS-00213786		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J969	01/01/2007	IMS Health Information Services Agreement (J&J Master Agreement)	JAN-MS-03108923	JAN-MS-03108974		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J970	01/01/2007	"IMS HEALTH Information Services Agreement AGREEMENT No.: J&J-MasterAgreement07-09"	JAN-MS-03108975	JAN-MS-03109026		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J971	01/01/2007	"IMS HEALTH Information Services Agreement AGREEMENT No.: J&J-MasterAgreement07-09"	JAN-MS-03109087	JAN-MS-03109138		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J972	01/15/2007	{Email} Master KOL Listing	JAN-MS-02533808	JAN-MS-02533810		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J973	2/27/2007	Email from G. Vorsanger to group re First Three Final Tableids	JAN-MS-02310916	JAN-MS-02310917		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J974	5/2/2007	Tapentadol Pain Clinician Advisory Board Executive Summary	JAN-MS-01241846	JAN-MS-01241850		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J975	5/9/2007	DUR meeting recording and transcription	OUCOP-00038926			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J976	5/9/2007	DURB Meeting Packet	OKAG-00006046	OKAG-00006121		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J977	5/11/2007	FW: Tapentadol Ad Bd. Exec Summary	JAN-MS-01241845	JAN-MS-01241845		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J978	05/16/2007	{PowerPoint} Emotive Drivers Qualitative Physician and Patient Research	JAN-MS-00504451			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J979	5/31/2007	{Approval Form} S50 Trade Coupon	JAN-MS-02011314	JAN-MS-02011319		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J980	6/5/2007	Duragesic First Annual Progress Report	JAN-MS-00213785	JAN-MS-00213785		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J981	6/5/2007	Duragesic First Annual Progress Report Attachments	JAN-MS-00213786	JAN-MS-00213786		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J982	6/14/2007	Duragesic Revised Risk Management Plan (redline)	JAN-MS-00213784	JAN-MS-00213784		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J983	6/15/2007	Letter re Revised Risk Management Plan	JAN-MS-00213780	JAN-MS-00213780		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J984	6/29/2007	Duragesic PSUR May 2006-Apr 2007	JAN-MS-00213795	JAN-MS-00213795		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J985	06/29/2007	FDA Periodic Safety Update Report- Fentanyl	JAN-MS-00213795	JAN-MS-00213795		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J986	07/01/2007	"QuintilesIMS Fifteenth Amendment to Information Services Agreement No. COBS-0608-1213"	JAN-MS-03109070	JAN-MS-03109072		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J987	07/03/2007	RE: Smart Moves, Smart Choice Coverage: Kansas City Star	JAN-MS-00501425	JAN-MS-00501427		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J988	7/9/2007	KOL Slides	JAN-MS-02012737	JAN-MS-02012737		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J989	7/13/2007	DUR meeting packet; FDA/DEA updates				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J990	7/17/2007	[Memorandum] Summary of Ortho-McNeil tapentadol Public Relations Activities/ April-June 2007	JAN-MS-01244657	JAN-MS-01244659		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J991	09/04/2007	Email from Paul Simms to Wesley Dorey: "RE: Target List - Filter Ability by Region, Rep, RDT, etc."	JAN-MS-02750931	JAN-MS-02750932		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J992	09/11/2007	[PDF] THREE-PARTY EDUCATIONAL GRANT AGREEMENT Regarding a Continuing Education or Independent Education Grant	JAN-MS-00408253	JAN-MS-00408257		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J993	9/12/2007	DUR meeting packet; Utilization Review of Narcotic Analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J994	9/12/2007	DUR meeting packet; Utilization Review of Narcotic Analgesics				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J995	9/12/2007	DUR meeting recording and transcription	OUCOP-0039022			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J996	9/12/2007	DURB Meeting Packet	OKAG-00006637	OKAG-00006710		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J997	9/12/2007	DUR meeting packet re vote to approve CoP recs re QLS				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J998	9/27/2007	Email from L. Wilson to group re Duragesic FDA Electronic Sampling	JAN-MS-02003147	JAN-MS-02003147		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J999	09/28/2007	[Email] RE: Thanks for an excellent meeting!	JAN-MS-002856314	JAN-MS-002856314		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1000	10/10/2007	DUR meeting packet w/FDA release re stopping marketing of unapproved hydrocodone				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1001	10/22/2007	Email from Wes Dorley to Scott Trembley: "RE DURAGESIC DEFEND AND GROW"	JAN-MS-02751055	JAN-MS-02751057		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1002	10/31/2007	Pain Management Health Education Program Project Brief	JAN-MS-00503337	JAN-MS-00503340		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1003	11/08/2007	Health Care Compliance Training	JAN-MS-02390078	JAN-MS-02390142		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1004	11/16/2007	FW: Duragesic Slide Deck - Med Comm comments attached	JAN-MS-00747490	JAN-MS-00747491		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1005	12/03/2007	Sriram Venkataraman, et al., The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link?, Management Science, Vol. 53, No. 11, pp. 1688-1701, December 3, 2007				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1006	12/10/2007	[Letter] American Academy Family Physicians - MedEd "Learning Link"	JAN-MS-00945651	JAN-MS-00945652		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1007	12/12/2007	Regulatory Agency Contact Report	JAN-MS-03124082	JAN-MS-03124087		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1008	12/14/2007	[Email] OMISA Letter of Agreement - Medscape Pain Resource Center - Grant #5019	JAN-MS-02498955	JAN-MS-02498956		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1009	12/14/2007	[Letter] Executed Copy of the CME Letter Agreement for Janssen's Independent Educational Grant	JAN-MS-02498957	JAN-MS-02498963		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1010	01/01/2008	What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Fishbain D., et al., Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review, Pain Medicine, Volume 9, Number 4, 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1011	1/2/2008	DUR meeting packet w/FDA news re following fentanyl insert, Memo from University of Oklahoma to DUR Members re: Packet Contents for Board Meeting - January 9, 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1012	1/7/2008	Efficacy and Safety of Tapentadol IR Over 90 Days for Relief of Low Back Pain or Osteoarthritis Pain	JAN-MS-01018741	JAN-MS-01018742		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1013	1/7/2008	Safety of Tapentadol IR for Opioid-experienced and Non-experienced Patient Populations after 90 Days of Exposure in Patients with Low Back Pain or Osteoarthritis Pain	JAN-MS-01018743	JAN-MS-01018745		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1014	1/7/2008	Long-term Use of Tapentadol Immediate Release for the Treatment of Low Back Pain and Osteoarthritis Pain: A Safety Study	JAN-MS-01018746	JAN-MS-01018748		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1015	1/7/2008	Tapentadol Immediate Release Provides Effective Analgesia of Acute Pain Following Orthopedic Surgery in a Randomized, Double-Blind, Placebo-controlled, Phase III Study	JAN-MS-01018749	JAN-MS-01018751		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1016	1/7/2008	Effective Relief of Acute Pain Following Orthopedic Surgery: Efficacy and Tolerability of Tapentadol Immediate Release in a Randomized, Double-blind, Placebo-Controlled, Phase III Study	JAN-MS-01018752	JAN-MS-01018754		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1017	1/7/2008	Tapentadol Immediate Release Provides Effective Acute Pain Relief Following Bunionectomy Surgery in a Randomized, Double-Blind, Active- and Placebo-controlled, Phase III Study	JAN-MS-01018755	JAN-MS-01018757		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1018	1/7/2008	Efficacy and Tolerability Data Supporting the Use of Tapentadol Immediate Release for the Relief of Pain from End-Stage Joint Disease	JAN-MS-01018758	JAN-MS-01018760		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1019	1/7/2008	Tapentadol Immediate Release Provides Effective Pain Relief in Patients Awaiting Primary Joint Replacement Surgery in a Randomized, Double Blind, Active- and Placebo-Controlled, Phase III Study	JAN-MS-01018761	JAN-MS-01018763		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1020	1/7/2008	Efficacy and Tolerability Data for Tapentadol Immediate Release: Pain Relief in Patients suffering from End-Stage Joint Disease	JAN-MS-01018764	JAN-MS-01018766		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1021	01/08/2008	CME/CE-Certified Workshop Announcement-Pain ("Individualizing Analgesic Regimens_Strategies to Reduce Abuse and Diversion")	JAN-MS-00946480	JAN-MS-00946481		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1022	01/08/2008	("Informational Pamphlet) Individualizing Analgesic Regimens - Strategies to Reduce Abuse and Diversion"	JAN-MS-00946482	JAN-MS-00946482		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1023	01/09/2008	DURB Meeting Packet, Jan, 9, 2008	OKAG-00005562	OKAG-00005614		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1024	1/11/2008	Tapentadol IR Safety Surveillance Plan	JAN-MS-00230429	JAN-MS-00230429		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1025	1/14/2008	Duragesic Progress Report Covering the Period 01 January 2004 to 31 March 2007	JAN-MS-00132845	JAN-MS-00132845		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1026	1/14/2008	[Email] Re: Duragesic - Dr. Rafael Justice (Texas)	JAN-MS-00281494	JAN-MS-00281494		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1027	1/15/2008	RADARS System Fentanyl Data Q3 2007	JAN-MS-02146501	JAN-MS-02146515		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1028	01/17/2008	PMLC Steering Committee Meeting - 01/17/2008	JAN-MS-00475321	JAN-MS-00475324		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1029	01/18/2008	Project Brief Meeting Title: Pain Management Leadership Council: Chronic Pain	JAN-MS-00475394	JAN-MS-00475394		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1030	1/23/2008	Nucynta IR NDA Cover Letter	JAN-MS-00230389	JAN-MS-00230389		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1031	1/23/2008	Nucynta IR Application to Market a New Drug	JAN-MS-00230390	JAN-MS-00230390		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1032	02/03/2008	Attendee list for Dec. 2008 FDLI Conference	JAN-MS-03124015	JAN-MS-03124015		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1033	2/7/2008	DUR meeting packet, cost primary consideration, Memo from University of Oklahoma to DUR Members re: Packet Contents for Board Meeting - February 13, 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1034	2/13/2008	DUR meeting recording and transcription	QUCOP-00038901			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1035	02/13/2008	DURB Meeting Packet, Feb. 13, 2008	OKAG-00001828	OKAG-00001890		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1036	2/22/2008	[Email] Timelines and budget for APT-EM (attachment - APT-EM CME budget)	JAN-MS-00392809	JAN-MS-00392809		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1037	03/10/2008	[PDF] MEDICAL EDUCATION DEPARTMENT MONTHLY REPORT	JAN-MS-00407539	JAN-MS-00407641		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1038	3/12/2008	DUR meeting packet; FY 2007 Annual Review	OKAG-00000445			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1039	03/12/2008	DURB Meeting Packet, Mar. 12, 2008	OKAG-00000445	OKAG-00000552		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1040	3/12/2008	[Approval Form] Physician Survey	JAN-MS-01239438	JAN-MS-01239448		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1041	3/18/2008	Duragesic Third Risk Management Plan Progress Report	JAN-MS-00132850	JAN-MS-00132850		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1042	3/19/2008	[Email] For Review: Draft Press Release on Tapentadol OA wait list study for APS	JAN-MS-01241634	JAN-MS-01241634		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1043	3/19/2008	[Email] For review: Confidential draft: 90 day safety study	JAN-MS-01241636	JAN-MS-01241636		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1044	03/19/2008	[Email] FOR REVIEW: Draft press release on bunionectomy study	JAN-MS-02498895	JAN-MS-02498895		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1045	3/24/2008	B. Moskovitz email to R. Desiraju and others re Duragesic Development Plan for a Matrix Patch	JAN-MS-02005184	JAN-MS-02005185		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1046	4/1/2008	RADARS System Fentanyl Data Q4 2007	JAN-MS-02146542	JAN-MS-02146553		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1047	4/3/2008	DUR meeting packet w/vote to PA narc analgesics, Memo from University of Oklahoma to DUR Members re: Packet Contents for Board Meeting - April 9, 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1048	4/9/2008	DUR meeting recording and transcription	OUCOP-00038916			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1049	4/11/2008	[Email] For Review: Tapentadol Insider Articles	JAN-MS-01234042	JAN-MS-01234045		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1050	4/16/2008	National Association of School Nurses Launches Educational Program to Address Surge of Prescription Drug Abuse by America's Youth	JAN-MS-00500040	JAN-MS-00500041		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1051	4/16/2008	Copy Review Approval Form and Cover Sheet - NEOPathways	JAN-MS-00813527	JAN-MS-00813543		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1052	04/16/2008	[Form] Copy Review Approval Form - Tapentadol	JAN-MS-03778931	JAN-MS-03778931		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1053	04/17/2008	RE: Smart Moves, Smart Choice Coverage: Kansas City Star	JAN-MS-00504036	JAN-MS-00504039		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1054	4/22/2008	RE: Updated: Tapentadol Core Team Meeting	JAN-MS-01237304	JAN-MS-01237306		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1055	4/24/2008	Let's Talk Pain Web Manuscript Draft	JAN-MS-01234242	JAN-MS-01234257		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1056	4/24/2008	[Email] LTP Web Site Manuscript	JAN-MS-01234241	JAN-MS-01234241		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1057	5/6/2008	NeoPathwaysinPain submission-soft copies	JAN-MS-00813526	JAN-MS-00813526		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1058	5/14/2008	DURB Meeting Packet	OKAG-0000754	OKAG-00000818		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1059	5/20/2008	2009 budget requests for Tapentadol and Carisbamate	JAN-MS-00276491	JAN-MS-00276492		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1060	06/03/2008	FW: Neo Pathways Materials (1 of 3)	JAN-MS-02402894	JAN-MS-02402894		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1061	6/6/2008	Draft June 6, 2008; Neo Pathways: New Directions in Pain	JAN-MS-01136210	JAN-MS-01136210		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1062	06/12/2008	Rep recruiting	JAN-MS-00274248	JAN-MS-00274251		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1063	6/16/2008	Duragesic Fourth Risk Management Plan Progress Report	JAN-MS-00151777	JAN-MS-00151777		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1064	6/17/2008	Duragesic PSUR May 2007-Apr 2008	JAN-MS-00132853	JAN-MS-00151773		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1065	06/18/2008	"IMS HEALTH Information Services Agreement AGREEMENT No.: COBS- SFE0608-1213"	JAN-MS-03108859	JAN-MS-03108872		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1066	06/18/2008	"IMS HEALTH Information Services Agreement AGREEMENT No.: COBS- SFE0608-1213"	JAN-MS-03108873	JAN-MS-03108886		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1067	06/18/2008	IMS HEALTH Information Services Agreement AGREEMENT No.: COBS- SFE0608-1213	JAN-MS-03109073	JAN-MS-03109086		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1068	06/19/2008	Michael Law, et al., Effect of Illicit Direct to Consumer Advertising on Use of Etanercept, Mometasone, and Tegaserod in Canada: Controlled Longitudinal Study, British Medical Journal, Vol. 337, a1055				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1069	06/26/2008	[Email] INROADS Syllabus & Primer (attachment)	JAN-MS-00406423	JAN-MS-00406423		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1070	6/30/2008	Tapentadol Copy Review Meeting Agenda-July 9, 2008	JAN-MS-01234739	JAN-MS-01234740		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1071	07/01/2008	ASHP guidelines on the pharmacy and therapeutics committee and the formulary system, ASHP Reports, Am J Health-Syst Pharm, Vol. 65, pp. 1272-83, 2008				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1072	07/14/2008	Conrad & Associates; Finding Relief: Pain Management for Older Adults (internal copy with references) (July 14, 2008)	JAN-MS-00476706			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1073	07/22/2008	Guidance Document on Educational Support	JAN-MS-05457397			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1074	07/22/2008	Guidance Document on Educational Support	JAN-MS-05457397	JAN-MS-05457445		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1075	08/02/2008	PriCara Post Operative Pain Management in Gynecology Surgery Advisory Board Meeting, 08/02/2008	JAN-MS-00476488	JAN-MS-00476504		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1076	8/14/2008	[Email] Comments on Pain Survey	JAN-MS-00947215	JAN-MS-00947215		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1077	09/08/2008	NFO Pathways Speaker NewsChannel Segment #2 submission to CRC	JAN-MS-00472000	JAN-MS-00472010		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1078	09/16/2008	Cover email from M. Wanat to David Moore re: GYN AD Board Exec. Summary	JAN-MS-00476487	JAN-MS-00476487		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1079	9/23/2008	[Report] Nucynta: Redefining Success in Pain Management	JAN-MS-01136399	JAN-MS-01136404		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1080	9/26/2008	Duragesic Revised Risk Management Plan	JAN-MS-00151804	JAN-MS-00151804		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1081	9/26/2008	Duragesic Revised Risk Management Plan (redline)	JAN-MS-00151805	JAN-MS-00151805		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1082	9/26/2008	Letter re Revised Risk Management Plan	JAN-MS-00151803	JAN-MS-00151803		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1083	10/02/2008	Email re: PriCara Prices	JAN-MS-00476730	JAN-MS-00476730		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1084	10/6/2008	Email re: Dr. Crass	OHCA-00423106			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1085	10/6/2008	[Email] Outcomes Inc. Pain Study Final Report & Website	JAN-MS-00947213	JAN-MS-00947213		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1086	10/15/2008	[Approval Form] Let's Talk Pain MAT Releases	JAN-MS-01233375	JAN-MS-01233378		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1087	10/17/2008	Email re Prices for painmgtpriCara	JAN-MS-00476732	JAN-MS-00476732		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1088	10/22/2008	Email from Maryann Gribbin to Jill Lavitski, Veronica Cruz, Kathy Phee, et al.	JAN-MS-05433748	JAN-MS-05433749		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1089	11/03/2008	[Report/Memo] Pain Management Advisory Board, PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc - Executive Summary	JAN-MS-00278194	JAN-MS-00278203		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1090	11/20/2008	Nucynta IR Summary Review	JAN-MS-03089129	JAN-MS-03089142		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1091	11/20/2008	Nucynta IR NDA Approval Letter from FDA	JAN-MS-01232317	JAN-MS-01232356		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1092	12/05/2008	[Word Doc] Duragesic Product Risk Management Team Contact Information	JAN-MS-00593374	JAN-MS-00593374		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1093	12/5/2008	Nucynta pharmacy leave behind	JAN-MS-04146535	JAN-MS-04146541		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1094	12/10/2008	DURB Meeting Packet, Dec. 10, 2008	OKAG-00004814	OKAG-00004931		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1095	12/11/2008	Duragesic Fifth Risk Management Plan Progress Report	JAN-MS-00151810	JAN-MS-00151810		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1096	12/18/2008	[Email] tapentadol fair balance statement- ISI	JAN-MS-00327211	JAN-MS-00327212		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1097	1/1/2009	Alan Schatzberg et al., Textbook of Psychopharmacology, Chapter 66: "Treatment of Chronic Pain Syndromes" 4th Edition, American Psychiatric Publishing				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1098	1/5/2009	[Email] Tapentadol Product Launch Training Deliverables/timeline	JAN-MS-01124828	JAN-MS-01124828		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1099	01/06/2009	RE: Prescribe Responsibly.com	JAN-MS-00264010	JAN-MS-00264011		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1100	01/07/2009	[Email] Med/Reg/HCC Review: Tapentadol 24 Hour Launch Training Workshops (Due Jan 6th)	JAN-MS-00469968	JAN-MS-00469970		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1101	1/8/2009	[Email] Review of 2008 Pain Initiatives/NIDA - Updated with Presentation	JAN-MS-00943833	JAN-MS-00943833		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1102	1/8/2009	[Email] MRC Review: Alpha version of Annotated 10-Day-End-Stage Joint Disease Study Backgrounder	JAN-MS-01124830	JAN-MS-01124831		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1103	1/08/2009	DUR meeting packet w/SoonerCare Lock-in Program criteria, Packet Contents for Board Meeting - January 14, 2009				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1104	01/14/2009	DURB Meeting Packet, Jan. 14, 2009	OKAG-00015460	OKAG-00015519		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1105	01/14/2009	Pain Franchise "Digital Deployment Strategy" 2009 PR Activities	JAN-MS-00277462	JAN-MS-00277463		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1106	01/16/2009	Tapentadol "Let's Talk Pain" 2009 PR Activities	JAN-MS-00500042	JAN-MS-00500043		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1107	1/16/2009	[Agreement] Tapentadol "Prescribe Responsibly" 2009 PR Activities	JAN-MS-00944802	JAN-MS-00944803		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1108	01/21/2009	Tapentadol "WIP Analyst Presentation" 2009 PK Activities	JAN-MS-00500405	JAN-MS-00500406		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1109	01/21/2009	Tapentadol "WIP Analyst Presentation" 2009 PR Activities	JAN-MS-00507009	JAN-MS-00507009		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1110	1/22/2009	Tapentadol "Prescribe Responsibly" 2009 PR Activities	JAN-MS-01246704	JAN-MS-01246705		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1111	01/23/2009	Ketchum scope of work for WIP analyst presentation	JAN-MS-00507008	JAN-MS-00507008		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1112	1/23/2009	FW: Prescribe Responsibly.com	JAN-MS-01246700	JAN-MS-01246703		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1113	02/02/2009	[Email] Post-MRC Training PDFs (FYI-Dave, Carole)	JAN-MS-00836973	JAN-MS-00836975		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1114	02/11/2009	DURB Meeting Packet, Feb. 11, 2009	OKAG-00000139	OKAG-00000190		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1115	2/13/2009	Email re: This will probably drive up the hydrocodone even more	OHCA-00153003			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1116	02/13/2009	[Presentation] Tapentadol IR Training (February 13, 2009)	JAN-MS-00468261			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1117	2/19/2009	Tapentadol "Prescribe Responsibly" 2009 PR Activities	JAN-MS-00350790	JAN-MS-00350792		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1118	2/27/2009	Prescribe Responsibly Conference Call Summary	JAN-MS-00944824	JAN-MS-00944825		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1119	3/4/2009	EDGR Meeting: Medical Affairs Comments	JAN-MS-00947602	JAN-MS-00947603		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1120	03/09/2009	FDA Kicks Off Opioid REMS Discussion; Asks for Industry Collaboration	JAN-MS-00484776	JAN-MS-00484777		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1121	3/10/2009	Nucynta IR PADER Nov 2008-Feb 2009	JAN-MS-00235114	JAN-MS-00235114		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1122	03/11/2009	DURB Meeting Packet, Mar. 11, 2009	OKAG-0000308	OKAG-0000372		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1123	03/11/2009	DUR's meeting packet	OKAG-0000308	OKAG-0000372		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1124	03/19/2009	Two-Party CE Educational Grant Agreement (Re Grant ID #25601)	JAN-MS-00918175	JAN-MS-00918180		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1125	3/24/2009	[Email] Prescribe Responsibly: PriCara Education Project - Updated Web Site Overview and Case Study Template	JAN-MS-00944828	JAN-MS-00944829		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1126	3/24/2009	[Word Doc] PriCara Prescribe Responsibly Web Site Content Outline	JAN-MS-00944830	JAN-MS-00944832		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1127	03/29/2009	[Memorandum] AAPM Meeting Notes	JAN-MS-00929255	JAN-MS-00929257		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1128	03/31/2009	Banta-Green, Caleb J. - "Opioid use behaviors, mental health and pain—Development of a typology of chronic pain patients"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1129	4/2/2009	FW: Prescribe Responsibly: Sermo Survey Results	JAN-MS-00946007	JAN-MS-00946007		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1130	4/2/2009	[Letter] Indemnification Letter	JAN-MS-01456438	JAN-MS-01456439		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1131	04/06/2009	[Email] Corporate Council Meeting Notes	JAN-MS-00929254	JAN-MS-00929254		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1132	04/08/2009	DURB Meeting Packet, Apr. 8, 2009	OKAG-00000555	OKAG-00000613		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1133	04/08/2009	DUR's meeting packet	OKAG-00000555	OKAG-00000613		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1134	04/16/2009	"Let's Talk Pain" Talk Show Key Messages	JAN-MS-00507596	JAN-MS-00507598		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1135	04/21/2009	[Email] Inside the Data next steps	JAN-MS-02214196	JAN-MS-02214197		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1136	4/27/2009	DEA conference attendance certificates	JAN-MS-03124016	JAN-MS-03124021		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1137	5/26/2009	Email from S. Nicholson to group re presentations and agenda for May 27-28 FDA meeting	JAN-MS-01048368	JAN-MS-01048368		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1138	5/26/2009	[Email] FW: 28019-Emerging Solutions in Pain (attachment)	JAN-MS-00394146	JAN-MS-00394147		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1139	6/4/2009	Draft Charter of the Opioid REMS Industry Working Group	JAN-MS-01152825	JAN-MS-01152828		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1140	6/5/2009	Nucynta IR PADER Feb 2009-May 2009	JAN-MS-00235118	JAN-MS-00235118		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1141	06/09/2009	FW: Prescribe Responsibly: Jennifer Bolen Content	JAN-MS-00930038	JAN-MS-00930038		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1142	06/10/2009	DURB Meeting Packet, Jun. 10, 2009	OKAG-00010556	OKAG-00010601		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1143	06/10/2009	FW: Prescribe Responsibly: Introductory Text and Welcome Video	JAN-MS-00930049	JAN-MS-00930049		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1144	06/10/2009	DUR's meeting packet	OKAG-00010556	OKAG-00010601		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1145	06/15/2009	Prescribe Responsibly Web Site Manuscript, For Review	JAN-MS-00930063	JAN-MS-00930064		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1146	6/17/2009	Duragesic PSUR May 2008-Apr 2009	JAN-MS-00151818	JAN-MS-00165570		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1147	06/19/2009	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, Nucynta IR	JAN-MS-00236013			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1148	6/29/2009	Email from L. Schuessler to FDA attaching IWG Submission re REMS	JAN-MS-00677128	JAN-MS-00677128		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1149	6/30/2009	Johnson & Johnson sNDA for Duragesic matrix patch	JAN-MS-02371562	JAN-MS-023715623		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1150	7/8/2009	DUR meeting recording and transcription	OUCOP-00038946			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1151	7/8/2009	DUR meeting packet; 30 Day Notice to Apply Quantity Restrictions to Hydrocodone Combination Products				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1152	07/09/2009	Email from N. Nesser to L. Mitchell	OHCA-00153635	OHCA-00153635		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1153	07/09/2009	Email from Nancy Nesser to Lynn Mitchell	OHCA-00153635	OHCA-00153635		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1154	07/13/2009	[Email] APHA Grant Application Follow-Up #28713	JAN-MS-00918763	JAN-MS-00918765		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1155	7/31/2009	FDA Approval Duragesic sNDA for matrix patch	JAN-MS-02749196	JAN-MS-02749250		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1156	08/06/2009	Letter Notifying HCP of Removal from Speaker Bureau	JAN-MS-00837174	JAN-MS-00837174		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1157	08/06/2009	Drug Utilization Review Board Presentation Presentation, Oklahoma Health Care Authority	OKAG-00001069	OKAG-00001118		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1158	08/07/2009	Dr. Amirdelfan: Speaker Removal	JAN-MS-00837173	JAN-MS-00837173		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1159	08/11/2009	Chintagunta, Pradeep K., et al., Information, learning, and drug diffusion: The case of Cox-2 inhibitors, Quant Mark Econ, 7:399-443, August 11, 2009				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1160	08/12/2009	DURB Meeting Packet, Aug. 12, 2009	OKAG-00001069	OKAG-00001118		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1161	08/12/2009	Bruce Maskovitz Transcript	JAN-MS-00930203	JAN-MS-00930203		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1162	8/12/2009	RE: First copy review edits	JAN-MS-00934351	JAN-MS-00934352		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1163	8/12/2009	DUR meeting minutes re approval of QL on hydrocodone	OKAG-00001184			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1164	08/17/2009	[Email] Item Number for DURAGESIC DURAGESIC Matrix Important Safety Information (ISI) 01 DR09008	JAN-MS-00280637	JAN-MS-00280638		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1165	8/25/2009	Email re: Follow-up on Oklahoma Opioid data	OHCA-00153875			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1166	08/25/2009	Facing Pain Blog	JAN-MS-00507646	JAN-MS-00507647		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1167	08/26/2009	[Email] Please review: Prescribe Responsibly --additional copy on risk	JAN-MS-02206691	JAN-MS-02206691		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1168	09/02/2009	"[Email] Satellite Media Tour with American Chronic Pain Association: Safe Use of Pain Medicines"	JAN-MS-00930256	JAN-MS-00930256		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1169	09/02/2009	"[Word Doc] SMT/RMT: Making Sense of Pain Medicine Confusion Key Messages and Questions"	JAN-MS-00930258	JAN-MS-00930260		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1170	9/9/2009	DUR meeting recording and transcription				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1171	9/9/2009	DURB Meeting Packet	OKAG-00001174	OKAG-00001253		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1172	9/15/2009	Nucynta IR PADER May 2009-Aug 2009	JAN-MS-00235122	JAN-MS-00235122		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1173	09/16/2009	"[Announcement] Health Interview: Making Sense of Pain Medicine Confusion"	JAN-MS-00930257	JAN-MS-00930257		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1174	9/18/2009	Summary of Safety Results and Conclusions for Nucynta IR NDA 22304	JAN-MS-02214038	JAN-MS-02214159		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1175	9/18/2009	[Email] Pain Management-v2.ppt	JAN-MS-00395012	JAN-MS-00395012		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1176	09/24/2009	[Promo] Copy of invitation for CME/CE Dinner Symposium - High Stakes, Young Lives: Prescription Medications In Our Communities	JAM-MS-00394550	JAM-MS-00394554		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1177	10/2/2009	RADARS System Tapentadol Report Q2 2009	JAN-OK-00042464	JAN-OK-00042596		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1178	10/08/2009	Drug Utilization Review Board Presentation Presentation, Oklahoma Health Care Authority	OKAG-00009037	OKAG-00009099		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1179	10/14/2009	DUR meeting recording and transcription	OUCOP-00039004			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1180	10/14/2009	DURB Meeting Packet	OKAG-00009037	OKAG-00009099		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1181	10/14/2009	DEA Pharma Conference Attendees List	JAN-MS-03124074	JAN-MS-03124075		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1182	10/22/2009	"[Letter] Adding Quality to Life: New Strategies to Break the Cycle of Acute and Chronic Pain in Rehabilitation"	JAN-MS-00932484	JAN-MS-00932486		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1183	11/09/2009	[Email] Webcast Registration Update - ASCP Live Webcase on Pain Management in Long-Term Care	JAN-MS-00262924	JAN-MS-00262924		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1184	11/12/2009	DURB Meeting Packet	OKAG-00010911	OKAG-00010961		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1185	11/12/2009	Three-Party CE Educational Grant Agreement (Re Grant ID #36072)	JAN-MS-00919312	JAN-MS-00919316		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1186	11/12/2009	DUR's meeting packet	OKAG-00010911	OKAG-00010961		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1187	11/17/2009	Tapentadol (Nucynta) ER Safety Surveillance Plan	JAN-MS-00214423	JAN-MS-00214423		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1188	11/17/2009	[Email] AAPM (Pain Medicine) 2010 Invitation	JAN-MS-00323768	JAN-MS-00323769		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1189	11/30/2009	Nucynta ER NDA Cover Letter	JAN-MS-00214374	JAN-MS-00214374		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1190	11/30/2009	Nucynta ER Application to Market a New Drug	JAN-MS-00214352	JAN-MS-00214352		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1191	12/04/2009	[Report/Memo] From Linda Saunders (AGS) to PriCara, Edu Grant Committee - RE: Grant ID 41349	JAN-MS-00395594	JAN-MS-00395595		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1192	12/11/2009	Nucynta IR PADER Aug 2009-Nov 2009	JAN-MS-00235126	JAN-MS-00235126		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1193	12/16/2009	Email: Newsletter Articles	OSBP-00113546			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1194	12/17/2009	Press Release: State's Top "Doctor Shopper" Charged	06N-00001786			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1195	12/18/2009	[Email] Final Results Report for SMT/RMT: Making Sense of Pain Medicine Confusion	JAN-MS-00809240	JAN-MS-00809240		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1196	12/21/2009	Smart Moves, Smart Choices 2009 Program Success PPT	JAN-MS-02403095	JAN-MS-02403095		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1197	12/21/2009	National Association of School Nurses, et al., presentation: "Smart Moves, Smart Choices", A Prescription Drug Abuse Prevention Program				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1198	01/01/2010	Amendment to Information Services Agreement Dated 6/18/2008	JAN-MS-03108887	JAN-MS-03108904		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1199	01/01/2010	"IMS HEALTH AMENDMENT TO INFORMATION SERVICES AGREEMENT No. COBS-0608-1213 DATED JUNE 18, 2008 BETWEEN IMS HEALTH INCORPORATED ("IMS") AND CENTOCOR DRUG BIOTECH SERVICES, LLC ("CLIENT")"	JAN-MS-03108905	JAN-MS-03108922		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1200	01/01/2010	Quintiles IMS 14th Amendment to Information Services Agreement No COBS-0608-1213	JAN-MS-03109027	JAN-MS-03109044		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1201	01/01/2010	Long-term opioid management for chronic noncancer pain (Review), Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD006605, 2010 DOI: 10.1002/14651858.CD006605.pub2.				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1202	1/1/2010	Mary Nugent et al., Article entitled, "Long-Term Observations of Patients Receiving Transdermal Fentanyl After a Randomized Trial," Journal of Pain and Symptom Management, Vol. 21, No. 5, May 2001				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1203	1/5/2010	RADARS System Tapentadol Report Q3 2009	JAN-OK-00042597	JAN-OK-000042864		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1204	01/19/2010	Contract: Tapentadol 'Prescribe Responsibly' 2010 PR Activities (V. submitted Jan. 19, 2010)	JAN-MS-00252578	JAN-MS-00252579		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1205	1/19/2010	Tapentadol ER "Data Support/Medical Meetings/Regulatory Milestones" 2010 PR Activities	JAN-MS-00346877	JAN-MS-00346878		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1206	1/19/2010	Tapentadol "Program Management/Strategic Counsel" 2010 PR Activities	JAN-MS-00346879	JAN-MS-00346880		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1207	01/22/2010	[Email] Reminders on HCC Policy	JAN-MS-00258804	JAN-MS-00258805		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1208	01/25/2010	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, Nucynta IR	JAN-MS-00236191	JAN-MS-00236191		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1209	1/26/2010	Tapentadol "Lets Talk Pain" 2010 PR Activities	JAN-MS-00338784	JAN-MS-00338786		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1210	2/9/2010	[Memorandum] The Center for Practical Bioethics 2010 Annual Dinner	JAN-MS-00934165	JAN-MS-00934194		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1211	02/23/2010	[Invoice] Beth Israel Meidcal Center to Ortho-MCNeil Janssen	JAN-MS-00396768	JAN-MS-00396768		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1212	02/25/2010	[Email] Metrics fromMedscape	JAN-MS-00919038	JAN-MS-00919038		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1213	03/04/2010	Three-Party CE Educational Grant Agreement [Re Grant ID #46393]	JAN-MS-00931407	JAN-MS-00931413		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1214	03/10/2010	DURB Meeting Packet, Mar. 10, 2010	OKAG-00000375	OKAG-00000443		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1215	3/10/2010	Email from David Lin: "FW: 2010 PriCara PAIN Nucynta Contest FINAL"	JAN-MS-01044623	JAN-MS-01044623		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1216	3/11/2010	Email re ICD 10 Codes	OSDH-01448441			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1217	3/15/2010	Nucynta IR PADER Nov 2009-Feb 2010	JAN-MS-00235155	JAN-MS-00235155		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1218	03/16/2010	[Email] INROADS 2010 ASPMN Grant Submission (attachment - budget)	JAN-MS-00396800	JAN-MS-00396835		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1219	03/17/2010	Contract: Tapentadol 'Prescribe Responsibly' 2010 PR Activities (V. submitted March 17, 2010)	JAN-MS-00252455	JAN-MS-00252457		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1220	03/17/2010	[Report/Memo] INROADS into Pain Management: Meeting the Challenges of Managing Patients with Complex Pain Syndromes	JAN-MS-00396799	JAN-MS-00396799		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1221	3/17/2010	Email re Prescribe Responsibly Addendum	JAN-MS-00824694	JAN-MS-00824694		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1222	3/17/2010	Tapentadol "Prescribe Responsibly" 2010 PR Activities	JAN-MS-00824695	JAN-MS-00824697		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1223	3/18/2010	Email S. Nicholson to K. Naim, B. DeLemos, B. Moskovitz, and M. Kaufman re IWG Memorandum	JAN-MS-02569642	JAN-MS-02569642		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1224	3/18/2010	Memorandum to Participating IWG Companies re The Path Forward for Advancing the Development of the Class REMS for Certain Opioid Products	JAN-MS-02569643	JAN-MS-02569644		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1225	03/18/2010	Pain Product Delivery Concepts / IONSYS LCM Recommendations	JAN-MS-02494145	JAN-MS-02494146		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1226	03/18/2010	Email S. Nicholson to K. Naim, B. DeLemos, B. Maskovitz, and M. Kaufman re IWG Memorandum	JAN-MS-02569642	JAN-MS-02569642		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1227	03/27/2010	Let's Talk Pain Medication Safety Series Filming Schedule	JAN-MS-00923941	JAN-MS-00923941		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1228	4/5/2010	RADARS System Tapentadol Report Q4 2009	JAN-OK-00042865	JAN-OK-00043140		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1229	4/6/2010	Email from K. Naim to P. Pierce re Review Needed -- Response to 4 Companies' Request for a Telecon -- Opioid REMS	JAN-MS-02605687	JAN-MS-02605689		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1230	04/13/2010	[Report] Pain Action Initiative: A National Strategy - Tampa Report	JAN-MS-00923090	JAN-MS-00923091		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1231	4/26/2010	Nucynta (Tapentadol Hydrochloride) Immediate Release: First Safety Surveillance Plan Progress Report	JAN-MS-00235160	JAN-MS-00235160		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1232	4/29/2010	RADARS System Tapentadol Report 2009 Annual	JAN-MS-02237460	JAN-MS-02237734		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1233	04/29/2010	[Email] NUCYNNTA promotion in AI/GI sales team	JAN-MS-02236444	JAN-MS-02236444		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1234	5/2010	Steven S. Dudley, "Drug Trafficking Organizations in Central America: Transportistas, Mexican Cartels and Maras." Woodrow Wilson International Center for Scholars Mexico Institute: Working Paper Series on U.S. Mexico Security Collaboration and the University of San Diego Trans-Border Institute. http://wilsoncenter.org/topics/pubs/Drug%20Trafficking%20Organizations%20in%20Central%20America.%20Dudley.pdf				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1235	05/19/2010	Nucynta email, "focus on appropriate patient types"	JAN-OK-00137202			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1236	05/25/2010	[Email] NUCYNNTA Success Story	JAN-MS-02248336	JAN-MS-02248337		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1237	5/26/2010	Duragesic Eighth Risk Management Plan Progress Report	JAN-MS-00165627	JAN-MS-00165627		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1238	05/27/2010	Nat Advocacy Directors team ccall tomorrow	JAN-MS-00399853	JAN-MS-00399853		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1239	6/2/2010	{Email} Agenda/Overview for tomorrow's NUCYNTA ER Message Mapping	JAN-MS-00937839	JAN-MS-00937839		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1240	6/3/2010	{Word} NUCYNTA Message Mapping Workshop	JAN-MS-00937840	JAN-MS-00937841		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1241	6/8/2010	Nucynta IR PADER Feb 2010-May 2010	JAN-MS-00235169	JAN-MS-00235169		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1242	06/09/2010	DURB Meeting Packet, June 9, 2010	OKAG-00000821	OKAG-00000885		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1243	06/09/2010	DUR's meeting packet	OKAG-00000821	OKAG-00000885		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1244	6/15/2010	{Email} MRC review for NUCYNTA ER Launch materials	JAN-MS-00798399	JAN-MS-00798401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1245	6/17/2010	Duragesic PSUR May 2009-Apr 2010	JAN-MS-00165630	JAN-MS-00185346		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1246	6/29/2010	Email from B. Moskovitz to C. Rauschklob, M. Etropolski, U. Richarz re FDA Opioid REMS	JAN-MS-02233931	JAN-MS-02233932		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1247	7/1/2010	RADARS System Tapentadol Report Q1 2010	JAN-OK-00043141	JAN-OK-000043417		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1248	7/7/2010	Version 1.0 of LA/ER REMS Supporting Document	JAN-MS-01048568	JAN-MS-01048684		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1249	7/8/2010	Email from B. Moskovitz to Dr. D. Biondi and J. Peterson re Final IWG REMS & REMS SD	JAN-MS-01048566	JAN-MS-01048567		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1250	7/10/2010	{Email} Action Required: Field Trainer's Guide - PP & NEO - Final	JAN-MS-00810234	JAN-MS-00810234		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1251	07/13/2010	National Advocacy Directors Mtg: Thurs, July 15th	JAN-MS-00399863	JAN-MS-00399863		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1252	7/22/2010	Our Experience in EXALGO Risk Management, U.S. Food and Drug Administration, Joint Meeting of the Anesthetic and Life Support Drugs Advisory and Drug Safety and Risk Management Advisory Committees (Jul. 22, 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1253	7/22/2010	Outpatient Prescription Opioid Utilization in the U.S., Years 2000 – 2009, U.S. Food and Drug Administration (Jul. 22, 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS [Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them]
J1254	07/22/2010	Summary Minutes of the Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSADAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) (Jul. 22-23, 2010)				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1255	07/28/2010	AI/GI (sales force) tablet materials	JAN-MS-04022231	JAN-MS-04022292		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1256	07/30/2010	El Mundo, "Muere 'Nacho' Coronel, uno de los narcos más buscados y poderosos de México," 30 July 2010. https://www.elmundo.es/america/2010/07/30/mexico/1280446951.html				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1257	08/02/2010	[Word Doc] Copy Review Submission Cover Sheet from Advertising & Promotion for Project: "Let's Talk Pain Medication Safety Series." Segment 6: Use of Medical Devices.	JAN-MS-00006735	JAN-MS-00006760; JAN00006762		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1258	08/05/2010	Pain Awareness Month Video Series and Internal Awareness Campaign	JAN-MS-02407794			Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1259	08/06/2010	Executive Summary - Nucynta ER Dossier Advisory Board Conference	JAN-MS-00483644	JAN-MS-00483673		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1260	08/06/2010	Signed Pain Awareness Month Video Series SOW	JAN-MS-02407789	JAN-MS-02407790		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1261	8/10/2010	August 10, 2010 Copy Review Submission form for Smart Moves Smart Choice School Assembly Messaging. This review concerned the content for a 2010 LA school assembly featuring Dr. Drew.	JAN-MS-00342997	JAN-MS-00343022		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1262	08/18/2010	[Email] Updated Pain Summary Report	JAN-MS-00628296	JAN-MS-00628297		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1263	08/20/2010	[Email] FW: NAD Slides w support materials (attachment)	JAN-MS-00399873	JAN-MS-00399873		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1264	08/26/2010	[Email] Action Requested: Revised Tapentadol ER Message Map	JAN-MS-02401998	JAN-MS-02402000		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1265	9/2/2010	DUR meeting packet w/ONDCP article re uptick in substance abuse treatment admissions, Memo fro DUR re: Packet Contents for Board Meeting - September 8, 2010				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1266	9/8/2010	DURB Meeting Packet	OKAG-00015257	OKAG-00015336		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1267	9/10/2010	Nucynta IR PADER May 2010-Aug 2010	JAN-MS-00235190	JAN-MS-00235190		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1268	09/13/2010	NAD Slide Deck - Email from M. Wolfe to R. Cagungan re: NAP and NAD slides	JAN-MS-00400705	JAN-MS-00400705		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS {Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them}
J1269	10/4/2010	RADARS System Tapentadol Report Q2 2010	JAN-OK-00043418	JAN-OK-000043691		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1270	10/6/2010	Email from B. Moskovitz to group re Request for follow-up regarding FDA advisory meeting regarding REMS for extended opioids	JAN-MS-01977572	JAN-MS-01977574		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1271	10/11/2010	[Email] October E-News - Pain Care Policy Act Funding Update:	JAN-MS-00916363	JAN-MS-00916367		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1272	10/13/2010	DUR meeting recording and transcription	OUCOP-00039006			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1273	10/13/2010	DUR meeting packet re PA suboxone and other oxycodone & Butrans, Oklahoma Health Care Authority DUR Board Meeting Minutes of Meeting of 10/13/2010				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1274	10/13/2010	DUR meeting packet re 30 PA suboxone				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1275	10/13/2010	DUR meeting minutes re moving hydrocodone/APAP to T3 w/PA				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1276	11/02/2010	Approved Smart Moves assembly agenda and script for November 2, 2010 LA school assembly featuring Dr. Drew.	JAN-MS-00832842	JAN-MS-00832865		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1277	11/05/2010	[Email] NUCYNTA Branding Guidelines	JAN-MS-00832888	JAN-MS-00832889		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1278	11/5/2010	[Email] Revised Objectives Slide Deck	JAN-MS-00933929	JAN-MS-00933929		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1279	11/10/2010	DURB Meeting Packet	OKAG-00014799	OKAG-00014833		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1280	11/12/2010	Response to Janssen's request for comments regarding a proposed patient brochure for Nucynta IR	JAN-MS-02407424	JAN-MS-02407433		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1281	11/15/2010	Nucynta DTC Brochure DDMAC Comments	JAN-MS-02819788	JAN-MS-02819797		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1282	11/15/2010	[Email] DDMAC Comments for Nucynta Patient Brochure	JAN-MS-02819785	JAN-MS-02819787		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1283	11/16/2010	[Email] DDMAC Comments for Nucynta Patient Brochure	JAN-MS-02407423	JAN-MS-02407423		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1284	11/22/2010	Duragesic Ninth Risk Management Plan Progress Report	JAN-MS-00185379	JAN-MS-00185379		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1285	11/23/2010	Top Things Advocacy Partners/Pain Communities Care Most About	JAN-MS-00933198	JAN-MS-00933199		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1286	11/24/2010	Nucynta (Tapentadol Hydrochloride) Immediate Release: Second Safety Surveillance Plan Progress Report	JAN-MS-00235239	JAN-MS-00235239		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1287	12/03/2010	Marketing Sponsorship Agreement	JAN-MS-00929428	JAN-MS-00929428		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1288	12/08/2010	DURB Meeting Packet, Dec. 8, 2010	OKAG-00015011	OKAG-00015044		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1289	12/10/2010	Nucynta IR PADER Aug 2010-Nov 2010	JAN-MS-00235193	JAN-MS-00235193		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1290	12/13/2010	[Letter] Understanding the States of Pain to Improve Outcomes Grant 71479	JAN-MS-05399338	JAN-MS-05399339		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1291	12/14/2010	Nucynta Branded Materials Guidelines	JAN-MS-00364041	JAN-MS-00364041		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1292	12/21/2010	FOR REVIEW: Final Prescribe Responsibility Layout	JAN-MS-00320642	JAN-MS-00320642		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1293	01/05/2011	APF Pain Resource Locator				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1294	1/7/2011	Copy Review Cover Sheet - NEO Chronic	JAN-MS-00804624	JAN-MS-00804655		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1295	1/10/2011	RADARS System Tapentadol Report Q3 2010	JAN-OK-00043692	JAN-OK-00043967		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1296	01/13/2011	[Email] NUCYNTA ER Agenda for 1/20/2011 CRC Meeting	JAN-MS-02275256	JAN-MS-02275257		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1297	1/14/2011	Email from Tanya Nelson to Kimberly Deem-Eshelman attaching PRC comments to NEO Chronic	JAN-MS-00804623	JAN-MS-00804623		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1298	01/14/2011	Proposal for Understanding Acute Pain Wall Chart & Pocket Guide	JAN-MS-02407513	JAN-MS-02407516		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1299	01/14/2011	Proposal for Understanding Chronic Pain Anatomical Resources Wall Chart, Pocket Guide, Tear-Pad	JAN-MS-02407517	JAN-MS-02407519		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1300	1/18/2011	2011 Public Relations Activities	JAN-MS-00339068	JAN-MS-00339071		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1301	1/27/2011	[PDF] Work Order decile.ten communications NUCYNTA Speaker Training Webcasts	JAN-MS-00339158	JAN-MS-00339165		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1302	01/27/2011	[Email] Meeting Follow Up - Library / Acute Pain & Chronic Pain Anatomical Chart & Pocket	JAN-MS-02407510	JAN-MS-02407511		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1303	02/02/2011	Ketchum contract for "2011 Public Relations Activities"	JAN-MS-00826997	JAN-MS-00826000		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1304	02/02/2011	[Email] FAQ's: Review Needed	JAN-MS-00833974	JAN-MS-00833975		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1305	2/3/2011	Exhibit B - Work Order (attachment)	JAN-MS-00825437	JAN-MS-00825444		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1306	02/10/2011	[Email] Re: Accepted: 2011 NUCYNTA Speakers Bureau	JAN-MS-00254912	JAN-MS-00254912		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1307	03/01/2011	[Email] Sales Compensation Internal Medicine 2011 Incentive Plan Updates	JAN-MS-00868422	JAN-MS-00868423		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1308	3/3/2011	DUR meeting packet, FDA press release re fentanyl for breakthrough pain for cancer, Memo from DUR re: Packet Contents for Board Meeting - March 9, 2011				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1309	3/8/2011	FW: can you send me the status grid that we reviewed on Monday	JAN-MS-04219749	JAN-MS-04219749		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1310	3/9/2011	NAVIPPRO Drug Abuse Surveillance Report Q4 2010 (10/1/2010-12/31/2010)	JAN-OK-00009003	JAN-OK-00009049		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1311	3/9/2011	DURB Meeting Packet	OKAG-00013151	OKAG-00013225		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1312	03/09/2011	[Email] Meeting invite regarding Nucynta pricing strategies.	JAN-MS-00303265	JAN-MS-00303265		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1313	03/10/2011	FW: Southard	JAN-MS-00834292	JAN-MS-00834293		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1314	3/11/2011	Nucynta IR PADER Nov 2010-Feb 2011	JAN-MS-00235219	JAN-MS-00235219		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1315	3/16/2011	Tapentadol (Nucynta) ER Safety Surveillance Plan	JAN-MS-00228228	JAN-MS-00228228		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1316	03/16/2011	[Email] Meeting invite to review NUCYNTA Forecast.	JAN-MS-00246666	JAN-MS-00246666		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1317	3/16/2011	Nucynta website	JAN-MS-04190903	JAN-MS-04191187		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1318	3/17/2011	[Email] NUCYNTA Market Research: Urgent	JAN-MS-00344652	JAN-MS-00344653		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1319	3/23/2011	Email from F. Demiro re: JEREMY ADLER - SPEAKER REQUEST...URGENT!	JAN-MS-00823489	JAN-MS-00823490		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1320	3/27/2011	[Report] AAPM 27th Annual Meeting Overview	JAN-MS-01149255	JAN-MS-01149264		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1321	3/30/2011	Prescribe Responsibly Survey Results	JAN-MS-00320529	JAN-MS-00320532		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1322	04/01/2011	Work Order Project: Xponent Analysis	JAN-MS-02935308	JAN-MS-02935313		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1323	4/4/2011	RADARS Fentanyl Data Q4 2010	JAN-MS-01595930	JAN-MS-01596236		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1324	4/5/2011	RADARS System Tapentadol Report Q4 2010	JAN-OK-00043968	JAN-OK-00044299		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1325	04/05/2011	[Email] Meeting Invite to Michael for introduction to Katie	JAN-MS-00775541	JAN-MS-00775542		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1326	04/08/2011	Removal of HCP from speaker bureau	JAN-MS-00255154	JAN-MS-00255154		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1327	4/8/2011	[Email] Approval needed: Nucynta Speaker State License Issues	JAN-MS-04218304	JAN-MS-04218308		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1328	04/09/2011	APF Welcome to PainAid page				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

TRIAL EXHIBIT NO.	DATE	DESCRIPTION	PRODUCTION BEGIN	PRODUCTION END	DEPOSITION EXHIBIT NO.	STATE'S OBJECTIONS	TEVA'S OBJECTIONS (Teva reserves the right to object at trial to any Janssen exhibit because Teva has not had the opportunity to review them)
J1329	04/12/2011	Sam Quinones, "Dreamland: The True Tale of America's Opiate Epidemic" (New York 2015). 3 American Society of Addiction Medicine, "Definition of Addiction,"				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1330	04/12/2011	RE: Pain Coalition Review	JAN-MS-00402652	JAN-MS-00402654		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1331	4/12/2011	[Email] Approval needed: Nucynta Speaker State License Issues	JAN-MS-04218321	JAN-MS-04218327		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1332	4/13/2011	DUR meeting recording and transcription	OUCOP-00038923			Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1333	4/13/2011	DUR meeting packet; FY 2010 Annual Review				Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1334	04/13/2011	DURB Meeting Packet, Apr. 13, 2011	OKAG-00013781	OKAG-00013894		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1335	04/13/2011	DUR's meeting packet	OKAG-00013781	OKAG-00013894		Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1336	4/17/2011	RADARS System Tapentadol Report 2011 Annual	JAN-OK-00045574	JAN-OK-00045764		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1337	4/18/2011	RADARS System Tapentadol Report 2010 Annual	JAN-OK-00044300	JAN-OK-00044608		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1338	4/18/2011	2011 Smart Moves Toolkit PRC coversheet.	JAN-MS-00940782	JAN-MS-00940784		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1339	04/19/2011	DEA Pharma Training Seminar Cert of Participation	JAN-MS-03124071	JAN-MS-03124073		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1340	4/20/2011	PrescribeResponsibly.com Tools	JAN-MS-00804401	JAN-MS-00804401		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1341	4/27/2011	[Email] Revised ISI Treatment for Nucynta I-Pad	JAN-MS-00345073	JAN-MS-00345074		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1342	5/2/2011	Nucynta (Tapentadol Hydrochloride) Immediate Release: Third Safety Surveillance Plan Progress Report	JAN-MS_00235238	JAN-MS_00235238		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
J1343	05/03/2011	[Email] Share Point Site created for core NUCYNTA IR & ER Material	JAN-MS-00834291	JAN-MS-00834292		Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	